

From the Division KI-Alzheimer's Disease Research Center  
Department of Neurobiology, Care Sciences and Society  
Karolinska Institutet, Stockholm, Sweden

# **MITOCHONDRIA IN ALZHEIMER DISEASE: REGULATORY MECHANISMS AND CELL DEATH**

Louise Hedskog



**Karolinska  
Institutet**

Stockholm 2012

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet. Printed by Larserics Digital Print AB

Cover picture: GFP transfected hippocampal neuron visualized with confocal microscopy.

© Louise Hedskog, 2012

ISBN 978-91-7457-854-6

Dedicated to my family

*“It is always wise to look ahead, but difficult to look further than you can see”*

Winston Churchill



## ABSTRACT

Synaptic loss is the major correlate for cognitive decline in Alzheimer disease (AD). Processes taking place in the synapses are highly energy demanding and needs strict regulation, which makes the mitochondria and ER crucial at these sites so as to supply energy and spatially regulate intracellular calcium signaling. The ER and mitochondria interact with each other at a highly specialized region of ER called the mitochondria-associated ER membrane (MAM). At the MAM several processes are regulated, including calcium handling, metabolism of glucose, phospholipids and cholesterol as well as apoptosis, all of which are deranged in AD. The aim of this thesis was to obtain deeper understanding of processes that could be behind mitochondrial dysfunction and caspase activation, and thereby cause synapse loss. Caspases are activated both during normal plasticity and in apoptosis, and their activation is associated with elevated A $\beta$  production. In **Paper I**, we studied this relationship and showed that during caspase activation intracellular A $\beta$ 42/A $\beta$ 40 ratio increases due to caspase cleavage of presenilin 1 (PS1) residing in active  $\gamma$ -secretase complexes. Intracellular A $\beta$  is cytotoxic and interferes with various processes for example intra-mitochondrial accumulation cause damage to mitochondrial functions. A $\beta$  is imported into the mitochondria via the TOM40 pore. A specific polymorphic poly-T variant (rs10524523), in the *TOMM40* gene had been postulated to cause earlier disease onset of late-onset AD (LOAD) in APOE  $\epsilon$ 3/ $\epsilon$ 4 carriers. Knowing the importance of TOM40 protein we set out, in **Paper II**, to investigate the functional implication of this polymorphism. However, we could not identify any deficits in mitochondrial function or morphology. Nevertheless, the mitochondria are evidently affected by AD, as indication include altered calcium homeostasis and metabolism. These alterations can be linked to the MAM region, which is a region scarcely investigated in the brain. Therefore, in **Paper III**, studying MAM, we showed that it exists in synapses and is essential for both neuronal and astrocytic survival. Furthermore, we showed that MAM is altered in human AD brain as well as in APP<sub>Swe/Lon</sub> mice, and is so before the appearance of plaques. Moreover, MAM can be functionally modulated by the amyloid- $\beta$  peptide (A $\beta$ ). Based on evident alterations in mitochondrial function in AD, treatments enhancing mitochondrial resistance could be a promising strategy. The final study, **Paper IV**, concerned a potential novel drug, Dimebon (Latrepidine), intended for treatment of AD. We found it to enhance mitochondrial function both in absence and presence of stress, and, in turn, partially protect cells to maintain cell viability. Since mitochondrial function is essential for synaptic integrity drugs targeting the mitochondria could have disease-modifying effect.



# LIST OF PUBLICATIONS

This thesis is based on the following papers:

- I. **Louise Hedskog**, Camilla A. Hansson Petersen, Annelie I Svensson, Hedvig Welander, Lars O Tjernberg, Helena Karlström, Maria Ankarcrona.  
 $\gamma$ -Secretase complexes containing caspase-cleaved presenilin-1 increase intracellular A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> Ratio.  
*J Cell Mol Med. Oct 15, 2150-2163 (2011)*
- II. **Louise Hedskog**, Jesper Brohede, Birgitta Wiehager, Catarina Moreira Pinho, Priya Revathikumar, Lena Lilius, Elzbieta Glaser, Caroline Graff, Helena Karlström, Maria Ankarcrona.  
Biochemical studies of poly-T variants in the Alzheimer disease associated *TOMM40* gene.  
*J. Alzheimer Dis. May 16 (2012) [Epub ahead of print]*
- III. **Louise Hedskog**, Catarina Moreira Pinho, Riccardo Filadi, Laura Hertwig, Birgitta Wiehager, Annica Rönnbäck, Sandra Gellhaar, Anna Sandebring, Marie Westerlund, Caroline Graff, Bengt Winblad, Dagmar Galter, Homira Behbahani, Paola Pizzo, Elzbieta Glaser, Maria Ankarcrona.  
MAM is essential for neuronal survival and modulated by Alzheimer disease pathology.  
*Submitted for publication*
- IV. Shouting Zhang\*, **Louise Hedskog\***, Camilla A Hansson Petersen, Bengt Winblad, Maria Ankarcrona. \* *contributed equally*  
Dimebon (Latrepirdine) enhances mitochondrial function and protects neuronal cells from death.  
*J. Alzheimers Dis. 21, 389-402 (2010)*

# CONTENTS

1	Introduction .....	1
1.1	Alzheimer disease.....	1
1.1.1	Neuropathology.....	1
1.1.2	Pathophysiologic hypothesis.....	2
1.1.3	Genetics and risk factors .....	3
1.2	The involvement of caspases and cell death in AD.....	5
1.2.1	Apoptosis.....	5
1.2.2	Caspases in healthy brain.....	6
1.2.3	Caspases in AD and their relationship to A $\beta$ .....	7
1.3	A $\beta$ production, function and toxicity.....	8
1.3.1	Amyloid precursor protein.....	8
1.3.2	APP processing .....	9
1.3.3	The amyloid $\beta$ -peptide (A $\beta$ ) .....	11
1.3.4	The $\gamma$ -secretase complex .....	12
1.4	Mitochondria .....	15
1.4.1	Mitochondria: more than just a powerhouse .....	15
1.4.2	Mitochondrial dysfunction in neurons.....	16
1.4.3	A $\beta$ inside the mitochondria.....	18
1.5	Mitochondria-associated ER membrane (MAM).....	19
1.5.1	Distribution of mitochondria and ER in neurons .....	19
1.5.2	MAM the control station.....	20
1.5.3	MAM is connected to the mitochondria by tethering complex/es .....	21
1.5.4	MAM regulates apoptosis .....	21
1.5.5	MAM controls calcium homeostasis .....	21
1.5.6	The role of Sigma1R at MAM.....	22
1.5.7	MAM regulates lipid synthesis .....	22
1.5.8	Can A $\beta$ be transported into the mitochondria from MAM? .....	23
1.6	Treatment strategies.....	23
1.6.1	Targeting MAM dysfunction.....	23
1.6.2	Targeting oxidative stress .....	25
1.6.3	Dimebon .....	25
2	Aims.....	27
3	Methodological considerations .....	29
3.1	Ethics approval .....	29
3.2	Models used in the studies .....	29
3.2.1	Cells .....	29
3.2.2	Human postmortem tissue .....	29
3.2.3	Transgenic mouse models.....	29
3.3	Quantitative measurements of protein expression.....	30
3.4	Subcellular fractionation .....	30
3.5	Exposing cells to A $\beta$ .....	31
3.6	Study mitochondrial function.....	31
3.7	Visualization of proteins and organelles in fixed samples .....	31
3.8	Live cell imaging .....	32
3.9	Measurement of calcium signaling between ER and mitochondria .....	32



4	Results and discussion.....	33
4.1	Mitochondrial regulation and dysfunction in AD .....	33
4.2	Caspase cleavage of PS1 increases the A $\beta$ 42/A $\beta$ 40 ratio.....	33
4.3	<i>TOMM40</i> polymorphisms, implications for AD .....	34
4.4	MAM is modulated by AD pathogenesis .....	34
4.5	Targeting mitochondrial function .....	36
5	Concluding remarks and future perspectives .....	39
6	Acknowledgements .....	41
7	References .....	44

# LIST OF ABBREVIATIONS

A $\beta$	Amyloid $\beta$ -peptide
ABAD	A $\beta$ -binding alcohol dehydrogenase
AD	Alzheimer disease
ADAM	A disintegrin and metalloproteinase
AICD	APP intracellular domain
Aph1	Anterior pharynx defective-1
APLP	APP-like protein
ApoE	Apolipoprotein E
APP	Amyloid precursor protein
BACE	B-site APP cleaving enzyme
BBB	Blood brain barrier
caspCTF	Caspase-cleaved C-terminal fragment
COX	Cytochrome c oxidase
CTF	C-terminal fragment
$\Delta\Psi_m$	Mitochondrial membrane potential
Drp1	Dynamine-related protein 1
ELISA	Enzyme-linked immunosorbent assay
ER	Endoplasmic reticulum
FAD	Familial AD
GFAP	Glial fibrillary acidic protein
GFP	Green fluorescent protein
ICC	immunocytochemistry
IMM	Inner mitochondrial membrane
IP3R3	Inositol 1, 4, 5-triphosphate receptor type 3
Nct	Nicastrin
NICD	Notch intracellular domain
NTF	N-terminal fragment
LTD	Long term depression
LTP	Long term potentiation
mtDNA	Mitochondrial DNA
OMM	Outer mitochondrial membrane
OXPPOS	Oxidative phosphorylation
PreP	Presequence protease
MCI	Mild cognitive impairment
NFT	Neurofibrillary tangles
MAM	Mitochondria-associated ER membrane
Mfn2	Mitofusin-2
NMDA	N-methyl-D-aspartate receptor
PACS2	Phosphofurin acidic cluster sorting protein 2
PS	Presenilin
PSS1	Phosphatidylserine synthase
PTP	Permeability transition pore
RIP	Regulated intramembrane proteolysis
RFP	Red fluorescent protein
Sigma1R	Sigma-1 receptor
ROS	Reactive oxygen species
VDAC1	Voltage-dependent anion channel
TCA	Tricarboxylic acid cycle
TOM	Translocase of the outer membrane
TLC	Thin liquid chromatography

# 1 INTRODUCTION

## 1.1 ALZHEIMER DISEASE

Alzheimer disease (AD) is the most common form of dementia and affects millions of people worldwide. It is a complex, age-related, multifactorial disease affecting mainly the basal forebrain, cortex and hippocampus causing wide spread neurodegeneration, characteristic atrophy and enlargement of the ventricles (Wenk, 2003). Clinically, AD is characterized by gradual decline in memory and cognitive functioning, specifically planning, language, orientation, reasoning and performance of everyday activities, ultimately leading to death. At present there is no cure for AD and the drugs available on the market can only ameliorate symptoms. New technical advances have enabled researchers to study the disease in living patients and to investigate early events that occur before clinical symptoms are apparent. Presumably, the key to cure this devastating disease would be to diagnose it earlier and thereby enable treatment to be initiated much earlier than is the case today. Now treatment begins after symptoms are observed, though, by then, the patient already has wide spread pathology and neuronal loss. Still, the etiology of AD is largely unknown and there is a huge need for exploration of cellular pathways underlying the pathogenesis in the early phases in order to find promising, novel drug targets.

Mitochondria play essential and diverse roles in the physiology of eukaryotic cells. Besides ATP production, mitochondria participate in numerous intermediate metabolic reactions and play a central role in calcium homeostasis, apoptosis, cell signaling, proliferation, and differentiation. Impairment of mitochondrial function has been implicated in a wide variety of human diseases, including neurodegenerative disorders (Seppet et al., 2009). This thesis will explore some cellular processes disturbed in AD with its focus on the aberrant caspase activation, increased intracellular production of amyloid  $\beta$ -peptide ( $A\beta$ ) and the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM). The latter, a region, involved in regulating several pathways, including glucose, lipid metabolism, calcium homeostasis and apoptosis, all of which are altered in AD. Expanding knowledge about the mitochondria is important since mitochondrial abnormalities can play important roles in the etiology and progression of AD (Reddy and Beal, 2005).

### 1.1.1 Neuropathology

Molecular lesions arising from an accumulation of misfolded proteins in the aging brain are thought to cause oxidative and inflammatory damage, which in turn leads to energy failure and synaptic dysfunction. The neuropathological hallmarks of AD are characterized by extracellular neuritic plaques and intracellular neurofibrillary tangles (NFTs), which were first described in 1907 by Alois Alzheimer (Alzheimer et al., 1995). Not until 1980s were the main constituents of these lesions identified as  $A\beta$  and hyperphosphorylated tau, in plaques and NFTs, respectively (Masters et al., 1985; Grundke-Iqbal et al., 1986). At present, a definitive diagnosis of AD is made postmortem and includes neuropathological findings of plaques and NFTs. The pathological lesions are usually distributed in a characteristic way by which tau pathology is observed in the hippocampus and entorhinal cortex while prefrontal, parietal and temporal cortices exhibit most of the amyloid pathology (Braak and Braak, 1991). Another prominent feature is inflammation as both microglial activation and astrocytosis are important mediators of the disease progression (Tuppo and Arias, 2005;

Town, 2010). The pathology affects mainly the cholinergic and the glutamatergic neurotransmitter systems. The cholinergic system, thought to be particularly vulnerable to aging, resides in the basal forebrain and is heavily involved in higher cognitive functions, such as, learning and memory. Loss of cells in both the nucleus basalis of Meynert and the medial septal nucleus projecting to neocortex and hippocampus, respectively, are prominent features of AD. Glutamate is a major transmitter in the brain and the transmitter of cortical and hippocampal pyramidal neurons. The formation of new memories, through the mechanism of long-term potentiation (LTP), involves glutamate and its receptors. In AD, histological studies indicate loss of pyramidal neurons and their synapses (Francis, 2003). The pathological change correlating most strongly with cognitive decline is synapse loss, thought to start in hippocampus and entorhinal cortex. Neurons depend heavily on mitochondria for energy supply, and also as modulators of signaling pathways that involve intracellular calcium along their profoundly polarized shape at distances far away from soma. Mitochondrial dysfunction is an early feature in AD that might be implicated in synaptic dysfunction. This will be discussed separately in the section below entitled “Mitochondria”.

### 1.1.2 Pathophysiologic hypothesis

It is generally believed that A $\beta$  is important in the development of the neuropathic hallmarks of the disease, including: synapse loss, neurodegeneration, amyloid plaques, and neurofibrillary tangles (Hardy and Selkoe, 2002). This hypothesis is called the “**amyloid hypothesis**” and suggests that alteration in cleavage, processing and clearance of the amyloid precursor protein (APP) causes the pathogenesis of AD. This hypothesis has dominated the Alzheimer field as a pathophysiological explanation for about 20 years. This hypothesis has mainly survived as the top candidate due to the discovery of mutations causing familial AD (FAD) in the genes coding for amyloid precursor protein (APP) and presenilin 1 (PS1) and presenilin 2 (PS2), each of which influence production of A $\beta$ . Nevertheless, this hypothesis has received criticism due weak correspondence between the amount of amyloid plaque and the observed progression of clinical symptoms. Therefore, this hypothesis was recently updated to “**toxic A $\beta$  oligomer hypothesis**” as an attempt to explain the lack of correlation between plaque load and neurodegeneration and cognitive impairment (Benilova et al., 2012). Many other pathophysiological mechanisms have also been suggested. The oldest one is the “**cholinergic hypothesis**”, which is based on the relative selective loss of cholinergic neurons in nucleus basalis of Meynert (Bartus et al., 1982). The most commonly used drugs for treatment of AD, the acetylcholinesterase inhibitors (e.g. Donepezil, Tacrine and Galantamine), are targeted to compensate for the falling acetylcholine levels by reversibly blocking acetylcholine esterase. These drugs can only ameliorate symptoms and give modest improvements in memory and do not retard neurodegeneration.

Another major theory today that correlates well with clinical symptoms is the “**neuronal cytoskeletal degeneration hypothesis**” which suggests that cytoskeletal changes that give rise to the formation of NFTs are the cause of the pathogenesis (Braak and Braak, 1991). Hyperphosphorylated tau, which comprises NFTs, is a microtubule-associated protein. Tau is primarily expressed in axons of the neurons and is important to stabilize microtubules during their assembly. Hyperphosphorylation results in decreased affinity for microtubules, which deteriorates axonal trafficking (Alonso et al., 1997; Iqbal et al., 2005). There are mutations in tau but none known to cause AD. Instead, such mutations, are linked to other neurodegenerative diseases like frontotemporal dementia (Foster et al., 1997). It has been suggested that hyperphosphorylation of tau might be triggered by A $\beta$  accumulation. However, by what

mechanism A $\beta$  affects tau is not fully clarified. One suggestion is that A $\beta$  induces caspase cleavage of tau, since this truncation has been shown to proceed and be required for tangle formation (Hardy and Selkoe, 2002; de Calignon et al., 2010).

Additional new hypotheses have emerged e.g. the “**excitotoxicity hypothesis**”, which suggests that glutamate toxicity could be one of the underlying pathogenic mechanisms of AD (Molinuevo et al., 2005). The drug, memantine, is a NMDA receptor antagonist and the latest of drugs approved by the U.S Food and Drug Administration (FDA) for treatment of AD. This drug is usually used in combination with acetylcholinesterase inhibitors in the later stages of the disease.

Another is the “**mitochondrial hypothesis**” that postulates that age-related changes in mitochondria influence the susceptibility and vulnerability for environmental factors triggering AD pathology (Swerdlow et al., 2010). Aging mitochondria show increased production of reactive oxygen species (ROS) (Navarro and Boveris, 2007). Oxidative stress, in turn, leads to cellular lipid, protein and nucleic acid damage, eventually triggering apoptosis (Markesbery and Carney, 1999; Mattson, 2000). Accumulation of A $\beta$  in the mitochondria has been detected in our laboratory as well as in other labs. Inside the mitochondria, A $\beta$  disturbs essential mitochondrial functions leading to disturbances in energy production and induction of apoptosis. Recently, additional data supporting this hypothesis has emerged. Leuner et al. showed that oxidative stress, *per se*, triggers elevation of A $\beta$  production to toxic levels, which in turn impairs the mitochondria, thereby initiating a vicious cycle that incorporates ROS and A $\beta$  (Leuner et al., 2012). These events may indeed, be important in AD pathogenesis and may account for disturbed mitochondrial metabolism and synaptic dysfunction detected at early stages in the disease.

The triggering events behind AD are still somewhat of a mystery and the heterogeneity of AD implies that there are probably several triggers. It is possible that all the above-mentioned hypotheses intervene with each other in a complex, hard-to-dissect manner. Nevertheless, A $\beta$  probably has a central role in AD pathogenesis. However, with the many failures in drug development, which have mainly aimed to reduce A $\beta$  levels, research has now tended to shift from mainly A $\beta$  oriented to a wider, multi-candidate perspective. Other pathophysiological candidate areas for investigation that are being described today include hypometabolism, mitochondrial dysfunction, inflammation, dysfunctional autophagy, oxidative stress (NO), dysregulated calcium homeostasis, altered cholesterol and phospholipid metabolism. To understand what the triggers are, focus must be brought to pathophysiological events that precede A $\beta$  aggregation and tau hyperphosphorylation.

### **1.1.3 Genetics and risk factors**

Alzheimer disease is a multifactorial and heterogeneous disease where both genotype and environmental factors influence one’s susceptibility. Most of the AD cases are sporadic (without known genetic background) and only roughly 1% of the cases are autosomal-dominantly inherited familial AD (FAD). Familial AD has been linked to mutations in three genes, including *APP*, located on chromosome 21; *PSEN1* and *PSEN2*, located on chromosomes 14 and 1, respectively (Goate et al., 1991; Levy-Lahad et al., 1995; Sherrington et al., 1995). Most of the aggressive, early-onset forms of FAD are caused by mutations in the *PSEN1* gene. The mutations in *APP*, *PSEN1* and *PSEN2* affect A $\beta$  production in several ways, including increasing total A $\beta$  or shifting the A $\beta$ 42/A $\beta$ 40 ratio by increasing the formation of the more aggregate-prone A $\beta$ 42 or decreasing the formation of A $\beta$ 40 (St George-Hyslop, 2000).

Presenilin mutations, apart from characteristic A $\beta$  phenotypes, cause other biochemical changes, including: increased vulnerability to ER stress, disruption of intracellular calcium homeostasis, disruption of autophagy, disruption of neurotransmitter release and acceleration of the apoptotic processes (<http://www.molgen.ua.ac.be/Admutation/>) (Duff et al., 1996; Katayama et al., 2004; McCarthy, 2005; Thinakaran and Sisodia, 2006; Zatti et al., 2006; Miyoshi et al., 2009; Zhang et al., 2009; Lee et al., 2010; Parodi et al., 2010).

The cause of sporadic AD is thought to be a combination of genotype and several environmental risk factors, making certain individuals more susceptible to develop AD. Several environmental factors are thought to play a role in predisposing people to develop AD, especially cardiovascular risk factors including midlife cholesterol levels and high blood pressure. Others are age, female gender, head trauma, cerebral infarct, oxidative stress, depression and diabetes mellitus type 2 (Munoz and Feldman, 2000; Veurink et al., 2003). Several genes have been found to associate with AD, including *APOE*, *CLU*, *CRI*, *SORLI*, *PICALM* and *BINI*, however, the apolipoprotein E (*APOE*) gene remains the most strongly established risk factor for AD (Lambert and Amouyel, 2011). The *APOE* exists in three different alleles  $\epsilon$ 2,  $\epsilon$ 3 and  $\epsilon$ 4. Carriers of *APOE*  $\epsilon$ 4 have an increased risk (3-10 fold) of developing AD and as well as lowering the age of onset (Corder et al., 1993). *APOE* is a component of triglyceride-rich lipoprotein complexes carrying cholesterol and triglycerides between cells and in the blood. In the brain, *APOE* is thought to be particularly important since large lipoproteins do not pass the blood brain barrier (BBB) and the cholesterol metabolism is thought to be separated from the periphery. Twenty-five percent of the total cholesterol in the body resides in the brain. The cholesterol is produced mainly by the astrocytes and then transported by *APOE* to neurons and other cells in the brain. Cholesterol is an important building block for myelin, plasma membranes and lipid rafts, and thereby essential for brain plasticity and repair (Bjorkhem and Meaney, 2004). It has been suggested that lipid particles containing the  $\epsilon$ 4 allele contain less cholesterol and, thereby, deliver less cholesterol to the neurons as compared to the  $\epsilon$ 3 allele (Gong et al., 2002). *APOE* has also been associated with reduced clearance of A $\beta$  since  $\epsilon$ 4 carriers often have an increased plaque load (Dolev and Michaelson, 2004). Moreover,  $\epsilon$ 4 carriers display increased hyperphosphorylation of tau, reduced glucose metabolism, exacerbation of medial temporal lobe atrophy, reduced fMRI activity and connectivity as well as greater loss of white matter (Pievani et al., 2011; Canu et al., 2012; Patil et al., 2012). The  $\epsilon$ 4 protein mediates potentially detrimental effects upon the mitochondria via the lipid- and receptor-binding regions, resulting in mitochondrial dysfunction and neurotoxicity (Chang et al., 2005; Chen et al., 2011). However, the exact pathophysiological mechanism associating isoform  $\epsilon$ 4 with increased AD-risk are still not clear. Other diseases, like cardiovascular disease and atherosclerosis, are also associated with the  $\epsilon$ 4 allele (Verghese et al., 2011). *APOE* is located on chromosome 19 in a region of linkage disequilibrium (LD) that includes the genes: translocase of the outer mitochondrial membrane 40 (*TOMM40*), apolipoprotein C1 (*APOC1*) and poliovirus receptor-related 2 (*PVRL2*). Recent genome-wide association studies report that the gene, *TOMM40*, is associated with AD (Roses et al., 2009; Shen et al., 2010). Several polymorphisms have been identified in *TOMM40*, though, which polymorphisms and in what manner each contributes to the disease is unknown. One of these polymorphism, a poly-T repeat, was studied in **paper II** and will be discussed further in the section entitled “A $\beta$  inside the mitochondria” and in the “Results and Discussion” section below.


Interestingly, some factors decrease the risk of developing AD. For instance, a mutation in APP at the  $\beta$ -secretase cleavage site, which reduces BACE1 cleavage, thereby lowering the production of A $\beta$ , has been found to protect against AD and cognitive decline in elderly (Jonsson et al., 2012) (for information about  $\beta$ -secretase cleavage, see the section “APP processing”). Furthermore, postmortem studies on 86-89 year-old individuals that regardless of profound accumulation of plaques and tangles in their brains had remained cognitively intact, point towards the mitochondria. The cognitively intact individuals showed preserved insulin response and no accumulation of A $\beta$  in their mitochondria, unlike AD patients, who showed profound accumulation of A $\beta$  oligomers and deranged insulin signaling (Tagliavola, Poster, AAIC, 2012, Vancouver, Canada).

## 1.2 THE INVOLVEMENT OF CASPASES AND CELL DEATH IN AD

### 1.2.1 Apoptosis

Synaptic damage, neuronal network loss and cell death are processes giving rise to the characteristic brain atrophy seen in AD. Apoptosis has been implicated as the main cell death mechanism by which synapses degenerate and neurons are lost in AD (Stadelmann et al., 1999a; Louneva et al., 2008a; Albrecht, S. et al., 2009). Caspases, a group of cysteine proteases cleaving after aspartyl residues, play an essential role in apoptosis. Upon activation, caspases target a broad spectrum of cellular proteins, ultimately leading to disassembly of the cell (Alnemri et al., 1996). In contrast to necrosis, apoptosis is strictly regulated and is characterized by several morphological and biochemical changes, including cell shrinkage, nuclear fragmentation, chromatin condensation, plasma membrane blebbing, exposure of phosphatidylserine on the cell surface and, finally, engulfment by phagocytes. Regulation of the apoptotic process and equilibrium between cell division and apoptosis are essential for the organism. Disturbance can result in cancer or degenerative disease depending on either inappropriate suppression or activation of apoptosis. There are two main routes to initiate apoptosis, one involves stimulation of death receptors by external ligands (death receptor pathway) and one arises within the cell (mitochondrial pathway) activated by various forms of cellular stress such as oncogenes, DNA damage, hypoxia, oxidative stress, excitotoxicity or deprivation of survival factor (see Figure 1).

Both these routes activate the caspase cascade. Based on their function, the size of their prodomain, homology in amino acid sequence and cleavage specificity, caspases can be divided into one inflammatory group (caspase-1, -4, -5, -11, -12, -13 and -14) and one group regulating apoptosis. Those regulating apoptosis are divided into two classes: initiator caspases (caspase -2, -8, -9 and -10) and effector caspases (caspase-3, -6 and -7). These reside in the cells as zymogens (procaspases) and are activated post-translationally. The N-terminal contains the prodomain, which is required for activation. Caspase-2 and -9 contain the caspase recruitment domain (CARD) and caspase-8 and -10 contain the death effector domain (DED). The protein-protein interactions between these two domains are involved in procaspase activation and downstream caspase activation. Mitochondria are central in apoptotic signaling, both by providing ATP that supports the high energy demanding events during apoptosis, and by releasing death proteins from the intramembrane space (e.g. cytochrome c, Omi/HtrA2, Smac/DIABLO) after the mitochondria permeability transitions pore (PTP) opening.



**Figure 1:** Apoptosis is induced by the extrinsic or the intrinsic pathway. The **intrinsic pathway** is initiated with outer mitochondria membrane permeabilization by upregulation of proapoptotic Bcl-2 proteins (e.g. Bid and Bax), and by the repression of anti-apoptotic Bcl-2 protein and IAPs, which lead to release of apoptotic mediators e.g. Smac/DIABLO and cytochrome C. These factors activate the caspase cascade through caspase-9 leading to cell death. The **extrinsic pathway** is initiated by death ligands activating the caspase cascade through Caspase-2, -8 and -10 leading to caspase-3 activation and cell death.

### 1.2.2 Caspases in healthy brain

Caspase activation is not only involved in apoptosis but also in other processes including red blood cell development and microglia activation and as recently shown also in remodeling of dendrites, spines and synaptic connections in the healthy brain (Gilman and Mattson, 2002; Lamkanfi et al., 2007; Burguillos et al., 2011; Hyman, 2011). Caspase-3, earlier thought to be activated exclusively during apoptosis, can be activated in a transient fashion mediating neuronal plasticity, including: long-term depression (LTD), long-term potentiation (LTP), synaptic reorganization, and neurite retraction in the healthy brain without completion of the apoptotic program (Mattson et al., 1998; Gilman and Mattson, 2002; Gulyaeva et al., 2003; de Calignon et al., 2010; Li et al., 2010). Furthermore, caspase-3/7 and caspase-8 have been shown to regulate microglia activation, also without completion of the apoptotic program (Burguillos et al., 2011). Therefore, it is suggested that certain cell types (e.g. neurons and microglia) utilize apoptotic signaling pathways to regulate processes such as plasticity or activation. However, since aberrant caspase activation and apoptosis also have been linked to synaptic loss and neurodegeneration in AD (Mattson et al., 1998; Stadelmann et al., 1999b; Louneva et al., 2008b) caspases must maintain activity in a transient fashion to hinder massive caspase activation and ultimate completion of the apoptotic program. Apoptosis might be restricted by trophic factors (Heerssen and Segal, 2002), cell adhesion proteins (Benson et al., 2000) and autophagy. In a rat model of subarachnoid hemorrhage, activation of autophagy was associated with neuroprotection against apoptosis by decreasing bax translocation to the mitochondria, thereby reducing early brain injury (Jing et al., 2012). Caspases are naturally controlled by various inhibitors such as the inhibitor of the apoptosis protein (IAP) family and Bcl-2 family proteins, which inhibit apoptosis by binding to active caspases. Eight members of the IAP



family have been described so far, including X-linked inhibitor of apoptosis (XIAP), neuronal apoptosis inhibitory protein (NAIP), survivin and livin. XIAP has dual functions, both as potent inhibitor of caspase activation and as an E3 ubiquitin ligase targeting caspases for degradation (O'Riordan et al., 2008). Currently, XIAP is the only caspase inhibitor known to inactivate active caspases (Eckelman et al., 2006). In AD, XIAP has been shown to be downregulated and XIAP to be upregulated (Christie et al., 2007). Such upregulation of XIAP might, unfortunately, not be sufficient to adequately regulate caspase activity in the AD brain since a significant amount of XIAP is inactivated by S-nitrosylation (SNO-XIAP). This inactivation, as reported recently, was caused by nitrosative stress inhibiting the E3 ligase and antiapoptotic activity of XIAP and, thereby, could play a role in causing aberrant caspase activation in AD (Nakamura et al., 2010). At present, the exact mechanism and factors that may be involved in keeping caspases active in a transient fashion are not fully understood. Increased understanding of the dysregulated apoptotic processes in AD would be important to gain therapeutic perspective on how to intervene and hinder aberrant caspase activation.

### 1.2.3 Caspases in AD and their relationship to A $\beta$

Several lines of evidence indicate excessive caspase activation in the AD brain. Activity of several caspases, especially caspase-3 and -6, has been demonstrated in both postmortem AD brains, postsynaptic densities in AD brains as well as in the cerebrospinal fluid of sporadic and FAD patients (Guo et al., 2004; Louneva et al., 2008b; Albrecht, P. et al., 2009; Albrecht, S. et al., 2009). Moreover, caspase activation and apoptosis have been linked to synaptic loss and neurodegeneration in human AD brain (Stadelmann et al., 1999a; Louneva et al., 2008a; Albrecht, S. et al., 2009; D'Amelio et al., 2011). Studies report that A $\beta$  induces LTD in a caspase-3 dependent manner (Jo et al., 2011). Several lines of evidence suggest a correlation between caspase activation and elevated A $\beta$  production (LeBlanc, 1995; Galli et al., 1998; Tesco et al., 2003; Takuma et al., 2005a; Cicconi et al., 2007; Xie et al., 2007). It has been suggested that caspases induce increased  $\beta$ -secretase cleavage of APP. This phenomenon can be explained by caspase-3 cleavage of GGA3, an adaptor protein involved in BACE trafficking, which thereby stabilize BACE (Tesco et al., 2007). Caspases cleave numerous other substrates, including the AD associated proteins APP, tau, PS1 and PS2. The cleavage of tau induces mitochondrial dysfunction and is required for tangle formation *in vivo* (Quintanilla et al., 2009; de Calignon et al., 2010). Caspase cleavage of APP generates two putative toxic peptides C31 and Jcasp (Park et al., 2009). However, elevated A $\beta$  production observed after caspase activation occurs independently of caspase cleavage of APP (Tesco et al., 2003). The role of PS1 and PS2 in apoptosis has been studied by several groups showing that PS1 and PS2 in most cases accelerate the apoptotic program (Wolozin et al., 1996; Alves da Costa et al., 2002; Alves da Costa et al., 2003; Fluhner et al., 2004; Cai et al., 2006; Miyoshi et al., 2009). We have recently investigated caspase cleavage of PS1 and found that the elevation of the intracellular A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio can indeed partly be explained by the formation of  $\gamma$ -secretase complexes containing caspase cleaved PS1 (PS1caspCTF) as shown in **Paper I**. This will be further discussed under the subheading "The  $\gamma$ -secretase complex" and in section "Results and Discussion".

Axonal degeneration has been associated with caspase-6 activation. Caspase-6-knockout neurons have been shown to be protected against excitotoxicity, nerve growth factor deprivation and myelin-induced axonal degeneration (Uribe et al., 2012). However, caspase-6-knockout mice display a hypoactive phenotype with learning deficits, thus indicating that caspase-6 activity is important for neuronal health. Caspase-6 activity must, however, be accurately regulated in order to hinder axonal degeneration (Uribe et al., 2012). Recently, a

ligand for death receptor 6 (DR6) was identified, which downstream activates caspase-6. Interestingly, it is the N-terminal fragment of APP, produced after  $\beta$ -secretase shedding (by BACE1 or meprin  $\beta$ ), that binds to DR6 during trophic-factor deprivation and, thereby, induces caspase-6 dependent axonal degeneration (Nikolaev et al., 2009; Jefferson et al., 2011). Thus, transient caspase activity is important for several biological processes, implying that caution should be taken when considering caspase inhibition as a therapy for AD. Nevertheless, modulation might have positive results as demonstrated in the triple-transgenic AD mouse model lacking pathology when overexpressing anti-apoptotic protein Bcl-2 (Rohn et al., 2008).

### **1.3 A $\beta$ PRODUCTION, FUNCTION AND TOXICITY**


#### **1.3.1 Amyloid precursor protein**

Amyloid precursor protein (APP) is an integral type I transmembrane protein with a long N-terminal domain and short cytoplasmic C-terminal domain (see Figure 2). Two homologues to APP have been identified, including APP-like proteins 1 and 2 (APLP1 and APLP2), which share sequence similarity to APP, though lacking the A $\beta$  part (Sprecher et al., 1993). Their function is not yet clarified but it has been proposed that the APP family members play a role in neurite outgrowth, synaptic plasticity, neuronal protein trafficking, transmembrane signal transduction, cell adhesion and neuronal survival (Mattson, 2004; Zheng and Koo, 2006; Zhang et al., 2012). Upon cell adhesion, APP together with other APP family members is thought to dimerize into homodimers or heterodimers in the process of cell adhesion (Soba et al., 2005). Double- and triple-knockout studies reveal that, while APP/APLP1-knockout mice survive, other combinations, including APP/APLP2, APLP1/APLP2 and APP/APLP1/APLP2 each individually show early postnatal lethality (Zhang et al., 2012), reduced number of synaptic vesicles and deteriorated presynaptic terminals at birth (Wang et al., 2005). When only knocking down APP, the mice show reduced brain and body weight, reduced grip strength, impaired spatial memory and LTP. This phenotype could be rescued in APP-N-terminal-part knock-in mice (Ring et al., 2007). Overexpression, on the other hand, results in the phenotype resembling Down syndrome (trisomy 21) and in premature death (Moechars et al., 1996). Overexpression is furthermore associated with degeneration of forebrain cholinergic neurons in a mouse model of Down syndrome due to decreased retrograde transport of nerve growth factor (Salehi et al., 2006). APP is ubiquitously expressed throughout the body and exists in three different isoforms 695, 751 and 770. The isoforms 751 and 770 express a Kunitz protease inhibitor (KPI) sequence in their N-terminal domain and are expressed in all cell types except neurons, which instead express the isoform 695. In neurons, the 695 isoform has been found localized to synapses both in post-synaptic densities and in adhesion complexes (Marotta et al., 1992). In AD, a shift in APP isoform in neurons towards KPI-containing isoforms has been detected, a shift that is associated with increased A $\beta$  production (Menendez-Gonzalez et al., 2005; Bordji et al., 2010). Transportation of APP has been described to occur by fast moving (3  $\mu$ m/s) large tubules and vesicles out in the neurites by microtubules motors (Goldsbury et al., 2006), and carried along axons to synaptic terminals (Lazarov et al., 2002). Many post-translational modifications have been described in the ectodomain of APP, including N- and O-glycosylation, sulfation and phosphorylation (Gandy et al., 1988; Weidemann et al., 1989; Hung and Selkoe, 1994). Upon phosphorylation at T668, APP has been shown to inhibit neuronal calcium oscillations (Santos et al., 2011). Furthermore, the ectodomain purportedly contains several different domains, including a growth factor-like domain; neuroprotective and neurotrophic domains; and copper-, zinc- and heparin-binding site domains (Chasseigneaux and Allinquant, 2012). Several ligands to APP have been suggested, including A $\beta$ , F-spondin, and Netrin-1 (Lorenzo et al., 2000; Ho and Sudhof, 2004). APP is typically transported from ER

through the secretory pathway to the plasma membrane; however, in AD, APP is reported to also accumulate in the mitochondria (Anandatheerthavarada et al., 2003; Devi et al., 2006). APP contains a mitochondrial targeting signal at the N-terminal part consisting of at least the positively charged residues, 40, 44 and 51. Upon import into the mitochondria, APP is arrested at the acidic sequence 220-290, thereby causing APP to be stuck in the mitochondrial import pore, leaving a large C-terminal part (containing the A $\beta$  region) outside in the cytoplasm (Devi et al., 2006). The accumulation of APP in the mitochondria hinders the import of other proteins and causes mitochondrial dysfunction and impaired energy metabolism (Anandatheerthavarada et al., 2003; Devi et al., 2006). Recently, the C-terminal part of APP was shown to become inserted into the OMM where it could be processed by mitochondrial  $\gamma$ -secretase complexes (Pavlov et al., 2011). Overexpression of APP has been shown to cause mitochondrial fragmentation and abnormal mitochondrial distribution, which was suggested to be caused by C99 or A $\beta$  since the phenotype could be rescued by  $\beta$ -secretase inhibitors (Wang et al., 2008). Also A $\beta$  and C99 have been observed to accumulate in the mitochondria at early points during disease course (Lustbader et al., 2004; Caspersen et al., 2005; Manczak et al., 2006; Hansson Petersen et al., 2008; Devi and Ohno, 2012). These data suggest that APP and its metabolites could, indeed, play an active role causing mitochondrial dysfunction. The accumulation of A $\beta$  inside the mitochondria will be discussed further under the subheading “A $\beta$  inside the mitochondria”.

### 1.3.2 APP processing

APP is processed through two pathways: the non-amyloidogenic and the amyloidogenic pathways (see Figure 2), the latter of which accounts for generation of A $\beta$  through sequential cleavage by  $\beta$ - and  $\gamma$ -secretase. The enzymes that are thought to serve as  $\beta$ -secretases, include membrane-bound aspartyl proteases; and so far BACE1 has been described as the main one. However, cathepsin B and Meprin  $\beta$  have also been suggested (Vassar, 2004; Cole and Vassar, 2007; Jefferson et al., 2011; Hook et al., 2012; Kindy et al., 2012). The cleavage of APP by  $\beta$ -secretase generates two fragments: one extracellularly released soluble ectodomain (sAPP $\beta$ ) and one membrane-anchored fragment (C99). The subsequent  $\gamma$ -secretase processing of C99 results in the generation of A $\beta$  and the APP intracellular domain (AICD) (see Figure 2).  $\gamma$ -Secretase determines the C-terminal of A $\beta$  through sequential cleavage of C99, generating tri- and tetra-peptides from the C99 stub. There are two proposed alternative cleavage-pathways starting at the  $\epsilon$ -site that releases AICD and generates either A $\beta$ 48 or A $\beta$ 49. The subsequent shortening of A $\beta$ 48 and A $\beta$ 49 are made by carboxypeptidase-like  $\gamma$ -cleavages where A $\beta$ 49 are further processed to A $\beta$ 46>A $\beta$ 43>A $\beta$ 40, and A $\beta$ 48 gives rise to A $\beta$ 45>A $\beta$ 42>A $\beta$ 38 (Takami et al., 2009; Chavez-Gutierrez et al., 2012). The shortening of the long A $\beta$  decreases the hydrophobicity and increases the probability for it to be released from the membrane. It has been shown that the first cleavage at the  $\epsilon$ -site determines which of the two cleavage-pathways will be chosen *in vivo* (Funamoto et al., 2004). FAD mutations are thought to have already affected the  $\epsilon$ -site cleavage site, causing a shift towards the A $\beta$ 48 production lineage (Chavez-Gutierrez et al., 2012; Golde et al., 2012).



**Figure 2.** APP processing. APP is processed either by the amyloidogenic pathway by the  $\beta$ - and  $\gamma$ -secretases or by the non-amyloidogenic pathway by  $\alpha$ - and  $\gamma$ -secretases.  $\beta$ -secretase cleavage generates C99 that is further processed to A $\beta$  and AICD.  $\alpha$ -Secretase cleavage generates C83 which gives rise to p3 and AICD.

The non-amyloidogenic pathway involves cleavage by  $\alpha$ -secretase (ADAM10 and ADAM17), which belong to the zinc protease super family (Allinson et al., 2003; Vincent and Govitrapong, 2011) and by  $\gamma$ -secretases. The  $\alpha$ -secretase cleaves APP within its A $\beta$  peptide sequence, preventing its production, while generating a longer soluble ectodomain (sAPP $\alpha$ ) and one membrane-anchored fragment (C83). The subsequent  $\gamma$ -secretase processing of C83 results in the generation of p3 and the APP intracellular domain (AICD) (see Figure 2). The biological functions of the cleavage products are not fully known, but AICD is thought to translocate to the nucleus where it is involved in transcriptional regulation of different genes (e.g. APP, GSK-3 $\beta$ , KAI1, neprilysin, BACE1, EGFR and LRP1) including genes involved in apoptosis (p53) (Cao and Sudhof, 2004; Kerr and Small, 2005; Pardossi-Piquard et al., 2005; Zhang et al., 2011). AICD also modulates cellular calcium homeostasis and ATP content (Hamid et al., 2007). The physiological role of sAPP $\alpha$ , which differ by only 16 amino acids at its C-terminus as compared to sAPP $\beta$ , is purportedly neuroprotective and is far more potent in regulating neuronal activity (Barger and Mattson, 1996; Turner et al., 2003; Turner et al., 2007; Taylor et al., 2008). The products of the amyloidogenic pathway, sAPP $\beta$  and C99, have been proposed to possess opposite functions, that is, they activate cell death pathways and cause synaptic and memory deficits (Nikolaev et al., 2009; Tamayev et al., 2012). However, recently, both sAPP $\alpha$  and sAPP $\beta$  have been shown to regulate the proliferation and differentiation of neuronal precursor cells deriving from the subgranular zone of the rat hippocampus (Baratchi et al., 2012). Thus, today, the whole understanding of APP metabolites and their role in AD pathogenesis is lacking.

The fate of APP depends on trafficking within the cell. Sortilin-1, a newly discovered risk factor for AD, directs the trafficking of APP from the plasma membrane into the cell where it can be processed by BACE1, preferably in intracellular compartments (Rogaeva et al., 2007). BACE1 has been found along the secretory pathway including trans-Golgi network, endosomes and lysosomes and exhibit its highest activity at acidic pH (Cole and Vassar, 2007). In the brain, BACE1 is heavily expressed in axons and presynaptic terminals of the mossy fiber pathway as well as in the amygdala (Vassar et al., 2009). In sporadic AD patients, BACE1 expression level and activity have been found to be elevated (Yang et al., 2003). This elevation could in some cases be explained by a defect in a microRNA controlling BACE1 expression (Hebert et al., 2008). Apoptotic processes and A $\beta$  have also been suggested to elevate BACE1 expression levels (Xie et al., 2007; Sadleir and Vassar, 2012). BACE1-knockout mice exhibit

hypomyelination and altered neurological behaviors such as reduced grip strength and elevated pain sensitivity (Laird et al., 2005; Hu et al., 2006; Willem et al., 2006; Gersbacher et al., 2010). Inhibition of BACE causes side effects, including: schizophrenic symptoms, increased mortality, epileptic seizures, hyperactivity, anxiety and impaired axon guidance, probably due to the lack of cleavage of its other substrates including neuregulin 1, seizure-protein 6, L1, CHL1 and contactin-2 (Kuhn et al., 2012). The  $\alpha$ -secretase, apart from cleaving APP, is implicated in the control of cytokine and growth-factor shedding at the plasma membrane e.g. Notch, tumor necrosis factor- $\alpha$  and epidermal growth factor. This enzyme acts primarily at the plasma membrane where the cleavage of its substrates, including APP, takes place (Zhang et al., 2012). The  $\gamma$ -secretase complex will be discussed separately under the subheading “The  $\gamma$ -secretase complex”.


### **1.3.3 The amyloid $\beta$ -peptide ( $A\beta$ )**

In FAD, the mutations in APP, PS1 or PS2 are thought to increase the  $A\beta_{42}/A\beta_{40}$  ratio. In sporadic AD, several events have been shown to increase  $A\beta$  production, e.g. ROS production or decreased expression of  $A\beta$ -degrading enzymes, including insulin-degrading enzyme (IDE), neprilysin, cathepsin B and PreP (Miners et al., 2008; Alikhani et al., 2011; Leuner et al., 2012). The biophysical and biochemical properties of  $A\beta$  vary according to its length, the longer are more prone to aggregate. The two main forms are  $A\beta_{40}$  and  $A\beta_{42}$ , the latter of which is the main constituent of amyloid plaques. Also  $A\beta_{43}$  has been detected in plaques (McGowan et al., 2005; Welander et al., 2009). Despite the difference in only two and three amino acids,  $A\beta_{42}$  and  $A\beta_{43}$  are more hydrophobic and their aggregation potential is much higher than that of  $A\beta_{40}$ . Several research groups have demonstrated that the relative level of  $A\beta_{42}$  in relationship to  $A\beta_{40}$  is critical for the pathogenesis of the disease, suggesting a central role of  $A\beta_{42}$  in the development of AD. Even a minor increase in the  $A\beta_{42}/A\beta_{40}$  ratio induces formation of toxic oligomers, signifying that  $A\beta_{40}$ -monomers could prevent aggregation and toxicity of  $A\beta_{42}$  (Yan and Wang, 2007; Jan et al., 2008; Kuperstein et al., 2010). Studies even suggest that such minor changes of  $A\beta_{42}$  or  $A\beta_{43}$  might trigger a pathogenic cascade and drive the seeding of plaques (Masters and Selkoe, 2012). What drives the transition from normal  $A\beta$  production to a pathological state is not fully understood. The complexity of  $A\beta$  peptides has become greater still, with the identification of several other enzymatic processes that are involved in modifying the  $A\beta$  pool. For example,  $A\beta$  peptides can further be modified by aminopeptidase, glutaminylcyclase or isomerase, each generating N-terminally truncated peptides. Further modification by phosphorylation and pyroglutamate reactions result in a mix of more than 20  $A\beta$  variants (De Strooper, 2010; Portelius et al., 2011; Benilova et al., 2012). These might participate differently in normal brain or in oligomerization and fibrillization in AD-afflicted brain. The dominant hypothesis articulating of which  $A\beta$  species are most toxic points toward the soluble oligomers that exist between monomeric  $A\beta$  and the amyloid  $A\beta$  fibrils in the plaques. Whether the polymerization of  $A\beta$  occurs intracellularly or extracellularly is not clear. Some studies claim that it mainly occurs in intracellular compartments, in particular, endosomes or lysosomes, where the concentration of  $A\beta$ -peptides can be enriched and where the low pH has the capacity to promote the oligomerization. When these are later secreted they become potential seeds for extracellular plaques (Hu et al., 2009). Moreover,  $A\beta$  is mainly thought to exert its toxicity intracellularly. More evidence for this was recently found in a study of an autophagy-deficient mouse crossed with a tgAPP mouse. Deficiency in autophagy leads to intracellular  $A\beta$  accumulation and severe cognitive deficits. This finding implicates intracellular  $A\beta$  as being cytotoxic, thus accounting for its protective role as it, consequently, is secreted into extracellular space (Nilsson, Poster, AAIC, 2012, Vancouver, Canada).

The physiological role of A $\beta$  is not known, but since it normally is continuously and abundantly produced already from embryogenesis, it might not be associated only with neurotoxicity. For instance, A $\beta$  at low concentrations has been shown to be neuroprotective, enhancing the survival of neurons, and to have neurotrophic properties stimulating neuronal (A $\beta$ 40) or astrocytic (A $\beta$ 42) cell fate of primary neural progenitor cells (Chen and Dong, 2009; Giuffrida et al., 2009). Activity-dependent co-secretion of A $\beta$ , together with neurotransmitters, suggests that A $\beta$  acts as a modulator at the synapse. A $\beta$  depresses excitatory synaptic transmission inhibiting LTP. Therefore A $\beta$  might participate in negative feedback regulating neuronal activity (Hsieh et al., 2006; Hook et al., 2012). Such co-secretion has been found from dense core secretory vesicles containing a variety of neurotransmitters including catecholamine, dopamine, norepinephrine and neuropeptides (Hook et al., 2012). Furthermore, A $\beta$  may have a biological role in lipid metabolism, demonstrating a capacity to reduce synthesis of both cholesterol and sphingomyelin (Grimm et al., 2005). Thus, the production of A $\beta$  might be of physiological importance in the central nervous system. However, dysregulated production, impaired secretion from cells, intracellular accumulation or defective clearance from the brain probably play fundamental roles in the pathophysiology of AD.

### 1.3.4 The $\gamma$ -secretase complex

$\gamma$ -Secretase is a multi-protein complex consisting of at least four subunits: PS1 or PS2, Nicastrin, anterior pharynx defective-1 (Aph-1) and presenilin enhancer-2 (Pen-2) (see Figure 3).



**Figure 3.** Illustration of the  $\gamma$ -secretase complex. It consists of at least Pen2, PS, Nicastrin (Nct) and Aph-1. PS undergoes endoproteolysis generating a N-terminal fragment (NTF) and a C-terminal fragment (CTF). The CTF can later be cleaved by caspases in the large cytosolic loop. The active site in PS is shown by asterisks.

The assembly of the four subunits takes place within the endoplasmic reticulum (ER) where the  $\gamma$ -secretase complex remains until it is fully assembled (Capell et al., 2005). Membrane protein folding is carefully supervised by the quality control (consisting of e.g. chaperones) within the ER ensuring that misfolded proteins do not leave the ER. Initially, Aph-1 and Nicastrin are assembled together before the remaining components are added (Takasugi et al., 2003). The addition of Pen-2 is thought to result in a conformational change in Nicastrin that promotes endoproteolysis of presenilin (Takasugi et al., 2003). Presenilin undergoes endoproteolytic

cleavage in the large cytosolic loop (Ala299) generating N- and C-terminal fragments (NTF and CTF). The two fragments form a heterodimer within the  $\gamma$ -secretase complex harboring the two highly conserved aspartic acid residues, D257 and D385 in the six and seven transmembrane domains, which form the active site. PS is a multi-membrane-spanning protein with 9 transmembrane regions that, after endoproteolysis in the large cytosolic loop, are separated into NTF and CTF containing 6 and 3 transmembrane regions, respectively (see Figure 3). The CTF contains most of the large cytosolic loop, which is involved in regulating the enzymatic activity of the  $\gamma$ -secretase complex at the  $\gamma$ -cleavage site thereby adjusting A $\beta$  species formed (Deng et al., 2006). This can, for example, be seen in cell lines on a PS-deficient background, and in the absence of the entire loop in the PS1 $\Delta$ exon10 mouse model. These mice exhibit a great reduction of A $\beta$ 40, though A $\beta$ 42 level is unchanged, which is accompanied by exacerbation of plaque pathology (Deng et al., 2006; Wanngren et al., 2010). Allosteric changes in PS1 conformation have been shown to underlie changes in the A $\beta$ 42/A $\beta$ 40 ratio (Uemura et al., 2009). This is the case for the FAD mutations in PS1, which cause closer conformation of the  $\gamma$ -secretase complex, favoring the A $\beta$ 42 production lineage (Uemura et al., 2009). Caspases can cleave PS1 in the CTF-part at Asp333 and Asp345, generating a ~12 kDa C-terminal fragment that is missing a large part of the loop domain (Kim et al., 1997; Grunberg et al., 1998). In our laboratory, it has previously been shown that caspase-cleaved PS1CTF (caspCTF), despite the truncation in the large cytosolic loop, forms active  $\gamma$ -secretase complexes in cells exposed to apoptotic stimuli (Hansson et al., 2006). As we show in **Paper I**, this truncation increases the intracellular A $\beta$ 42/A $\beta$ 40 ratio and could, therefore, partly account for the elevated A $\beta$  production seen during caspase activation. This finding is further discussed in the section “Results and Discussion”. Animal studies have shown that PS1 is essential for embryonic development. PS1 double-knockout is lethal compared to PS2 double-knockout mice that are phenotypically normal (Donoviel et al., 1999; Handler et al., 2000). Furthermore, mice lacking both PS1 and PS2 in the postnatal forebrain exhibit reduced long-term memory formation and shortened neuronal survival, inducing neurodegeneration and memory loss, whereas, mouse models overexpressing A $\beta$  have failed to produce the characteristic AD phenotype (Saura et al., 2005; Shen and Kelleher, 2007).

$\gamma$ -Secretase is thought to work as an aspartyl-protease with its catalytic activity located inside the lipid bilayer through a process called regulated intramembrane proteolysis (RIP) (Selkoe and Kopan, 2003). The activity of the  $\gamma$ -secretase complex can be modulated by interacting proteins, for example, CD147, TMP21, GPR3 and  $\gamma$ -secretase activating protein (GSAP), which are suggested to thereby regulate A $\beta$  production (Zhou et al., 2005; Chen et al., 2006; Thathiah et al., 2009; He et al., 2010). New proteins that modulate the  $\gamma$ -secretase activity are identified frequently. For instance, two mitochondrial proteins that associate with the  $\gamma$ -secretase and affect A $\beta$  production have recently been reported, including NADH dehydrogenase (ubiquinone) iron-sulfur protein 7 (NDUFS7) and voltage-dependent anion-selective channel (VDAC1) (Frykman et al., 2012; Hur et al., 2012). NDUFS7 is the core subunit of complex I in the electron transport chain in the inner mitochondrial membrane and VDAC1 is an ion channel located at the outer mitochondrial membrane. Another is Erlin-2, which resides in lipid raft like regions on ER (Teranishi et al., 2012).

The  $\gamma$ -secretase complex cleaves type 1 transmembrane proteins. New substrates for the  $\gamma$ -secretase complex are frequently being discovered. To date, more than 90 have been described, including Notch (signaling receptor cell, fate decisions during embryonic development, neuritic growth), CD44 (cell adhesion), E/N-cadherin (cell adhesion), p75<sup>NTR</sup> (neurotrophin co-

receptor), ErbB-4 (growth-factor-dependent receptor tyrosine kinase), and insulin receptor (glucose metabolism), to name a few (Lleo and Saura, 2011).

The  $\gamma$ -secretase complexes are described as being localized in various compartments of the cell, including: ER/Golgi (De Strooper et al., 1997), nuclear envelope (Kimura et al., 2001), endosomes (Vetrivel et al., 2004), lysosomes (Pasternak et al., 2003), mitochondria (Hansson et al., 2004), plasma membrane (Tarassishin et al., 2004), synaptic vesicles (Frykman et al., 2010) and intercellular contacts known as adherens junctions (Marambaud et al., 2002).  $\gamma$ -Secretase activity is enriched in lipid rafts, which are specialized regions in cellular membranes situated in plasma membrane or intracellular compartments such as the mitochondria-associated ER membrane (MAM) (Urano et al., 2005; Hur et al., 2008; Area-Gomez et al., 2009). Interestingly, one recent study implies that the  $\gamma$ -secretase complex has its highest activity at MAM (Area-Gomez et al., 2009), a highly specialized subregion in ER that enables close contact with the mitochondria. MAM will be discussed separately under the subheading “Mitochondria-associated ER membrane”.

Therapeutics aimed at inhibiting  $\gamma$ -secretase activity have been associated with severe side effects, probably due to suppression of cleavage of the other substrates, especially Notch. Therefore,  $\gamma$ -secretase modulators (GSMs) that selectively reduce A $\beta$  production without affecting the other substrates are potentially safer, leading this class to currently be investigated (Tomita, 2009). The GSMs exert their mode of action by binding to either APP or the subunits of the  $\gamma$ -secretase complex, while PS is thought to be the primary target (Jumpertz et al., 2012).

Some researchers postulate that PSs possess other functions apart from being a component in the  $\gamma$ -secretase complex, including regulating calcium homeostasis, autophagy and neurotransmitter release (Zhang et al., 2009; Lee et al., 2010; Zhang et al., 2010). FAD mutations in PS result in deranged calcium signaling and several reports have indicated that associated neuronal calcium disruptions are early events in AD pathogenesis. Studies of fibroblasts lend support to this description, showing that abnormally high amounts of calcium are detected upon inositol-1,4,5-triphosphate (IP<sub>3</sub>) stimulation (Ito et al., 1994). Similar results were obtained in studies on cortical and hippocampal neurons from PS FAD mutant knock-in mice (Chan et al., 2000). Several explanations to this phenomenon have been postulated, including that PS affects various calcium channels (e.g. ryanodine receptors, IP<sub>3</sub>R and SERCA pump) and/or functions as a passive ER calcium leak channel controlling the steady state of calcium in ER (Tu et al., 2006; Zhang et al., 2010). In the case of FAD mutations in PS, these functions are disrupted and the loss of such leak function has been postulated to cause ER calcium overload (Zhang et al., 2010). Furthermore, a new function of PS2 has been described that involves regulating ER-to-mitochondria calcium fluxes at the MAM (Zampese et al., 2011).

In autophagy, PS has a fundamental role in targeting v-ATPase to lysosomes, promoting lysosomal acidification and proteolysis during autophagy (Lee et al., 2010). Autophagy is needed for proper degradation of proteins and organelles including the mitochondria. Defective lysosomal proteolysis causes pathogenic protein accumulation and defective mitochondrial turnover, which, indeed, could be implicated in AD pathogenesis. Moreover, defective autophagy has been associated with increased PS expression and  $\gamma$ -secretase activity (Ohta et al., 2010). Thus, it might be important to consider other biological roles of both PS and APP




apart from their involvement in A $\beta$  generation in order to understand the disease mechanisms behind both FAD and sporadic AD.

## 1.4 MITOCHONDRIA

### 1.4.1 Mitochondria: more than just a powerhouse

Mitochondria are cytoplasmic organelles originating from invading bacteria 1.5 billion years ago (Wallace, 1982). Some features remain reflecting this origin like double-membrane structures and a circular genome with mitochondrial-specific transcription, translation and protein assembly systems. To adapt to its new environment the mitochondria has reduced its genome to about 16 500 bp encoding 13 polypeptide, 2 mRNA and 22 tRNA genes. Thus, several essential mitochondrial genes have been transferred to the nucleus and approximately 1000 proteins are translated by free ribosomes in the cytosol and then imported into the mitochondria (Schatz, 1996).



**Figure 4.** Overview of mitochondria and oxidative phosphorylation. (A) Glucose is metabolized via glycolysis to pyruvate, which enters the mitochondria and converts into Acetyl-CoA, which is used for driving the tricarboxylic acid cycle (TCA) and, subsequently, oxidative phosphorylation (OXPHOS) where ATP is produced. OMM (outer mitochondrial membrane), IMS (intermembrane space) IMM (inner mitochondrial membrane). (B) OXPHOS is conducted by the electron transport chain. The transfer of electron from the donors (NADH and succinate) to the acceptor (O<sub>2</sub>) is coupled to proton transfer producing the electrochemical potential, which is used in complex V to produce ATP.

The import machinery consists of TOM and TIM complexes forming pores in the outer mitochondrial membrane (OMM) and inner mitochondrial membrane (IMM), respectively. The OMM is highly permeable to low-molecular-weight substances. While the IMM provides a barrier through which ions have to be actively transported via specific channels. The IMM houses the electron transport chain complexes (complex I-IV and the ATP synthase) responsible for ATP production via oxidative phosphorylation (OXPHOS) (see Figure 4A). At complex I, III and IV, protons are pumped across the IMM into the intermembrane space (IMS) creating the mitochondrial membrane potential ( $\Delta\Psi_m$ ). This electrochemical gradient is crucial for maintaining cellular viability since OXPHOS rely on the energy content of it (see Figure 4B). The brain accounts for only 2% of the body mass but is responsible for 20% of the oxygen consumption via OXPHOS (Papa, 1996). The matrix of mitochondria, house enzymes in the tricarboxylic acid cycle (TCA) and enzymes used to conduct beta-oxidation.

Mitochondria form highly dynamic tubules that continuously fuse and divide so as to control correct distribution, morphology and quality of the mitochondrial pool. The central components that mediate mitochondrial dynamics are the fusion proteins: mitofusin1, mitofusin 2 (Mfn1 and Mfn2) and optic atrophy type 1 (Opa1) and the fission protein, dynamin related protein 1 (Drp1) (Chan, 2006). As described above, mitochondria are key regulators of cell survival and death. Dysfunction of mitochondria leads to insufficient energy metabolism, reduced ATP production, impaired calcium buffering and increased generation of reactive oxygen species (ROS) (Beal, 2005). Neurons are metabolically active cells that consume a lot of energy at locations distant from the cell body. As a result, these cells are particularly dependent on mitochondrial function for energy conversion. Normally, cells contain a mix of healthy and defect mitochondria (heteroplasmy). As we age, the mitochondria pool weakens mainly due to oxidative insult to proteins, lipids and nucleic acids, which is also implicated in driving the aging process (Muller et al., 2010). Mitochondrial turnover via autophagy and fusion/fission is of great importance as this serves to maintain a healthy cellular pool of mitochondria, especially in post mitotic cells like neurons, where the mitochondrial pool cannot be renewed and limited replacement of damaged cells occur. Since aging is the main risk factor for sporadic AD and mitochondrial dysfunction is implicated in the aging process a role of mitochondria in sporadic AD has been suggested (Reddy, 2007).

#### **1.4.2 Mitochondrial dysfunction in neurons**

Several lines of evidence implicate that A $\beta$  exerts its toxicity intracellularly (Wilson et al., 1999; Gouras et al., 2000; Wirths et al., 2004; Aoki et al., 2008) and mitochondria are suspected to have a role in it. Neurons are vulnerable to oxidative insult since they have a high rate of energy and oxygen utilization, poor concentration of classical antioxidants, high levels of redox-active metals and high content of polyunsaturated lipids. Damage to mitochondria in neurons is detrimental since there is limited or no regeneration/replacement capacity of neurons in the brain. Mitochondria are the major source and target of oxidative stress. Reactive oxidative species (ROS) is produced during OXPHOS when electrons passing through the electron transport chain and some electrons leak out at complex I and complex III. These can react with oxygen and yield superoxide anions ( $O_2^-$ ), which then can be converted to hydrogen peroxide ( $H_2O_2$ ) by superoxide dismutase (SOD). The presence of  $Fe^{2+}$  accelerates the decomposition of  $H_2O_2$  to hydroxyl radicals ( $\cdot OH$ ), and nitric oxide ( $NO\cdot$ ) reacts with  $\cdot O_2^-$  to produce peroxynitrite (ONOO $\cdot$ ). The mitochondria are particularly susceptible to oxidative damage. Mitochondrial DNA has a mutation rate estimated to be 10 to 20 times higher than that of nuclear DNA. This sensitivity is due to the lack of protective histones and limited, available repair mechanisms (Brown et al., 1979). For protection, IMM incorporates a number of free radical scavengers, such as vitamin E, ascorbate, catalase and glutathione. There is also enzymatic removal of free radicals by manganese superoxide dismutase (MnSOD) in the mitochondria and by SOD in the cytoplasm. All 13 genes coding for proteins in the mitochondrial genome are essential for execution of normal OXPHOS (Manczak et al., 2005). Complex I is especially susceptible to the aging process since 7 of the 13 genes encoded in the mitochondrial genome code for subunits belonging to complex I. Therefore, complex I deficiency is commonly observed during aging and can trigger neurodegeneration (Abramov et al., 2010). Interestingly, recently, deficiency of complex I and III accompanied with ROS production was shown to be sufficient to induce increased production of A $\beta$ , which in turn triggered a vicious cycle of mitochondrial dysfunction more ROS and A $\beta$  production (Leuner et al., 2012). The triggering event for altered APP processing in sporadic AD is unknown; though hypothetically, this vicious cycle might explain some of the events leading to elevated A $\beta$

production. This is supported by other studies that found that H<sub>2</sub>O<sub>2</sub> and ROS elevate A $\beta$  levels in cells and mouse models (Sun et al., 2006). Several recent findings show that mitochondrial dysfunction is one of the earliest events in AD (Hauptmann et al., 2009; Rhein et al., 2009; Du et al., 2010). A $\beta$  has been detected inside mitochondria in postmortem AD brains, in transgenic mice overexpressing mutant APP and in human brain biopsies from patients with amyloidosis, as well as in neurons exposed to fluorescent A $\beta$  *in vitro* (Lustbader et al., 2004; Caspersen et al., 2005; Hansson Petersen et al., 2008). As described earlier, cognitively intact individuals with profound accumulation of plaques and tangles in their brains could be discriminated from individuals with AD based on absence of A $\beta$  accumulation in their mitochondria (Tagliavola, Poster, AAIC, 2012, Vancouver, Canada).


Early in the pathogenesis, a reduced number of mitochondria is observed in affected neurons (Hirai et al., 2001), brain glucose metabolism is decreased (Mosconi, 2005), the activities of both tricarboxylic acid (TCA) cycle enzymes (Bubber et al., 2005) and cytochrome c oxidase are reduced (Parker et al., 1990; Kish et al., 1992; Parker and Parks, 1995; Cardoso et al., 2004) and mitochondrial gene expression is upregulated perhaps as a compensatory mechanism (Reddy et al., 2004). Furthermore, maternal family history of AD predisposes to reduced brain glucose metabolism (Mosconi et al., 2007). Mitochondrial A $\beta$  accumulation has been shown to occur prior to plaque formation in tgAPP mice, indicating that this is an early event in AD's pathogenesis (Caspersen et al., 2005). Recent findings imply that protein modifications, including carbonyl, 3-nitrotyrosin, 4-hydroxy nonenal (HNE), and S-glutathionyl, could regulate the activity of the metabolic enzymes. Many of these modifications result in significant inhibition of enzyme activity and, therefore, are likely to be involved in the dysregulation of metabolic pathways in AD (Hedskog et al., 2012). Neurons can utilize glucose, lactate, and ketone bodies as energy sources (Izumi et al., 1998; Suzuki et al., 2011). OXPHOS is the main pathway used for energy production in the brain since 15 times more energy is produced from respiration as compared to glycolysis. Cellular energy production is highly regulated. The activities of glycolysis, TCA, and respiration are integrated via feedback, including inhibitory, via ATP (Pasteur effect) and citrate controlling the rate of glycolysis. From the blood, glucose is transported over the BBB (endothelial cells and astrocytes) via GLUT1 transporter and subsequently transported into neurons via GLUT3. During hypometabolism (as is the case in AD brain), the brain cells compensate by increasing the activity of glycolytic proteins, called the Warburg effect, to override transient energy deficits and hypoxic environment (Hedskog et al., 2012). Recently, neuronal cells that utilize the Warburg effect were shown to be resistant to A $\beta$  toxicity (Newington et al., 2011). Although, recent data from Suzuki and colleagues show that glycolysis is not enough for neuronal viability and survival in the long run (Suzuki et al., 2011). This study emphasizes the importance of lactate in synaptic plasticity. Lactate is produced by astrocytes (from glucose or glycogen metabolism) and transported to the neurons via monocarboxylate transporters. The inhibition of these channels, either on the astrocyte or neuronal side, causes impairment of LTP, substantiating the importance of a functional oxidative metabolism for neuronal plasticity (Suzuki et al., 2011). It is possible that the shift from OXPHOS to glycolysis that occurs in AD neurons can temporally provide enough ATP to sustain neuronal function. However, for the formation of LTP and other energy demanding processes a decreased glucose uptake in AD brain in combination with dysfunctional mitochondria may eventually result in synaptic failure and neuronal loss.

Abnormal mitochondrial structure (Baloyannis, 2006) and impaired balance of mitochondrial fusion and fission are found in the AD brain and in AD-animal models (Knott et al., 2008; Wang et al., 2009; Trushina et al., 2012). Exposure of neuronal cells in culture to conditioned

medium from cells stably expressing mutant forms of APP, or exposure to synthetic A $\beta$ , induces mitochondrial fragmentation and abnormal distribution, which results in mitochondrial fission, loss of dendritic spines, and eventually cell death (Rui et al., 2006; Wang et al., 2008). Also, autophagic degradation of mitochondria may be dysfunctional in AD. Lysosomal proteolysis and autophagy require PS1, and AD-related PS1 mutations disrupt this degradation pathway (Lee et al., 2010). Despite the evident alteration in mitochondrial dynamics and metabolism in AD, the underlying mechanisms are unclear. It could result from environmental toxin, A $\beta$  accumulation or acquired or inherited nuclear DNA and mtDNA mutations.

### 1.4.3 A $\beta$ inside the mitochondria

Inside mitochondria, A $\beta$  could interact with several proteins including complex IV in the electron transport chain (Rhein et al., 2009), A $\beta$ -binding alcohol dehydrogenase (ABAD) (Lustbader et al., 2004), cyclophilin D (CypD) (Du et al., 2008) and the mitochondrial DNA base excision repair (BER) system (Tagliavolterra, Poster, AAIC, 2012, Vancouver, Canada) (see Figure 5).



**Figure 5.** Illustration of A $\beta$  inside the mitochondria. Inside the mitochondria A $\beta$  can cause damage through interactions to various proteins including the mtDNA repair system (BER), complex IV in the electron transport chain (ETC), ABAD, and cypD causing PTP opening.

The binding to complex IV impairs OXPHOS and thereby the energy production, reducing the formation of ATP. ABAD is localized to the mitochondrial matrix and belongs to the short chain dehydrogenase reductase family. It has an essential physiological role in the metabolism of e.g. n-isopropanol,  $\beta$ -estradiol and keton body  $\alpha$ -3-hydroxybutyrate and its activity is important to protect against metabolic stresses caused by, for example, ischemia (Du Yan et al., 2000). Inactivation of its counterpart (scully) in *Drosophila* results in a lethal phenotype with multiple developmental abnormalities. The binding of A $\beta$  to ABAD is thought to disturb its normal function and cause mitochondrial dysfunction, increased ROS production and cell death (Takuma et al., 2005b). Inhibition of the interaction between A $\beta$  and ABAD improves mitochondrial function in a mouse model of AD (Yao et al., 2011). A $\beta$  interacts with CypD, a mitochondrial matrix protein that associates with the inner membrane during the opening of the mitochondrial permeability transition pore (PTP) (Du et al., 2008). Cortical mitochondria from CypD-deficient mice are resistant to A $\beta$ - and calcium-induced mitochondrial swelling and permeability transition. Moreover, Tg mAPP/CypD-null mice exhibit improved learning and memory and synaptic function both in 12- and 24-month-old animals (Du et al., 2008; Du et al., 2011). Inside the mitochondria, presequence protease (PreP), could degrade A $\beta$  (Falkevall et al., 2006). PreP can degrade A $\beta$ 40 and A $\beta$ 42, as well as A $\beta$  Arctic protein (E22G) at unique cleavage sites, including several sites in the hydrophobic C-terminal A $\beta$  segment that is prone to aggregate. Interestingly, PreP is an organellar functional analogue to the human insulin-

degrading enzyme (IDE). The importance of PreP in AD was recently further emphasized in reports that its activity was decreased in AD brain (Falkevall et al., 2006). The presence of A $\beta$  in mitochondria indicates that it is produced inside mitochondria or taken up from the outside, or both. Most likely, it is taken up from outside, despite finding that both APP (Anandatheerthavarada et al., 2003) and  $\gamma$ -secretase complexes (Hansson et al., 2004) are detected in the mitochondria (Pavlov et al., 2011). Our laboratory has shown that A $\beta$  is imported via the common mitochondrial import pore and thereafter localized to mitochondrial cristae (Hansson Petersen et al., 2008). APP, on the other hand, accumulates in the import pore of AD brain mitochondria, after the import having been arrested due to the acidic sequence described above (see the subheading “Amyloid precursor protein”). A consequence of TOM blockage is dysfunctional import of nuclear encoded proteins important for respiratory chain activity (Devi et al., 2006). Therefore, both A $\beta$  and APP in the mitochondria cause mitochondrial abnormalities, which could result in synapse loss, which are the most robust correlates of AD-associated cognitive deficits (Terry, 2000; Selkoe, 2002). Interestingly, Roses and colleagues recently found that a polymorphic poly-T variant in the *TOMM40* gene could be used to estimate age-of-onset for late-onset AD (LOAD) in ApoE  $\epsilon$ 3 carriers (Roses et al., 2009). ApoE  $\epsilon$ 3/4 carriers with long poly-T repeats linked to ApoE  $\epsilon$ 3 had an age of onset 7 years earlier than individuals with shorter repeats. Whether the long poly-T repeat resulted in a modified TOM40 protein was unknown and needed investigation. In **Paper II**, we investigated this in fibroblast cells from ApoE  $\epsilon$ 3/4 carriers. However, we could not identify any deficits in mitochondrial functioning or morphology. This will be further discussed in the “Results and Discussion” section.

## **1.5 MITOCHONDRIA-ASSOCIATED ER MEMBRANE (MAM)**


### **1.5.1 Distribution of mitochondria and ER in neurons**

In highly polarized cells such as neurons, bidirectional transport of various cargoes is of great importance. The dynamics have been observed for a variety of different organelles and vesicles including mitochondria, endosomes, proteosomes, lysosomes, peroxisomes, lipid droplets, secretory vesicles, viruses and intermediate filaments (Collins et al., 2002; Welte, 2004). In a neuron, mitochondria are transported and accumulate where the need for ATP production is especially high. Mitochondrial distribution efficiency is essential for neuronal development and survival. To maintain local energy and meet metabolic demand in all cellular regions, bidirectional motion along the microtubules is governed by growth factor signaling (e.g. NGF) and phosphatidyl-inositol (Chada and Hollenbeck, 2003; De Vos et al., 2003). The neuronal mitochondrial pool is heterogeneous and different properties of isolated synaptic and non-synaptic cortical mitochondria have been described, for example are the synaptic mitochondria more susceptible to calcium overload (Brown et al., 2006). Also the ER moves along the microtubules as both continuous networks and vesicular compartments (Waterman-Storer and Salmon, 1998; Bannai et al., 2004). The ER is a multifunctional organelle involved in protein folding and assembly, disulfide bond formation and calcium storage and to fulfill its many functions, the ER consists of specialized sub regions (Sitia and Meldolesi, 1992). At distal regions of the neurons, in for example spines, ER and mitochondria regulate calcium transients and, thereby, synaptic transmission (Pivovarova et al., 2002). Correct calcium handling by the two organelles and the calcium signaling between them is controlled by microtubules (Mironov et al., 2005). The interaction between ER and mitochondria in the synapse has been postulated to shape intracellular calcium signals and modulate synaptic and integrative neuronal activities (Mironov and Symonchuk, 2006). The specialized region of ER responsible for this interaction

is called the mitochondria-associated ER membrane (MAM) (Rizzuto et al., 1998; Csordas et al., 2006; Hayashi et al., 2009). Extensive investigation of the ER-mitochondrial interplay has been performed in yeast; however, limited research has been conducted on this interaction in cells of the brain. This will further be discussed in the next paragraph.

### 1.5.2 MAM the control station

Mitochondria and ER, important modulators of several pathways, are connected at specific contact points at a highly specialized region of ER called the mitochondria-associated ER membrane (MAM). At these points the metabolism of glucose, phospholipids, fatty acids, and cholesterol, as well as calcium homeostasis and apoptosis is regulated (Hayashi et al., 2009), (Simmen et al., 2005). Defective processes here could account for abnormalities routinely detected in AD patients, including: elevated cholesterol (Stefani and Liguri, 2009), altered fatty acid (Martin et al.), glucose (Hoyer et al., 1988), phospholipid (Pettegrew et al., 2001) metabolism, and abnormal calcium homeostasis (Bezprozvanny and Mattson, 2008). To date, more than two dozen proteins have been found to be concentrated in MAM (Area-Gomez et al., 2009) including proteins involved in calcium homeostasis (e.g. inositol triphosphate receptor isoform 3 [IP3R3] and Sigma non-opioid intracellular receptor 1 [Sigma1R]), in lipid metabolism (e.g. fatty acid co-A ligase 4 [FACL4] and phosphatidylserin synthase 1 [PSS1]), in intermediate metabolism (e.g. glucose-6-phosphatase), in cholesterol metabolism (e.g. acyl-coenzyme A: cholesterol acyltransferase 1 [ACAT]), and in apoptosis regulation (phosphofurin acidic cluster sorting protein 2 [PACS2]) (Rusinol et al., 1994; Hayashi et al., 2009) (see Figure 6). Increased ER-mitochondrial coupling has been shown to promote mitochondrial respiration and bioenergetics during early phases of ER stress (Bravo et al., 2011).



**Figure 6.** Illustration of signal transduction and metabolism at the MAM region. PACS2 can translocate tBid to the mitochondria and thereby induce cell death. Calcium is transported from ER to mitochondria via IP3R3-grp75-VDAC1 complex. Sigma1R (Sig1R) that normally is bound to BiP regulates the IP3R3 channel. Inside the mitochondria calcium activates enzymes in the TCA cycle leading to enhanced ATP production. Calcium can be transported back to MAM and at MAM be bound to chaperones, e.g. calnexin (CNX), calreticulin (CRT) and Bip. The phospholipid, phosphatidylserine, produced by PSS1 in MAM is transported over to the mitochondria to be converted to phosphatidylethanolamine (PtdEtn), which either is used for cardiolipin synthesis or transported back to MAM for conversion into phosphatidylcholine. Cholesterol is produced in ER and for the synthesis of steroids and neurosteroids, cholesterol is transported to the mitochondria for the conversion to pregnenolone (Preg), which then is transported back for the synthesis of progesterone (Prog). Since the  $\gamma$ -secretase complex has been postulated to exhibit high activity at MAM we speculate that at these tight ER-mitochondria contact points, A $\beta$  is transported over and into the mitochondria.

### **1.5.3 MAM is connected to the mitochondria by tethering complex/es**

The MAM region has been extensively studied in yeast. In this organism MAM is, apart from the above-mentioned processes, also involved in coordinating mitochondrial DNA replication, growth, protein import and maintenance of proper tubular morphology of mitochondria (Kornmann et al., 2009). Moreover, the tethering complex that couples ER to mitochondria has been described and is composed four proteins (Mmm1, Mdm12, Mdm10 and Mdm34). This complex is called the ER-mitochondria encounter structure (ERMES) (Kornmann et al., 2009). Disruption of ERMES impairs phospholipid exchange between ER and mitochondria since the enzymes responsible are located at either the MAM or the mitochondrial side. Recently, another study performed in yeast showed that proteins involved in shaping ER (called lastins in mammals) also play a role in maintaining functional contacts (Voss et al., 2012). Little is known about MAM in mammals and no homologues for ERMES components have yet been found. Several proteins have been suggested to participate in ER-mitochondrial bridging including IP3R, VDAC, grp75, Sigma1R, PACS2 and Mfn2 (Hayashi et al., 2009).

### **1.5.4 MAM regulates apoptosis**

The ER-mitochondrial interface regulates apoptosis by several pathways, including calcium control and Bid translocation by PACS2 (Grimm, 2012). PACS2 is a multifunctional sorting protein that controls ER-mitochondrial communication, membrane traffic and apoptosis (Youker et al., 2009). PACS2 KO by RNAi causes loss of MAM-mitochondrial coupling and mitochondrial fragmentation (Simmen et al., 2005). In response to apoptotic stimuli, PACS2 binds dephosphorylated Bid and traffics Bid to mitochondria where Bid is cleaved into its active form, truncated Bid (tBid) (Simmen et al., 2005). At the mitochondria, tBid interacts with Bax, promoting its insertion and oligomerization causing membrane permeabilization and the release of apoptotic molecules (see Figure 1 and Figure 6).

### **1.5.5 MAM controls calcium homeostasis**

Calcium is a highly versatile second messenger that controls critical cellular responses, and which requires tight regulation, especially at the synapse where spatio-temporal patterning of calcium signaling is important for proper transmission. Calcium is essential for the enzymatic activity of many metabolic pathways in the mitochondria. However, excessive amounts can cause calcium overload accompanied by opening of the PTP pore enabling release of apoptotic mediators. Many proteins at MAM control the shuttle of calcium, thereby regulating the metabolic state of the mitochondria. The ATP produced provides energy for the SERCA pump to reload ER with calcium. Calcium is transported into the mitochondria via IP3R3 located at the ER side and the voltage-dependent anion channel (VDAC1) in the OMM (see Figure 6). This calcium signaling regulates mitochondrial metabolic activity since several enzymes in the TCA, require calcium to be active. One protein thought to regulate calcium transport is Sigma1R, which normally binds to the calcium binding chaperone, BiP; and, upon activation after ligand binding or by decreased luminal calcium concentration, BiP and Sigma1R, dissociates and Sigma1R becomes active. The upregulation and redistribution of Sigma1R after ER stress mediates cell protection against apoptosis. Sigma1R has been shown to interact with various ion channels and Ankyrin B (Hayashi and Su, 2001; Maurice and Su, 2009). Recently, Sigma1R has been shown to regulate ER-to-mitochondria calcium fluxes by stabilizing the IP3R3 channel by preventing degradation by the ubiquitin-proteasome system (Hayashi and Su, 2007). IP3R3 is also regulated by anti-apoptotic factors (e.g. Bcl-2), the interaction by which is thought to prevent mitochondrial calcium overload (Hayashi and Su, 2007).

### 1.5.6 The role of Sigma1R at MAM

Sigma1R has, apart from being involved in calcium signaling, been described as a unique ligand-regulated molecular chaperone, involved in the activity of several neurotransmitter systems (especially cholinergic and glutamatergic pathways), cell survival (Bcl-2 expression), learning processes, memory, mood alteration and regulation of hippocampal dendritic spine formation (Hayashi and Su, 2007; Tsai et al., 2009; Meunier and Hayashi, 2010; van Waarde et al., 2011). It is strongly expressed in both neurons and glia (Hayashi and Su, 2005). The intracellular localization of Sigma1R is mainly in lipid rafts in ER (i.e. MAM) but also nuclear, plasma membrane and mitochondrial localization has been described (Klouz et al., 2002; van Waarde et al., 2011). Sigma1R was first mischaracterized as an opioid receptor but later identified as a unique ligand-regulated molecular chaperone acting primarily at the MAM (Su et al., 1988; Hayashi and Su, 2003; Hayashi and Su, 2007). It has high affinity for diverse classes of psychotropic drugs (e.g. psychotomimetic drugs and neuroleptics), and has been proposed to play a role in a variety of diseases, including addiction, amnesia, pain, depression and stroke (Maurice and Su, 2009). To date, no endogenous ligands have been verified, however, neurosteroids, the hallucinogen, N,N-Dimethyltryptamine (DMT), and shingolipids have been suggested as agonists, and progesterone suggested as an antagonist (Fontanilla et al., 2009; Ramachandran et al., 2009; Johannessen et al., 2011). Activation of Sigma1R has been associated with anti-amnesic and neuroprotective effects and has been shown to protect against various pathological conditions including delirium in AD patients, ischemia, diabetes, inflammation, as well as A $\beta$  toxicity (Marrazzo et al., 2005; Meunier et al., 2006; Furuse and Hashimoto, 2010; Ruscher et al., 2011). This will be discussed more in detail under the subheading “Treatment strategies”.

### 1.5.7 MAM regulates lipid synthesis

Enzymes in phospholipid and cholesterol synthesis pathways are localized on the MAM side and the mitochondrial side, calling for close contact between MAM and mitochondria for proper synthesis. Phospholipid biosynthesis is carried out as follows; phosphatidylserine synthase (PSS1) is located at MAM and catalyzes the formation of phosphatidylserine (PtdSer) from serine, which is transported into the mitochondria where it is converted to phosphatidylethanolamine (PtdEth) by phosphatidylserine decarboxylase. This intermediate is either used in the mitochondria to form cardiolipin or transported back to MAM for the conversion into phosphatidylcholine (major component of biological membranes) by the phosphatidylethanolamine methyltransferase-2 located in MAM (Hayashi et al., 2009) (see Figure 6). A reduced rate of lipid exchange, in turn, slows down aminoglycerophospholipid turnover, resulting in impaired cardiolipin synthesis accompanied by decreased mitochondrial membrane maintenance. Synthesis of steroids also depends on shuttling between ER and mitochondria since cholesterol, after its synthesis in ER, is transported to mitochondria for the catalyzed reaction by the cholesterol side-chain cleavage enzyme, forming pregnenolone, which then is transported back to ER for the synthesis of progesterone and several other steroids and neurosteroids (e.g. allopregnenolone, dehydroepiandrosterone) (Baulieu et al., 2001). Mounting evidence also indicates that localized in MAM are enzymes involved in ceramide and sphingolipid metabolism (Rusinol et al., 1994; Bionda et al., 2004).

In AD, a reduction in phosphatidylethanolamine (Pettegrew et al., 2001) and alterations in cholesterol metabolism have been detected (Stefani and Liguri, 2009)). The deranged biosynthesis of cholesterol in ER is thought caused by e.g. Seladin-1 downregulation. This in turn lowers the level of cholesterol in lipid rafts, which has been associated with increased A $\beta$  production signifying the importance of functional cholesterol biosynthesis (Bionda et al.,



2004). This is further supported by the finding that the neurosteroid, allopregnenolone, is reduced in the prefrontal cortex of AD patients (Marx et al., 2006). Interestingly, treatment with allopregnanolone reverses cognitive deficits in a triple transgenic mouse model of AD (Marx et al., 2006). Moreover, variations in plasma levels of sphingomyelins and ceramides are early predictor of memory impairment (Mielke et al., 2010). Thus, abnormal lipid metabolism in the brain could impair membrane lipid homeostasis, membrane repair and steroid signaling, and ultimately result in deteriorating synapses and neuronal networks.

### **1.5.8 Can A $\beta$ be transported into the mitochondria from MAM?**

Interestingly, both APP and the  $\gamma$ -secretase complex are enriched in MAM in mouse brain. Furthermore,  $\gamma$ -secretase has been demonstrated to exert its highest activity at MAM (Area-Gomez et al., 2009). This suggests that A $\beta$  might be produced in MAM where the close proximity to the mitochondria might enable A $\beta$  translocation into the mitochondria, and consequently cause damage (see Figure 6). Thus, we believe that MAM harbors important clues for understanding AD-pathophysiology.

## **1.6 TREATMENT STRATEGIES**

To date, as described above, there are two classes of drugs approved to treat AD, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonist (memantine). These drugs provide symptomatic relief but are weak agents modifying the disease pathophysiological process. Lately much effort has been made to find disease-modifying drugs that are targeted to reduce A $\beta$  production ( $\gamma$ -secretase inhibitors/modulators, BACE1 inhibitors), prevent its aggregation or promote its clearance (active/passive immunization); or to affect tau phosphorylation and assembly. Unfortunately, none of these drugs have demonstrated efficacy in Phase III clinical trials. The failures of these clinical trials have raised a number of questions, from who to include in a clinical trial, to questions about our understanding of AD pathophysiology and biology. Hence, AD is increasingly considered as a heterogeneous and multifactorial disease that needs to be treated early with drugs covering multiple targets, the mitochondrion being one of them (Ankarcrona et al., 2010; Mielke et al., 2010). We believe that therapeutic interventions that affect the MAM region or the mitochondria could restore healthy regulation of glucose and lipid metabolism, calcium homeostasis and cell death signaling, each of which is evidently disturbed in AD.

### **1.6.1 Targeting MAM dysfunction**

#### *1.6.1.1 Targeting lipid metabolism*

The lipid metabolism, as described earlier, is dysfunctional in AD. This could be due to altered regulation or ineffective transport of lipid intermediates between ER and mitochondria. Membrane cholesterol in lipid raft has been suggested to play a role in A $\beta$  formation (Crameri et al., 2006). Lowered expression of seladin-1, an enzyme involved in cholesterol synthesis in ER, has been detected in AD, and studies in animal models demonstrate that lowering of cholesterol in lipid rafts increases A $\beta$  generation, substantiating the importance of functional cholesterol biosynthesis (Crameri et al., 2006; Stefani and Liguri, 2009). This is further supported by the fact that inhibitors against ACAT, the enzyme converting membrane cholesterol into cytoplasmic cholesterol-ester have been shown to reduce amyloid pathology in an AD mouse model (Puglielli et al., 2001; Hutter-Paier et al., 2004). In addition, treatment

with the neurosteroid, allopregnanolone, has shown promising results in a triple transgenic mouse model of AD (Wang et al., 2010).

### 1.6.1.2 Targeting Sigma1R

Sigma1R is another promising target at MAM and is implicated in cellular differentiation, neuroplasticity, neuroprotection and cognitive processes of the brain (Marrazzo et al., 2005; Hayashi and Su, 2008). Several drugs show affinity for Sigma-1R, including donepezil, antipsychotics (haloperidol, rimcazole), selective serotonin reuptake inhibitors (fluvoxamine, sertraline) and monoamine oxidase inhibitors (clorgyline) (van Waarde et al., 2011). Depletion of Sigma1R by RNA interference (RNAi) causes inhibition of growth, survival-signaling cascades and induces cell death. The antagonist, rimcazole, produces the same effect. Sigma1R-KO mice display depressive, anxiety-like phenotype and altered motor behaviors. Moreover, the female mice demonstrated reduced levels of 17 $\beta$  estradiol levels and memory deficits associated with age (van Waarde et al., 2011). Treatment of aged rats with Sigma1R agonist (PRE-084) improved the spatial learning deficits that had emerged with age (Maurice, 2001). Furthermore, Sigma1R activation (by the agonist SA4503) stimulates recovery after stroke by enhancing cellular transport of biomolecules required for brain repair, thereby stimulating brain plasticity (Ruscher et al., 2011). Polymorphisms in the sigma1R gene have been linked to frontotemporal lobe dementia (Luty et al., 2010). A positron emission tomography (PET) study of AD patients concluded that the density of Sigma1R is lower early in AD pathogenesis. (Mishina et al., 2008). Similarly, reduced number of Sigma1R-binding sites is found in the CA1 area of the hippocampus in AD, which correlates with pyramidal cell loss in this region (Jansen et al., 1993). The mechanism of action of Sigma1R agonist is not fully understood, however, it is possible that it involves ER-to-mitochondria calcium fluxes via stabilization of IP3R3, thereby activating the calcium sensitive enzymes in the TCA cycle. Increased formation of ATP can, in turn, stimulate neuroprotection and neurite outgrowth leading to improvements in cognition and cerebral metabolism (Hayashi and Su, 2007). As we reported in **Paper III**, Sigma1R is also present in mitochondria, though its function is mostly unknown. However, our data suggest that it can modulate calcium uniporters in the IMM. Indeed, regarding the mode of action, much information points toward a role in regulation of calcium channels and since calcium homeostasis is altered in AD, Sigma1R agonist treatment potentially might aid its restoration. Taking into account the neuromodulatory role of the Sigma1 receptor, agonists can affect a large variety of processes in neurons, and in glia cells (astrocytes and oligodendrocytes), and, thereby, perform neuroprotective actions. Sigma1R agonists might, therefore, be of interest as an AD-therapeutic agent especially targeted to early disease stages where it can increase cellular resistance against various pathogenic processes.

### 1.6.1.3 Targeting cell death processes

MAM encompasses crucial determinants of life and death, including calcium signaling, Bcl2 family members and PACS2 (Decuypere et al., 2011). Rupture of the OMM plays a crucial role in the intrinsic cell death pathway and causes caspase activation. Drugs that interfere with caspase activation might provide therapeutic effect by, for instance, hindering caspase cleavage of IP3R3 (causes mitochondrial calcium overload) (Decuypere et al., 2011), PS1 (causes elevation of A $\beta$ 42/A $\beta$ 40 ratio, see **Paper I**) and tau (required for tau hyperphosphorylation) (de Calignon et al., 2010). The drug doxycycline averts A $\beta$  toxicity by preventing A $\beta$  fibrillization by inhibiting caspase 3 activation, as shown in studies using a neuroblastoma cell line and in a Drosophila AD model (Costa et al., 2011). However, many peptides designed to directly inactivate caspases, e.g. z-VAD or z-LEHD-FMK, have shown successful therapeutic effect against neuronal injury after hypoxia and cerebral ischemia injuries *in vivo*, yet have been

found to be ineffective for neuroprotection. Caspase inhibitors disturb the normal homeostasis of the cell and might cause activation of alternative pathways of death. Therefore, caspase inhibition might not be effective as AD treatment. Alternatively, drugs targeting mitochondrial function may be more promising since these could prevent the release of pro-apoptotic factors.

### 1.6.2 Targeting oxidative stress

Strategies targeting oxidative and nitrosative stress, which are considered important players in AD onset and progression, hold disease-modifying potential (Ankarcrona et al., 2010). Several interventions make it possible to overcome challenges of ineffective uptake over the BBB and limited concentration in the mitochondria (Murphy and Smith, 2007). One strategy is to conjugate the antioxidant to lipophilic cations for example using triphenylphosphonium (TPP<sup>+</sup>), which enable rapid BBB and neuronal membrane crossing and to be concentrated (several hundred-fold) in the mitochondria (Murphy and Smith, 2007). Applying this technique, MitoQ and Mito-E<sub>2</sub> were developed. MitoQ is a compound that brings reducing power into the mitochondria in form of coenzyme Q10 (ubiquinone), an endogenous antioxidant and component of the mitochondrial electron transport chain, and which show potential in AD animal models (McManus et al., 2011). Mito-E<sub>2</sub> brings vitamin E into the mitochondria, and has also shown promising results in cell and animal models (Murphy and Smith, 2007; Leo et al., 2008). Moreover, the drug methylene blue (MTC), a tau antiaggregant, has shown promising results in clinical trials (Gura, 2008). Apart from affecting tau aggregation, MTC also has other properties, including function as an antioxidant (Atamna et al., 2008), as an alternative electron carrier that bypasses complex I/III (Wen et al., 2011) and can induce autophagy (Congdon et al., 2012). Interfering with mitochondrial ROS overproduction with mitochondrial-targeted catalase lengthen life span in mice (Schriner et al., 2005) and reduces abnormal APP processing in a AD mouse models (Schriner et al., 2005). Some antioxidants, e.g. trolox or superoxide dismutase, have also been shown to reduce A $\beta$  production by reversing elevation of BACE1 activity apparent after ischemia (Guglielmotto et al., 2009). In the mitochondria, A $\beta$  can interact with ABAD as described earlier. Small molecules that interfere with this interaction have emerged as additional potential drug targets for AD (Xie et al., 2006).

### 1.6.3 Dimebon

Mitochondrial dysfunction is evident in AD already at early stages in the disease progression. Therefore, rescuing mitochondrial functions is a promising therapeutic strategy since it could have disease modifying effect. The drug, Dimebon (Latrepirdine), which showed pro-cognitive and neuroprotective effects in a Russian Phase II clinical trial (Doody et al., 2008), was a new, hot candidate for AD treatment. Dimebon was originally approved as an antihistamine in the former Soviet Union in the 1980's (Matveeva, 1983) but was withdrawn from the market with the advent of more effective treatments. However, research on Dimebon continued. Around year 2000, it received renewed interest due to discovery of its neuroprotective effects (Lermontova et al., 2000; Bachurin et al., 2001; Wu et al., 2008). Dimebon's mode of action was unknown. It showed low affinity to acetylcholinesterase and NMDA receptors, yet high affinity to histamine, adrenergic, dopaminergic and serotonergic receptors. In our laboratory, we explored its mode of action and concluded that some of its neuroprotective effects could be mediated via stabilizing mitochondrial function (as shown in **Paper IV**). This will be further discussed in the section "Results and Discussion". Unfortunately, recently, two Phase III AD clinical trials failed to meet primary and secondary efficacy endpoints. The CONNECTION study was designed akin to the Russian phase II clinical trial. In this trial that was conducted for one year, mild-to-moderate AD patients were enrolled and received either Dimebon or placebo

for six months. Thereafter, the trial was designed so that also the placebo group were given Dimebon. The results after six-month treatment showed no significant change from baseline, in either group. The CONCERT study was designed as a double drug-therapy trial, in which Dimebon was an add-on to donepezil. Also in this study, mild-to-moderate AD patients were enrolled. This study was conducted for one year, after which, again, the study failed to meet the endpoint criteria. Thus, Dimebon failed to show improvement of cognition in AD at mild-to-moderate disease stage. Perhaps, treatment provided at an earlier disease stage, prior to the widespread pathology and neuronal loss as would be later manifest could bring greater efficacy. Dimebon will be further discussed in the section “Results and Discussion”.

In summary, targeting MAM and/or mitochondria could potentially reverse failing mitochondrial bioenergetics, including glucose and lipid metabolism, calcium homeostasis, ROS production, intracellular A $\beta$  production and cell survival. Therefore, these targets represent promising strategy for AD therapy.

## 2 AIMS

The general aim of this thesis was to explore mechanisms underlying mitochondrial dysfunction in AD bringing into focus regulatory mechanisms and caspase activation. Mitochondria are key players in determining cellular fate, including life or death decisions. Already subtle changes in the intracellular A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio are linked to A $\beta$  oligomerization and toxicity, which has been observed during mitochondrial ROS production and activation of caspases.

- **Paper I.** To investigate by what mechanism caspases alter the intracellular A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio and to explore implications of these mechanisms for sporadic AD.

Intracellular A $\beta$  has been found to accumulate in the mitochondria where it causes damage to metabolic pathways, mtDNA repair and increases the likelihood of PTP opening. A $\beta$  might be produced in MAM, subsequently transported over to the mitochondrial side, and imported via the TOM40 pore, the common import machinery through which all nuclear-encoded mitochondrial protein has to be transported. The *TOMM40* gene is in linkage disequilibrium with the *APOE* gene and polymorphisms exist that are associated with AD.

- **Paper II.** To study functional implications of the recently identified poly-T repeat in the *TOMM40* gene linked to lowered age-of-onset of LOAD in ApoE  $\epsilon$ <sub>3/4</sub> carriers, in regards to mitochondrial function.

MAM regulates vital biological processes, including metabolism of glucose and lipids, calcium homeostasis and regulation of cell death, all of which become dysregulated in AD. Both ER and mitochondria are important players in maintaining proper synaptic function. However, little is known about MAM in neurons, especially as concerns AD perspective.

- **Paper III.** To examine the importance of MAM for neuronal survival, and in relation to AD pathogenesis.

Treatment strategies targeting the mitochondria could have beneficial disease modulatory effects since increasing the mitochondrial resistance towards cellular stressors could strengthen the synapses and thereby hinder dysfunction and loss of synapses.

- **Paper IV.** To investigate mode of action of Dimebon, a potential novel drug for treatment of AD.



## 3 METHODOLOGICAL CONSIDERATIONS

### 3.1 ETHICS APPROVAL

Ethical permissions for using animal and human tissues were obtained from the Regional Ethics Committee for Animal Research in Stockholm South and the Regional Ethics Committee of Stockholm.

### 3.2 MODELS USED IN THE STUDIES

For conducting these studies we have used a variety of models systems including conventional cell lines, human fibroblast cell cultures derived from biopsies, mouse primary neuronal cell cultures, AD-mouse models ( $APP_{Swe/Lon}$  and  $APP_{Arc}$ ) and human postmortem cortical brain tissue.

#### 3.2.1 Cells

The conventional cell lines used included mouse blastocyst (BD8) cells in **Paper I** and neuroblastoma (SH-SY5Y) cells in **Papers I, III** and **IV**. Conventional immortalized cell lines are an excellent tool used to study molecular and cellular processes in a simple and controlled environment and do not require ethical permission. However, they are usually poor representations of cells found in intact tissues. The SH-SY5Y cell line, which is a cancer cell line, can be differentiated into neuronal-like cells upon retinoic acid treatment that induce attenuation of proliferation and extension of neuritic processes (**Paper IV**). This model represents a good substitute to primary neuronal cultures since it does not require sacrificing animals. Nevertheless, for a more comprehensive analysis of processes occurring in neurons, primary cultures are needed. Here, we have used cortical (**Paper IV**) and hippocampal (**Paper III**) primary neurons from mouse embryos. In **Paper II**, we used fibroblast cell cultures generated from skin biopsies from individuals in AD families.


#### 3.2.2 Human postmortem tissue

To study how expression of different proteins is affected in AD, we have used human postmortem cortical tissue (**Paper III**), which is of great value for studying disease mechanisms. However, cautions should be taken since postmortem tissue represents the end stage of the disease and does not give information about progressive mechanisms. Moreover, differences between sample handling and postmortem times can differ substantially and thereby affect protein expressions.

#### 3.2.3 Transgenic mouse models

To be able to follow disease progression transgenic mouse models,  $APP_{Swe/Lon}$  and the  $APP_{Arc}$ , have been used (**Paper III**). The  $APP_{Swe/Lon}$  mouse model overexpresses the Swedish (K670N/M671L) and London (V717I) mutation and, subsequently, accumulates large quantities of dense-core and diffuse amyloid plaques (see Figure 7) (Rockenstein et al., 2001). The  $APP_{Arc}$  mouse model overexpresses the Arctic mutation (E693G), which is an intra- $A\beta$  mutation (see Figure 7) that gives rise mainly to diffuse  $A\beta$  deposits (Ronnback et al., 2012). The  $APP_{Arc}$  model has a milder amyloid pathology affecting primarily the subiculum as opposed to the  $APP_{Swe/Lon}$  mouse model that develops mature plaques as early as 3-4 months and exhibits widespread amyloid pathology, affecting neocortex, hippocampus, thalamus and olfactory regions. Studying these two animal models can give valuable information on how

different A $\beta$  pathologies (A $\beta$ -peptides vs. A $\beta_{Arc}$ -peptides) affect particular biological processes and pathways at different stages of disease. Nevertheless, the pathology in animal models does only represent some aspects of AD; tau pathology, for instance, is lacking. Therefore, one should be cautious when interpreting data acquired from transgenic animals.



**Figure 7.** Illustration of APP showing the cleavage sites for  $\alpha$ -,  $\beta$ -, and  $\gamma$ -secretases and the position of Swedish, Arctic, London and Indiana mutations.

### 3.3 QUANTITATIVE MEASUREMENTS OF PROTEIN EXPRESSION

For quantification of protein levels, we used Western blot (**Paper I, II and III**) and enzyme-linked immunosorbent assay (ELISA) (**Paper I and III**). Both these methods are based on antibody detection. Antibodies have affinity for specific epitopes that at certain circumstances can be hidden in the proteins. This can be caused by for example conformational changes and aggregation. Therefore, this is something that is important to keep in mind when interpreting data generated from antibody-based methods.

A good complement is immunohistochemistry, which was used in **Paper III**, and with which protein expression levels can be visualized and studied in different brain regions. This method is, however, more qualitative than quantitative. Another method used for detection of proteins is liquid chromatography-mass spectrometry (LC-MS), which can be either qualitative or quantitative depending on internal standards. In **Paper I**, an ion-trap mass spectrometer (Agilent 6330) was used to qualitatively analyze A $\beta$ -peptides secreted from cell lines with the aim of identifying long A $\beta$ -peptides (>A $\beta$ 42). This was however, not fully successful; though A $\beta$ 42 could be detected and this information used to verify our earlier ELISA data.

### 3.4 SUBCELLULAR FRACTIONATION

Many proteins reside in certain compartments within the cells, and are destined for specific activities. Their intracellular localization can be studied by subcellular fractionation. In order to investigate protein expression at the MAM region and to study ER-mitochondrial contacts in synapses (**in Paper III**) we fractionated mouse brains on percoll gradients according to previously described protocols (Dunkley et al., 2008; Wieckowski et al., 2009). Caution should be taken when interpreting pureness of fractions after subcellular fractionation since these almost certainly contain contamination from other cellular regions, generating artifacts. Therefore, for comprehensive analysis of pureness, expression of several organelle specific proteins could be studied by Western blot and the fractions could be studied by electron microscopy.



### 3.5 EXPOSING CELLS TO A $\beta$

Studying the impact of A $\beta$  on various biological processes is important to understand AD pathogenesis. However, which A $\beta$  species (A $\beta$ 40, A $\beta$ 42) and assembly forms (monomer, oligomer, fibrils) are the most toxic is highly debated. Currently, soluble oligomers (beta-sheet structures) are thought to have more influence on toxicity than monomers ( $\alpha$ -helical or random coil structures) or fibrils (parallel beta-sheet conformation) (Iversen et al., 1995). We chose, in **Paper III**, to use conditioned media from the well characterized CHO7PA2 cell line that overexpresses the Indiana mutation (APPV17F) (see Figure 7), primarily secreting oligomeric A $\beta$  species (Walsh et al., 2002). Our selected concentration for A $\beta$  in our experiments were either 2.5 nM or 4.5 nM (total A $\beta$ 40 and A $\beta$ 42), which are thought to resemble concentrations that neurons are exposed to in the brain (Cleary et al., 2005).

### 3.6 STUDY MITOCHONDRIAL FUNCTION

There are several ways to study mitochondrial function. Here, we used techniques that assess different aspects including  $\Delta\Psi_m$  (**Paper II, IV**), complex II activity by MTT-assay (**Paper IV**), ATP production (**Paper IV**) and mitochondrial biogenesis (**Paper II and IV**). MTT assay is a colorimetric technique, in which the color change that occurs when tetrazolium salt is reduced to formazan is measured. This reaction is mainly catalyzed by complex II in the electron transport chain and is, therefore, an indicator of the cells redox activity. Maybe however, other enzymes residing in the cytosol also have this capacity and, therefore, cautions ought to be made when interpreting activity as strictly mitochondrial oriented. ATP levels are studied, as a measure of the coupling of OXPHOS, here, by employing a luminescent method (**Paper IV**). However, a more illuminating view of the bioenergetic state of the mitochondria could be given assessing the ADP/ATP ratio. The  $\Delta\Psi_m$  is used to drive the phosphorylation of ADP at complex V in order to generate ATP. To monitor alternations in the  $\Delta\Psi_m$ , the cationic dye TMRM, which accumulates inside the mitochondria in proportion to the  $\Delta\Psi_m$ , was used. Mitochondrial biogenesis was assessed by one of two different ways, either by quantifying mitochondrial volume density on electron microscopy pictures (**Paper II**) or by quantifying mtDNA copy number by quantitative real time PCR (**Paper IV**). The measurement using electron microscopy pictures was performed by point counting using a 2 cm and 1 cm square lattice (Weibel 1979).

### 3.7 VISUALIZATION OF PROTEINS AND ORGANELLES IN FIXED SAMPLES

Confocal microscopy is a widely used tool to study various cellular processes since it enables visualization along one focal plane by employing a spatial pinhole that eliminates out-of-focus light, increasing optical resolution and contrast. Since only one focal plane is visualized, it enables visualization of protein and organelle interactions. Using the Zeiss LSM510 META confocal microscope we imaged chromatin condensation (**Paper I**), distribution of MAM proteins (**Paper III**), and ER- mitochondrial interactions (co-localization) after A $\beta$  treatment (**Paper III**). For this purpose we used 2D co-localization method in the LSM 510 software program. However, care must be taken when attributing significance to the 2D method since signals used in calculations might originate from outside the focal plane of interest. Therefore, 3D methods have gained increased interests since the calculated co-localization originates from volume reconstruction and, therefore, has the capacity to reduce these problems.

Transmission electron tomography (TEM) is a method to image cellular structures with higher magnification. This technique utilizes a beam of electrons to increase the resolution instead of photons, which are used in a regular microscope to create the image. We used this technique to study mitochondrial morphology (**Paper II**) and ER-mitochondrial interactions in synaptosomes (**Paper III**).

### **3.8 LIVE CELL IMAGING**

Live cell imaging is a widely used technique to study dynamic networks in cells. We performed several live cell analyses using the Zeiss LSM510 META confocal microscope, including visualizing of  $\Delta\Psi_m$  using the dye TMRM (**Paper II, IV**), viability of hippocampal neurons after siRNA transfection (**Paper III**), and distribution of mitochondria and ER using Cell-Light probes (**Paper III**). For quantification of changes in  $\Delta\Psi_m$ , the TMRM intensities were analyzed at different time point using the LSM 510 software program. For this purpose it is important to ensure constant focus, which can be controlled by simultaneous visualization of e.g. nucleus.

### **3.9 MEASUREMENT OF CALCIUM SIGNALING BETWEEN ER AND MITOCHONDRIA**

Spatiotemporal calcium measurements in intracellular compartments including ER, cytosol and mitochondria give valuable insights into biological processes. One method developed for this purpose utilizes aequorin, a protein isolated from a luminescent jellyfish. This protein is an apoenzyme and needs a prosthetic group (cofactor) for its function. The cofactor is coelenterazine, which contains several calcium binding sites. Upon calcium binding the protein undergoes a conformational change and through oxidation converts coelenterazine into the excited coelenteramide, which emits blue light when relaxing to its ground state. This emitted light can be measured by a luminometer. Advantages of using aequorin include easy transfection, that no optical excitation is needed and well tolerability by the cells. One limitation is, however, that the prosthetic group, coelenterazine, requires continuous addition since it is consumed when reacting with calcium. In **Paper III** we used this method to study the calcium signaling between ER and mitochondria.

## 4 RESULTS AND DISCUSSION

### 4.1 MITOCHONDRIAL REGULATION AND DYSFUNCTION IN AD

Low glucose metabolism and mitochondrial impairment are observed already at early stages of AD. The triggering events causing altered bioenergetics and mitochondrial dysfunction are not fully understood. We speculate that alterations in MAM functioning may partly underlie these defects. Glucose and lipid metabolism, calcium homeostasis and cell death regulation are processes that are impaired in AD, and all are controlled in MAM. Growing evidence also suggests that A $\beta$  can be produced in MAM. For an illustrational overview of the **Paper I to IV** see Figure 8.

### 4.2 CASPASE CLEAVAGE OF PS1 INCREASES THE A $\beta$ 42/A $\beta$ 40 RATIO

The pathology of AD affects the regulation of cell death as demonstrated by aberrant activation of caspases, which is a prominent feature of AD and has been implicated in synaptic degeneration and neuronal loss (Stadelmann et al., 1999a; Louneva et al., 2008b; Albrecht, S. et al., 2009). Active caspases have been detected in cerebrospinal fluid and postmortem brain tissue of sporadic and FAD patients, and in AD-mouse models, and these correlate with elevated A $\beta$  production (Tesco et al., 2003; Albrecht, P. et al., 2009). The mechanism by which caspase activation causes elevated A $\beta$  is not fully understood. Caspases can cleave proteins involved in A $\beta$  generation, including APP, PS1 and PS2; however, the truncation of APP does not seem to influence A $\beta$  production (Tesco et al., 2003). The  $\gamma$ -secretase complex contains either PS1 or PS2. Those incorporating PS1 are more common and also more likely to be involved in APP processing (Franberg et al., 2011). Moreover, the majority of FAD mutations are located in PS1 as compared to PS2 or APP. PS1 can be cleaved at Asp333 and Asp345 in the loop region by several caspases including 1, 3, 6, 7, 8 and 11 causing the loss of half of the loop (Kim et al., 1997; van de Craen et al., 1999) (see Figure 3). The loop region has previously been shown to possess regulatory functions in regards to A $\beta$  production (Deng et al., 2006). Therefore, in **Paper I**, we aimed to investigate caspase cleavage of PS1 more carefully. Previously, in our laboratory we had shown that PS1, despite the loss of half the loop domain after caspase cleavage (caspCTF), is still part of active  $\gamma$ -secretase complexes (Hansson et al., 2006). Thus, we wanted to investigate if this truncation could change the cleavage preferences in APP. To do so, we established stable cell lines either expressing wild type CTF (wtCTF) or caspCTF. As expected, caspCTF formed active  $\gamma$ -secretase complexes together with Nicastrin, Pen-2, Aph-1 and PS1-NTF. When studying the A $\beta$  profile generated from these  $\gamma$ -secretase complexes we identified a shift at the  $\gamma$ -site. The caspCTF-containing  $\gamma$ -secretase complexes had an increased intracellular A $\beta$ 42 production, resulting in a significant elevation of A $\beta$ 42/A $\beta$ 40 ratio as compared to wtCTF-containing  $\gamma$ -secretase complexes. Thus, the increased production of A $\beta$ 42 during apoptosis can be at least partly explained by the formation of caspCTF-containing  $\gamma$ -secretase complexes (see Figure 8). Interestingly, activation of caspases is not only a consequence of the pathophysiology of AD but is actually continuously occurring in a transient fashion in normal brain physiology. This is seen, for example, in neurons in which activation of caspase enables synaptic reorganization and neurite retraction. Therefore, activation of caspases is important for neuronal plasticity (Li et al., 2010). Consequently, caspase cleavage of PS1 could occur both under normal plasticity and in pathological conditions, during which caspases are activated. When studying the intracellular localization of caspCTF in healthy mouse brain we identified this truncated form of PS1 in several compartments, however, most abundantly in lysosomes, plasma membrane and, interestingly,

also in MAM (**Paper III**) (see Figure 8). This means that, locally in MAM, the A $\beta$ <sub>42/40</sub> ratio could be elevated to influence MAM's many regulatory functions, and at this site, A $\beta$  could be transported over into the mitochondria where damage could trigger mitochondrial dysfunction (see Figure 8).


### 4.3 TOMM40 POLYMORPHISMS, IMPLICATIONS FOR AD

A $\beta$  has been detected inside the mitochondria in AD patients, and at an early stage of pathology in AD mouse models. Accumulation of A $\beta$  inside the mitochondria has recently been shown to represent a phenomenon separating individuals with profound AD lesions into two groups one that develops AD and one that remains cognitively intact. The group that developed AD exhibited accumulation of A $\beta$  in their mitochondria whereas the group that remained cognitive intact did not (Tagliatalata, Poster, AAIC, 2012 Vancouver, Canada). Inside the mitochondria A $\beta$  interacts with several proteins, e.g. complex IV, cyclophilin D and ABAD, which causes mitochondrial dysfunction. The pathway by which A $\beta$  is transported into the mitochondria has previously been investigated in our laboratory showing that import follows the common route via the Tom40-import pore, through which all the 1000 nuclear-encoded mitochondrial proteins are imported (Hansson Petersen et al., 2008) (see Figure 8). Several polymorphisms that have been associated with increased risk of late-onset AD have been identified in the *TOMM40* gene. The *TOMM40* gene is located on chromosome 19 in a region of linkage disequilibrium (LD) with *APOE*. Much effort is being brought to identify whether, in addition to *APOE*, the LD-block contains other risk factors influencing AD. The polymorphism, rs10524523, in *TOMM40*, has received particular attention since one of its variants was shown to lower the age-of-onset of LOAD by 7 years in *APOE*  $\epsilon$ 3/4 carriers (Roses et al., 2009). Thymidine stretches of varying length in intron 6 comprise rs10524523. The linkage disequilibrium between the *TOMM40* and *APOE* genes ensures that the  $\epsilon$ 4 allele will always be inherited along with a long poly-T repeat, whereas the  $\epsilon$ 3 allele is inherited with either a very long or a short poly-T repeat. In **Paper II** we used biochemical methods to investigate rs10524523. We could not detect any functional implications of this polymorphism in regards to (i) expression levels of TOM40 protein and mRNA, (ii) TOM40 mRNA splicing, or (iii) mitochondrial function and morphology. Therefore, we think that this specific polymorphism does not participate in a significant manner in mitochondrial dysfunction. However, several other polymorphisms might be worth investigating (see Figure 8).

### 4.4 MAM IS MODULATED BY AD PATHOGENESIS

MAM are connected to mitochondria and interaction between ER and mitochondria via its contact points are crucial for proper cell function. In AD, the disturbed glucose, phospholipid and cholesterol metabolism, the altered calcium homeostasis and the dysregulated cell death might indeed be linked to MAM alterations. Having found in the literature a scarcity of knowledge about MAM in the brain and in diseases like AD, we, in **Paper III**, set out to investigate it. We report, that (i) proteins enriched in MAM (e.g. PACS2, PSS1, Sigma-1R, IP3R3) are ubiquitously expressed in neurons and expressed both in soma and at distal parts of the neurites and in synapses, (ii) MAM function is essential for neuronal and astrocytic survival since siRNA treatment against PACS2 and Sigma-1R causes degeneration, and that (iii) the MAM region is altered in the human AD brain, and before the appearance of plaques, at least in the APP<sub>Swe/Lon</sub> mouse model. In addition, A $\beta$  exposure at nM concentration of hippocampal neurons increased (i) the expression of MAM proteins, (ii) the number of contact points between ER and mitochondria and (iii) the transfer of calcium from ER to mitochondria, modulating especially calcium uptake mechanisms on the mitochondrial side, as shown in SH-SY5Y cells treated with a combination of A $\beta$  and Sigma-1R agonist. Thus, physiological

concentrations of A $\beta$  do modulate ER-mitochondria contact points and calcium shuttling, from the ER to the mitochondria, causing an increase in mitochondrial-calcium concentration, which in the long run may lead to Ca<sup>2+</sup> overload and neuronal toxicity. Our data indicate that ER-mitochondria contacts could be affected by A $\beta$  during the progress of AD pathogenesis and that MAM modulation may be involved in altered neuronal activity in AD (see Figure 8). This is the first study describing the distribution of MAM in the brain, the subcellular localization of MAM in neurons and the influence of A $\beta$  on MAM protein expression, regulation of contact points and calcium transfer into mitochondria. Moreover, emerging evidence suggests that A $\beta$  actually could be produced in MAM since high activity of the  $\gamma$ -secretase complex has been reported in the MAM region. In concordance, our data further support this theory since we also detected APP, C99 and PS in MAM (**Paper III**). Moreover, preliminary data also indicate that BACE1 is located there (data not shown). Interestingly, we also detected caspCTF in MAM, which locally could change the A $\beta$ 42/A $\beta$ 40 ratio at these spots. We suggest a novel function of A $\beta$  as a regulator of ER-mitochondria contacts, which may result in altered mitochondrial function both under physiological and pathological conditions, depending on dose and time (see Figure 8). A $\beta$  might regulate (i) calcium uptake into the mitochondria (**Paper III**) and thereby regulate the energetics of mitochondria, (ii) production of both cholesterol and sphingomyelin (Grimm et al., 2005) and (iii) fluidity of the lipid-raft like lipid bilayer that MAM is composed of, and do so by binding to sphingolipids. On the other hand, A $\beta$  can (i) accumulate in the mitochondria causing severe damage, (ii) cause elevation of mitochondrial ROS production (iii) cause release apoptotic mediators from the mitochondria.



**Figure 8.** Overview of the studies. In **Paper I** we showed that  $\gamma$ -secretase complexes containing caspCTF increase the intracellular A $\beta$ 42/A $\beta$ 40 ratio. In **Paper II** we studied a specific polymorphism in the *TOMM40* gene consisting of a poly-T stretch with varying length. Even though no functional implication was found regarding this polymorphism, others could be worth investigating. In **Paper III** we found that the MAM region is altered in AD and the ER-mitochondria contact points and calcium transport increases after A $\beta$  exposure. In the last study, **Paper IV**, we looked at the mode of action of a potential novel AD drug, Dimebon, and found that it enhances mitochondrial function and increases the resistance against various stressors. We hypothesize that A $\beta$  produced at MAM could modulate the MAM region, modulate the amount/distance of ER-mitochondria contact points and be the region where A $\beta$  is transported over to the mitochondria.

## 4.5 TARGETING MITOCHONDRIAL FUNCTION

The final study, **Paper IV**, concerned the potential novel drug, Dimebon (Latrepiridine), intended for treatment of AD (Doody et al., 2008). We investigated Dimebon's mode of action in two *in vitro* models, primary mouse cortical neurons and SH-SY5Y cells. After one to five days incubation with nM concentrations of Dimebon, increased  $\Delta\Psi_m$  accompanied with increased cellular ATP levels was observed in both cell systems. Pretreatment with Dimebon made cells more resistant to calcium overload and loss of  $\Delta\Psi_m$ . Moreover, cells exhibited increased resistance towards induction of cell death after growth factor deprivation (see Figure 8). Thereby, our study suggests that Dimebon affects the bioenergetics of the mitochondria and thereby protects cells against various cell stressors. Notably, resistance towards calcium stress was only observed in pretreated cells. Thus, Dimebon enhanced mitochondrial function, however, for optimal protection and for maintenance of cell viability, pretreatment is preferable. Recent studies on Dimebon have shown that Dimebon can ameliorate A $\beta$  induced mitochondrial impairments (Eckert et al., 2012) and increase cerebral glucose utilization in aged mice (Day et al., 2011). These data further support Dimebon's bioenergetic effects. Other modes of action have also been suggested including modulation of PTP (Bachurin et al., 2003), protection against A $\beta$  toxicity (Bachurin et al., 2001), and decrease aggregation of TDP-43 and  $\gamma$ -synuclein (Yamashita et al., 2009; Bachurin et al., 2012). Interestingly, in three model systems Dimebon treatment was shown to increase the secretion of A $\beta$ . The treatment of APP<sub>Swe</sub> overexpressing cells and synaptoneurosomes isolated from APP<sub>Swe/Ind</sub> mice (1-10 min or 6 h with Dimebon) elevated the secretion of A $\beta$ . Injection of Dimebon into the brains of APP<sub>Swe</sub> mice showed a 40% increase in A $\beta$ 40 in interstitial fluid 10 h post-injection (Steele et al., 2009). Increasing A $\beta$  secretion could be beneficial since secretion has been associated with neuroprotection in contrast to intracellular A $\beta$  accumulation, which causes severe damage (Nilsson, Poster, AAIC, 2012, Vancouver, Canada). By strengthening the mitochondria and increasing A $\beta$  secretion from neurons, Dimebon exhibits properties that could be important for generating disease-modifying effects. Unfortunately, as described earlier, Dimebon has recently failed two Phase III AD clinical trials ([www.alzforum.org/new/detail.asp?id=2387](http://www.alzforum.org/new/detail.asp?id=2387)). Nevertheless, the rich pharmacological profile of Dimebon is a basis to suggest it could be effective against other neurodegenerative diseases such as Huntington disease and neurological diseases like Schizophrenia. A Phase II clinical trial for Huntington disease has shown promising results (Kieburz et al., 2010). Also a recent Phase II clinical trial for Schizophrenia, in which Dimebon was administered as an add-on to risperidone therapy, showed positive outcome. Several cognitive measures were improved possibly via serotonin receptor (5-HT<sub>6</sub>) blockage (Morozova et al., 2012).

Drugs restoring the function of mitochondria and/or MAM might have disease-modulatory effect. The importance of a proper interaction between ER and mitochondria is evident as demonstrated in two other neurodegenerative diseases: GM1-gangliosidosis and Charcot-Marie-Tooth neuropathy type 2a. In GM1-gangliosidosis, GM1-ganglioside accumulates in MAM where the interaction with IP3R leads to clustering of IP3R and increased calcium signaling resulting in calcium-dependent mitochondrial apoptosis (Sano et al., 2009). Charcot-Marie-Tooth neuropathy type 2a is a disease caused by missense mutations in Mfn2. The interaction between ER and mitochondria depend on Mfn2 and absence of Mfn2 diminishes these interactions, thereby hampering calcium signals to the mitochondria. It is speculated that the mutations causing the disease might involve similar mechanisms (Zuchner et al., 2004; de Brito and Scorrano, 2008). Hence, the understanding of MAM *per se* and in regards to mitochondrial function is just in the beginning and research in this field might shed light to

several pathophysiological mechanisms involved in AD as well as other neurodegenerative diseases.





## 5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES

In many respects, neurons, to sustain proper function, depend on an ability to form and maintain synapses, an operation which requires adequate energy supply and calcium handling. Mitochondria are the main energy providers in the brain and are the site for numerous biosynthetic and catabolic pathways essential for cell function. Their distribution is thought to be controlled by local energy and metabolic demand. Maintaining sufficient energy and metabolic supply to all cellular regions throughout the cell is a great challenge and becomes exceedingly difficult in polarized cells like neurons. Consequently, efficient control of mitochondrial distribution and expedient transport in response to different needs is essential for neuronal development and survival. Recently, it become clear that the mitochondrion does not act entirely alone; it needs to interact with ER to enable many processes. ER distribution is, as well, heavily regulated to ensure transport to all cellular regions. At the MAM region, ER interacts with the mitochondria, ensuring proper regulation of glucose, phospholipid and cholesterol metabolism, calcium homeostasis and apoptosis. All of these processes are known to be defective in AD. Since it is well established that mitochondrial bioenergetics and function are deranged already at early stages of AD, it is possible that alterations in MAM function may partly underlie these defects.

We have detected MAM in the synapse where calcium homeostasis, energy metabolism and cell death signaling needs to be heavily regulated. With the knowledge that synapse dysfunction and synapse loss are events correlating best with cognitive impairments, we speculate that MAM function plays a pivotal role in synaptic integrity. Both dysfunctional mitochondria and aberrant caspase activation are prominent features of synapse dysfunction (Wei et al., 2010; Zempel et al., 2010; Trushina et al., 2012). Caspase activation is important for synaptic reorganization, LTD, LTP and plasticity in the brain, where caspase cleavage of structural proteins, like the actin skeleton, enables change in morphology. The activity of caspases must, however, be heavily regulated so to not cause aberrant activation and execution of the cell death program. Since the feature of plasticity involves activation of caspases, this means that several proteins during the process of activation can be cleaved, including PS1 and tau. The formation of caspCTF and the consequent elevation in intracellular A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio might be an important factor in plasticity, particularly since A $\beta$  has been reported to regulate AMPA receptor internalization. Also the cleavage of tau might enable microtubule derangement. In any case, caspase activity can, indeed, also cause both A $\beta$  toxicity and tau hyperphosphorylation (Quintanilla et al., 2012). Already, minor changes in intracellular A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio have been shown to be detrimental (Masters and Selkoe, 2012) and both A $\beta$  and caspase-cleaved tau impair mitochondria (Quintanilla et al., 2012). Since the  $\gamma$ -secretase complex, APP and BACE1 are all located to MAM we speculate that A $\beta$  from this location can easily be transported over to the mitochondria and then be imported via the TOM40 pore (Hansson Petersen et al., 2008) (see Figure 8). Moreover, we have detected caspCTF in MAM, which further suggests that the A $\beta$ <sub>42</sub>/A $\beta$ <sub>40</sub> ratio could locally change in this region. Intra-mitochondrial A $\beta$  accumulation is an early phenomenon in the synapses and might indeed be one of the reasons for dysfunction and loss.

There are several polymorphisms in the *TOMM40* gene that associates with increased risk of developing AD. Interestingly, *TOMM40* and *APOE* are in linkage disequilibrium with each

other, making it hard to separate risks associated with either gene. In our study, we did not learn of any functional implications concerning the specific poly-T repeat-polymorphism that had attracted a lot of attention after its claimed association to disease onset of AD. However, there are several other polymorphisms that might affect the mitochondria function and, thereby, increase the susceptibility for developing AD.

Based on our observations we hypothesize that A $\beta$  can interfere with processes on the MAM side as well on the mitochondrial side, affecting bioenergetics, lipid metabolism, calcium signaling and cell death regulation in the vulnerable synapse, which depends on correct distribution and contact between the two organelles. A $\beta$  produced at these spots can, in theory, either be of physiological benefit or be a cause of damage. The drug Dimebon, tested for a variety of neurological disorders, has a wide pharmacological profile enhancing inter alia mitochondrial bioenergetics and A $\beta$  secretion. These characteristics might definitely be of importance for disease-modifying treatments aiming to reestablish synaptic integrity by restoring mitochondrial function and decreasing intracellular A $\beta$  levels. The reason for the failure of Dimebon in the Phase III clinical trials might be due to the fact that treatment at the stage of mild-to-moderate AD is too late. At this stage, restoring synaptic and neuronal function is difficult due to the advanced pathology. In conclusion, we believe that drugs targeting MAM and/or the mitochondria could serve as potential disease-modifying therapies. Drugs that have the capacity to restore mitochondrial glucose and lipid metabolism, calcium homeostasis and cell death signaling could potentially prevent synaptic dysfunction and loss. For efficacy, therapy should be started at the earliest possible disease stage, preferably before the mild-to-moderate stage. However, many important questions remain concerning the nature of communication at MAM in regards to AD, and in what ways it might be possible to therapeutically intervene.

## 6 ACKNOWLEDGEMENTS

I wish to express my sincere gratitude to everyone who has been involved in this thesis work and to family and friends who have supported me through these years. It has been both challenging and exciting! A special thank you goes to:

**Maria Ankarcrona**, my main supervisor, for being the perfect supervisor! You are a great researcher with whom I'm so happy to have had the opportunity to get to know. Thank you for your encouragement, guidance and for believing in me and my ideas and for all support in research and outside.

**Homira Behbahani**, my co-supervisor, for giving me support as I needed and for your knowledge in the mitochondria field.

**Elzbieta Glaser**, my co-supervisor, for being the expert in biochemistry and for your input and support during these years.

All collaborators and co-authors. Special thanks to **Bengt Winblad** for your support over the years and for creating a great research atmosphere here at KI-ADRC, **Helena Karlström** for your input in several projects, for always being helpful and for all the nice chats, **Caroline Graff** for your valuable input in research and outside, **Annica Rönnbäck** for your positivity, your help with IHC and for proof reading this thesis, **Lars Tjernberg** for being the A $\beta$  expert, for your critical thinking and for proofreading the A $\beta$  part of this thesis, **Catarina Pinho** for all the brainstorming and for the great work on the MAM project, **Paola Pizzo** and **Riccardo Filadi** for your expertise in calcium measurements and great input on the MAM paper, **Dagmar Galter** for your valuable knowledge about IF and your help with situ hybridization for the MAM paper and **Jesper Brohede** for all your contribution for the TOM project.

Present lab companion **Birgitta Wiehager** for being such a warm and positive person. It has been a privilege to work with you and you are a person that I feel I always can turn to for advice. Former lab companions **Camilla Hansson Petersen** for being the perfect supervisor during my master thesis, for all our laughs over the years and for being in Copenhagen, it's just so nice to visit you there, **Shouting Zhang** for your enthusiasm and for introducing me into Chinese thinking, **Laura Hertwig** for the lovely time at the lab and outside, see you in Berlin soon.. achja!!

All the people at KI-ADRC, former KASPAC and the other divisions, both former and present for your knowledge and for creating a nice research atmosphere. **Susanne Frykman** for nice discussions about various methods, **Kevin Grimes** for all interesting chats and for proof reading this thesis, **Pavel Pavlov**, for being a mitochondria expert, **Sofia Schedin-Weiss**, **Erik Sundström**, **Amelia Marutle**, **Nenad Bogdanovic**, **Angel Cedazo-Minguez**, **Lars-Olof Wahlund**, **Marianne Schulzberg**, **Mircea Oprica**, **Agneta Nordberg**, **Elisabet Åkesson**, **Eirikur Benedikz**, **Ronnie Folkesson**, **Jie Zhu**, **Jinjing Pei**, **Ove Almkvist**, **Taher Darreh-Shori**, **Stina Unger-Lithner**, **Jan Johansson**, **Jenny Presto**, **Hanna Willander**, **Dag Årslund**.

The administrative personnel for all your help, a special thanks to **Gunilla Johansson**, **Anna Jorsell** and **Anna Gustafsson**.

**Lena Lilius** for all the help on the TOM project, **Eva-Britt** for always having the antibodies that I needed and for all the nice running competitions, **Lotta, Lena** (Hullan) and **Inga** for all the help and advice whenever I needed.

My office mates

**Annelie**, for being coolaste norrlandstjejen and **Johanna**, for being den mest välplanerade jag känner. Thank you for all your support, chats about everything, all the fun in the lab, the office and outside. **Andrea** our new office mate for being the Australian expert.

All the former and present PhD students and post docs for all the fun over the years including nice lunch/ coffee breaks, spex and pubs. I would especially like to thank **Anna** (Liljan) for being such a great friend, for making our annual skiing trips to the Alps into the best tradition ever and for being the toastmadame on my dissertation party, **Anna S, Mimi, Linn** (Limps) and **Jennie** for being such wonderful persons, for all the fun over the years and for your great friendships. **Liss-Eric** (sorry Eric that I made doubt.. but I guess we will never be too old), **Erik** (Hjorten), **Silvia** for trying to teach me Italian, **Patxi** for all the laughs and for being the perfect climbing teacher, **Lisa** for climbs, fun and spontaneity, **Tobbe** for being my running companion, **Heela** for your philosophic and poetic way of thinking, **Elena** for your positive energy, **Per** for all interesting chats, **Stephen, PH, Rafaella, Marta, Huei-Hsin, Jenny, Hedwig, Susanne, Behnosh, Nodi, Mustafa, Alina, Erika, Eni, Gabi, Rey, Babak, Carlos, Erik Hermansson, Henrik, Joje, Anton, Tamanna, Yasu** and **Hiro** for a nice time in and outside the lab.

The Italian lab,

**Paola, Tullio, Cristina, Paulo, Riccardo, Andrea, Diana, Eliza, Paola, Cristian** and **Valentina**, thank for your friendliness and for making my stay in Padova such a nice experience. Special thanks to **Andrea** for all nice dinners, events and pictures of the sun, **Anne** who made me climb a 1000 m mountain.

Mina vänner utanför labbet,

Vad hade jag gjort utan er... Det är hos er jag hämtat energi och tack vare er jag kommit i mål. **Hanna T** för att du kommer upp så ofta, för allt kul vi hittat på och alla galna resor. Mina söderböror, **Hanna Z** för promenader, joggingturer, snack om allt och för att du ställer upp som toastmadame på disputationfesten, **Karin** för alla middagar och häng på min eller din balkong och **Bea** för att du alltid är på, balkonghäng eller Balihäng eller nåt annat. **Charlotte** för allt kul vi hittat på från friluftsliv till underbara festnätter, ser fram emot att hälsa på dig i Georgien, **Johan** för att du är den bästa på att hoppa, **Mohammed** för att din energi och positivitet smittar, **David** för att du delar min snöentusiasm, **Isak, Pelle, Linda** för allt kul vi hittat på klättring/tältning/res/äventyr, ni är sådana stora energikällor. **Sara** för alla mysiga fikor och för din softa härliga inställning till livet, **Gry** och **Maja** för den gamla goa tiden i Lund.

Min fantastiska familj för allt ert stöd

Mina underbara föräldrar **Birgitta** och **Egil** för allt ert stöd och kärlek och för att ni alltid har trott på och uppmuntrat mig. Ni är de bästa föräldrarna man kan ha! Ser fram emot att se er mycket mer framöver. **Charlotte** för att du är den bästa systemen ever! Du är en klippan, en kämpe och en som jag alltid kan lita på. Vi får öva upp vår telepati nu när vi kommer vara så långt ifrån varandra. **Vilhelm** och **Petter** för att ni är underbara och att det alltid är så mysigt att träffa er.

Tack till alla stiftelser och fonder som har möjliggjort denna forskning: Gun och Bertil Stohnes stiftelse, Lundbecks stiftelse, Stiftelsen för Gamla tjänarinnor, Karolinska Institutet, Alzheimerfonden, Vetenskapsrådet, Knut och Alice Wallenberg stiftelse and Medivation, Inc. San Francisco, USA.

## 7 REFERENCES

- Abramov, A. Y., Smulders-Srinivasan, T. K., Kirby, D. M., Acin-Perez, R., Enriquez, J. A., Lightowers, R. N., Duchen, M. R. and Turnbull, D. M.** (2010). Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. *Brain* **133**, 797-807.
- Albrecht, P., Schmitz, M., Otto, M., Hemmer, B., Zerr, I., Hartung, H. P. and Methner, A.** (2009). Free caspase activity in CSF of patients with dementia. *Journal of neurology* **256**, 1561-1562.
- Albrecht, S., Bogdanovic, N., Ghetti, B., Winblad, B. and LeBlanc, A. C.** (2009). Caspase-6 activation in familial Alzheimer disease brains carrying amyloid precursor protein or presenilin I or presenilin II mutations. *J Neuropathol Exp Neurol* **68**, 1282-1293.
- Alikhani, N., Guo, L., Yan, S., Du, H., Pinho, C. M., Chen, J. X., Glaser, E. and Yan, S. S.** (2011). Decreased proteolytic activity of the mitochondrial amyloid-beta degrading enzyme, PreP peptidosome, in Alzheimer's disease brain mitochondria. *J Alzheimers Dis* **27**, 75-87.
- Allinson, T. M., Parkin, E. T., Turner, A. J. and Hooper, N. M.** (2003). ADAMs family members as amyloid precursor protein alpha-secretases. *J Neurosci Res* **74**, 342-352.
- Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W. and Yuan, J.** (1996). Human ICE/CED-3 protease nomenclature. *Cell* **87**, 171.
- Alonso, A. D., Grundke-Iqbal, I., Barra, H. S. and Iqbal, K.** (1997). Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. *Proc Natl Acad Sci U S A* **94**, 298-303.
- Alves da Costa, C., Mattson, M. P., Ancolio, K. and Checler, F.** (2003). The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart. *J Biol Chem* **278**, 12064-12069.
- Alves da Costa, C., Paitel, E., Mattson, M. P., Amson, R., Telerman, A., Ancolio, K. and Checler, F.** (2002). Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. *Proc Natl Acad Sci U S A* **99**, 4043-4048.
- Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. and Murtagh, F. R.** (1995). An English translation of Alzheimer's 1907 paper, "Über eine eigenartige Erkrankung der Hirnrinde". *Clin Anat* **8**, 429-431.
- Anandatheerthavarada, H. K., Biswas, G., Robin, M. A. and Avadhani, N. G.** (2003). Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. *J Cell Biol* **161**, 41-54.
- Ankarcrona, M., Mangialasche, F. and Winblad, B.** (2010). Rethinking Alzheimer's disease therapy: are mitochondria the key? *J Alzheimers Dis* **20 Suppl 2**, S579-590.
- Aoki, M., Volkman, I., Tjernberg, L. O., Winblad, B. and Bogdanovic, N.** (2008). Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain. *Neuroreport* **19**, 1085-1089.
- Area-Gomez, E., de Groof, A. J., Boldogh, I., Bird, T. D., Gibson, G. E., Koehler, C. M., Yu, W. H., Duff, K. E., Yaffe, M. P., Pon, L. A. et al.** (2009). Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. *Am J Pathol* **175**, 1810-1816.
- Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H. and Ames, B. N.** (2008). Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. *FASEB J* **22**, 703-712.
- Bachurin, S., Bukatina, E., Lermontova, N., Tkachenko, S., Afanasiev, A., Grigoriev, V., Grigorieva, I., Ivanov, Y., Sablin, S. and Zefirov, N.** (2001). Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. *Ann N Y Acad Sci* **939**, 425-435.
- Bachurin, S. O., Shevtsova, E. P., Kireeva, E. G., Oxenkrug, G. F. and Sablin, S. O.** (2003). Mitochondria as a target for neurotoxins and neuroprotective agents. *Ann N Y Acad Sci* **993**, 334-344; discussion 345-339.
- Bachurin, S. O., Shelkvnikova, T. A., Ustyugov, A. A., Peters, O., Khritankova, I., Afanasieva, M. A., Tarasova, T. V., Alentov, II, Buchman, V. L. and Ninkina, N. N.** (2012). Dimebon slows progression of proteinopathy in gamma-synuclein transgenic mice. *Neurotox Res* **22**, 33-42.
- Baloyannis, S. J.** (2006). Mitochondrial alterations in Alzheimer's disease. *J Alzheimers Dis* **9**, 119-126.

**Bannai, H., Inoue, T., Nakayama, T., Hattori, M. and Mikoshiba, K.** (2004). Kinesin dependent, rapid, bi-directional transport of ER sub-compartment in dendrites of hippocampal neurons. *J Cell Sci* **117**, 163-175.

**Baratchi, S., Evans, J., Tate, W. P., Abraham, W. C. and Connor, B.** (2012). Secreted amyloid precursor proteins promote proliferation and glial differentiation of adult hippocampal neural progenitor cells. *Hippocampus* **22**, 1517-1527.

**Barger, S. W. and Mattson, M. P.** (1996). Induction of neuroprotective kappa B-dependent transcription by secreted forms of the Alzheimer's beta-amyloid precursor. *Brain Res Mol Brain Res* **40**, 116-126.

**Bartus, R. T., Dean, R. L., 3rd, Beer, B. and Lippa, A. S.** (1982). The cholinergic hypothesis of geriatric memory dysfunction. *Science* **217**, 408-414.

**Baulieu, E. E., Robel, P. and Schumacher, M.** (2001). Neurosteroids: beginning of the story. *Int Rev Neurobiol* **46**, 1-32.

**Beal, M. F.** (2005). Mitochondria take center stage in aging and neurodegeneration. *Ann Neurol* **58**, 495-505.

**Benilova, I., Karran, E. and De Strooper, B.** (2012). The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. *Nature neuroscience* **15**, 349-357.

**Benson, D. L., Schnapp, L. M., Shapiro, L. and Huntley, G. W.** (2000). Making memories stick: cell-adhesion molecules in synaptic plasticity. *Trends in cell biology* **10**, 473-482.

**Bezprozvanny, I. and Mattson, M. P.** (2008). Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. *Trends in neurosciences* **31**, 454-463.

**Bionda, C., Portoukalian, J., Schmitt, D., Rodriguez-Lafresse, C. and Ardail, D.** (2004). Subcellular compartmentalization of ceramide metabolism: MAM (mitochondria-associated membrane) and/or mitochondria? *Biochem J* **382**, 527-533.

**Bjorkhem, I. and Meaney, S.** (2004). Brain cholesterol: long secret life behind a barrier. *Arterioscler Thromb Vasc Biol* **24**, 806-815.

**Bordji, K., Becerril-Ortega, J., Nicole, O. and Buisson, A.** (2010). Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-ss production. *J Neurosci* **30**, 15927-15942.

**Braak, H. and Braak, E.** (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* **82**, 239-259.

**Bravo, R., Vicencio, J. M., Parra, V., Troncoso, R., Munoz, J. P., Bui, M., Quiroga, C., Rodriguez, A. E., Verdejo, H. E., Ferreira, J. et al.** (2011). Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress. *J Cell Sci* **124**, 2143-2152.

**Brown, M. R., Sullivan, P. G. and Geddes, J. W.** (2006). Synaptic mitochondria are more susceptible to Ca<sup>2+</sup>-overload than nonsynaptic mitochondria. *J Biol Chem* **281**, 11658-11668.

**Brown, W. M., George, M., Jr. and Wilson, A. C.** (1979). Rapid evolution of animal mitochondrial DNA. *Proc Natl Acad Sci U S A* **76**, 1967-1971.

**Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P. and Gibson, G. E.** (2005). Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. *Ann Neurol* **57**, 695-703.

**Burguillos, M. A., Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L. et al.** (2011). Caspase signalling controls microglia activation and neurotoxicity. *Nature* **472**, 319-324.

**Cai, C., Lin, P., Cheung, K. H., Li, N., Levchook, C., Pan, Z., Ferrante, C., Boulianne, G. L., Foskett, J. K., Danielpour, D. et al.** (2006). The presenilin-2 loop peptide perturbs intracellular Ca<sup>2+</sup>-homeostasis and accelerates apoptosis. *J Biol Chem* **281**, 16649-16655.

**Canu, E., Frisoni, G. B., Agosta, F., Pievani, M., Bonetti, M. and Filippi, M.** (2012). Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage. *Neurobiol Aging* **33**, 1023-1033.

**Cao, X. and Sudhof, T. C.** (2004). Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. *J Biol Chem* **279**, 24601-24611.

**Capell, A., Beher, D., Prokop, S., Steiner, H., Kaether, C., Shearman, M. S. and Haass, C.** (2005). Gamma-secretase complex assembly within the early secretory pathway. *J Biol Chem* **280**, 6471-6478.

**Cardoso, S. M., Proenca, M. T., Santos, S., Santana, I. and Oliveira, C. R.** (2004). Cytochrome c oxidase is decreased in Alzheimer's disease platelets. *Neurobiol Aging* **25**, 105-110.

**Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., Stern, D., McKhann, G. and Yan, S. D.** (2005). Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. *Faseb J* **19**, 2040-2041.

**Chada, S. R. and Hollenbeck, P. J.** (2003). Mitochondrial movement and positioning in axons: the role of growth factor signaling. *J Exp Biol* **206**, 1985-1992.

**Chan, D. C.** (2006). Mitochondrial fusion and fission in mammals. *Annu Rev Cell Dev Biol* **22**, 79-99.

**Chan, S. L., Mayne, M., Holden, C. P., Geiger, J. D. and Mattson, M. P.** (2000). Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. *J Biol Chem* **275**, 18195-18200.

**Chang, S., ran Ma, T., Miranda, R. D., Balestra, M. E., Mahley, R. W. and Huang, Y.** (2005). Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. *Proc Natl Acad Sci U S A* **102**, 18694-18699.

**Chasseigneaux, S. and Allinquant, B.** (2012). Functions of Abeta, sAPPalpha and sAPPbeta : similarities and differences. *J Neurochem* **120 Suppl 1**, 99-108.

**Chavez-Gutierrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H. et al.** (2012). The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. *The EMBO journal* **31**, 2261-2274.

**Chen, F., Hasegawa, H., Schmitt-Ulms, G., Kawarai, T., Bohm, C., Katayama, T., Gu, Y., Sanjo, N., Glista, M., Rogaeva, E. et al.** (2006). TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. *Nature* **440**, 1208-1212.

**Chen, H. K., Ji, Z. S., Dodson, S. E., Miranda, R. D., Rosenblum, C. I., Reynolds, I. J., Freedman, S. B., Weisgraber, K. H., Huang, Y. and Mahley, R. W.** (2011). Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. *J Biol Chem* **286**, 5215-5221.

**Chen, Y. and Dong, C.** (2009). Abeta40 promotes neuronal cell fate in neural progenitor cells. *Cell Death Differ* **16**, 386-394.

**Christie, L. A., Su, J. H., Tu, C. H., Dick, M. C., Zhou, J. and Cotman, C. W.** (2007). Differential regulation of inhibitors of apoptosis proteins in Alzheimer's disease brains. *Neurobiol Dis* **26**, 165-173.

**Cicconi, S., Gentile, A., Ciotti, M. T., Parasassi, T., Serafino, A. and Calissano, P.** (2007). Apoptotic death induces Abeta production and fibril formation to a much larger extent than necrotic-like death in CGNs. *J Alzheimers Dis* **12**, 211-220.

**Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J. and Ashe, K. H.** (2005). Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nature neuroscience* **8**, 79-84.

**Cole, S. L. and Vassar, R.** (2007). The Alzheimer's disease beta-secretase enzyme, BACE1. *Mol Neurodegener* **2**, 22.

**Collins, T. J., Berridge, M. J., Lipp, P. and Bootman, M. D.** (2002). Mitochondria are morphologically and functionally heterogeneous within cells. *The EMBO journal* **21**, 1616-1627.

**Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H. and Duff, K.** (2012). Methylthionium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. *Autophagy* **8**.

**Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L. and Pericak-Vance, M. A.** (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-923.

**Costa, R., Speretta, E., Crowther, D. C. and Cardoso, I.** (2011). Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease. *J Biol Chem* **286**, 41647-41655.

**Crameri, A., Biondi, E., Kuehnle, K., Lutjohann, D., Thelen, K. M., Perga, S., Dotti, C. G., Nitsch, R. M., Ledesma, M. D. and Mohajeri, M. H.** (2006). The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. *The EMBO journal* **25**, 432-443.

**Csordas, G., Renken, C., Varnai, P., Walter, L., Weaver, D., Buttle, K. F., Balla, T., Mannella, C. A. and Hajnoczky, G.** (2006). Structural and functional features and significance of the physical linkage between ER and mitochondria. *J Cell Biol* **174**, 915-921.

**D'Amelio, M., Cavallucci, V., Middei, S., Marchetti, C., Pacioni, S., Ferri, A., Diamantini, A., De Zio, D., Carrara, P., Battistini, L. et al.** (2011). Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. *Nature neuroscience* **14**, 69-76.

**Day, M., Chandran, P., Luo, F., Rustay, N. R., Markosyan, S., LeBlond, D. and Fox, G. B.** (2011). Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography. *Neuroscience* **189**, 299-304.

**de Brito, O. M. and Scorrano, L.** (2008). Mitofusin 2 tethers endoplasmic reticulum to mitochondria. *Nature* **456**, 605-610.

**de Calignon, A., Fox, L. M., Pitstick, R., Carlson, G. A., Bacsikai, B. J., Spires-Jones, T. L. and Hyman, B. T.** (2010). Caspase activation precedes and leads to tangles. *Nature* **464**, 1201-1204.

**De Strooper, B.** (2010). Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. *Physiol Rev* **90**, 465-494.



**De Strooper, B., Beullens, M., Contreras, B., Levesque, L., Craessaerts, K., Cordell, B., Moechars, D., Bollen, M., Fraser, P., George-Hyslop, P. S. et al.** (1997). Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. *J Biol Chem* **272**, 3590-3598.

**De Vos, K. J., Sable, J., Miller, K. E. and Sheetz, M. P.** (2003). Expression of phosphatidylinositol (4,5) biphosphate-specific pleckstrin homology domains alters direction but not the level of axonal transport of mitochondria. *Mol Biol Cell* **14**, 3636-3649.

**Decuyper, J. P., Monaco, G., Bultynck, G., Missiaen, L., De Smedt, H. and Parys, J. B.** (2011). The IP(3) receptor-mitochondria connection in apoptosis and autophagy. *Biochim Biophys Acta* **1813**, 1003-1013.

**Deng, Y., Tarassishin, L., Kallhoff, V., Peethumnongsin, E., Wu, L., Li, Y. M. and Zheng, H.** (2006). Deletion of presenilin 1 hydrophilic loop sequence leads to impaired gamma-secretase activity and exacerbated amyloid pathology. *J Neurosci* **26**, 3845-3854.

**Devi, L. and Ohno, M.** (2012). Mitochondrial dysfunction and accumulation of the beta-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. *Neurobiol Dis* **45**, 417-424.

**Devi, L., Prabhu, B. M., Galati, D. F., Avadhani, N. G. and Anandatheerthavarada, H. K.** (2006). Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. *J Neurosci* **26**, 9057-9068.

**Dolev, I. and Michaelson, D. M.** (2004). A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. *Proc Natl Acad Sci U S A* **101**, 13909-13914.

**Donoviel, D. B., Hadjantonakis, A. K., Ikeda, M., Zheng, H., Hyslop, P. S. and Bernstein, A.** (1999). Mice lacking both presenilin genes exhibit early embryonic patterning defects. *Genes & development* **13**, 2801-2810.

**Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L. and Hung, D.** (2008). Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. *Lancet* **372**, 207-215.

**Du, H., Guo, L., Zhang, W., Rydzewska, M. and Yan, S.** (2011). Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. *Neurobiol Aging* **32**, 398-406.

**Du, H., Guo, L., Yan, S., Sosunov, A. A., McKhann, G. M. and Yan, S. S.** (2010). Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. *Proc Natl Acad Sci U S A* **107**, 18670-18675.

**Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A. A., McKhann, G. M., Yan, Y., Wang, C., Zhang, H., Molkentin, J. D. et al.** (2008). Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. *Nat Med* **14**, 1097-1105.

**Du Yan, S., Zhu, Y., Stern, E. D., Hwang, Y. C., Hori, O., Ogawa, S., Frosch, M. P., Connolly, E. S., Jr., McTaggart, R., Pinsky, D. J. et al.** (2000). Amyloid beta -peptide-binding alcohol dehydrogenase is a component of the cellular response to nutritional stress. *J Biol Chem* **275**, 27100-27109.

**Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D. et al.** (1996). Increased amyloid-beta<sub>42</sub>(43) in brains of mice expressing mutant presenilin 1. *Nature* **383**, 710-713.

**Dunkley, P. R., Jarvie, P. E. and Robinson, P. J.** (2008). A rapid Percoll gradient procedure for preparation of synaptosomes. *Nature protocols* **3**, 1718-1728.

**Eckelman, B. P., Salvesen, G. S. and Scott, F. L.** (2006). Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. *EMBO Rep* **7**, 988-994.

**Eckert, S. H., Eckmann, J., Renner, K., Eckert, G. P., Leuner, K. and Muller, W. E.** (2012). Dimebon Ameliorates Amyloid-beta Induced Impairments of Mitochondrial Form and Function. *J Alzheimers Dis* **31**, 21-32.

**Falkevall, A., Alikhani, N., Bhushan, S., Pavlov, P. F., Busch, K., Johnson, K. A., Eneqvist, T., Tjernberg, L., Ankarcrona, M. and Glaser, E.** (2006). Degradation of the amyloid beta-protein by the novel mitochondrial peptidosome, PreP. *J Biol Chem* **281**, 29096-29104.

**Fluhrer, R., Friedlein, A., Haass, C. and Walter, J.** (2004). Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis. *J Biol Chem* **279**, 1585-1593.

**Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B. and Ruoho, A. E.** (2009). The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. *Science* **323**, 934-937.

**Foster, N. L., Wilhelmsen, K., Sima, A. A., Jones, M. Z., D'Amato, C. J. and Gilman, S.** (1997). Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. *Ann Neurol* **41**, 706-715.

**Franberg, J., Svensson, A. I., Winblad, B., Karlstrom, H. and Frykman, S.** (2011). Minor contribution of presenilin 2 for gamma-secretase activity in mouse embryonic fibroblasts and adult mouse brain. *Biochemical and biophysical research communications* **404**, 564-568.

**Francis, P. T.** (2003). Glutamatergic systems in Alzheimer's disease. *Int J Geriatr Psychiatry* **18**, S15-21.

**Frykman, S., Hur, J. Y., Franberg, J., Aoki, M., Winblad, B., Nahalkova, J., Behbahani, H. and Tjernberg, L. O.** (2010). Synaptic and endosomal localization of active gamma-secretase in rat brain. *PLoS one* **5**, e8948.

**Frykman, S., Teranishi, Y., Hur, J. Y., Sandebring, A., Goto Yamamoto, N., Ancarcrona, M., Nishimura, T., Winblad, B., Bogdanovic, N., Schedin-Weiss, S. et al.** (2012). Identification of two novel synaptic gamma-secretase associated proteins that affect amyloid beta-peptide levels without altering Notch processing. *Neurochem Int* **61**, 108-118.

**Funamoto, S., Morishima-Kawashima, M., Tanimura, Y., Hirotani, N., Saido, T. C. and Ihara, Y.** (2004). Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. *Biochemistry* **43**, 13532-13540.

**Furuse, T. and Hashimoto, K.** (2010). Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease. *Ann Gen Psychiatry* **9**, 6.

**Galli, C., Piccini, A., Ciotti, M. T., Castellani, L., Calissano, P., Zaccheo, D. and Tabaton, M.** (1998). Increased amyloidogenic secretion in cerebellar granule cells undergoing apoptosis. *Proc Natl Acad Sci U S A* **95**, 1247-1252.

**Gandy, S., Czernik, A. J. and Greengard, P.** (1988). Phosphorylation of Alzheimer disease amyloid precursor peptide by protein kinase C and Ca<sup>2+</sup>/calmodulin-dependent protein kinase II. *Proc Natl Acad Sci U S A* **85**, 6218-6221.

**Gersbacher, M. T., Kim, D. Y., Bhattacharyya, R. and Kovacs, D. M.** (2010). Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit. *Mol Neurodegener* **5**, 61.

**Gilman, C. P. and Mattson, M. P.** (2002). Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility? *Neuromolecular medicine* **2**, 197-214.

**Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A. et al.** (2009). Beta-amyloid monomers are neuroprotective. *J Neurosci* **29**, 10582-10587.

**Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L. et al.** (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* **349**, 704-706.

**Golde, T. E., Ran, Y. and Felsenstein, K. M.** (2012). Shifting a complex debate on gamma-secretase cleavage and Alzheimer's disease. *The EMBO journal* **31**, 2237-2239.

**Goldsbury, C., Mocanu, M. M., Thies, E., Kaether, C., Haass, C., Keller, P., Biernat, J., Mandelkow, E. and Mandelkow, E. M.** (2006). Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. *Traffic* **7**, 873-888.

**Gong, J. S., Kobayashi, M., Hayashi, H., Zou, K., Sawamura, N., Fujita, S. C., Yanagisawa, K. and Michikawa, M.** (2002). Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. *J Biol Chem* **277**, 29919-29926.

**Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H. et al.** (2000). Intraneuronal Aβ<sub>42</sub> accumulation in human brain. *Am J Pathol* **156**, 15-20.

**Grimm, M. O., Grimm, H. S., Patzold, A. J., Zinser, E. G., Halonen, R., Duering, M., Tschape, J. A., De Strooper, B., Muller, U., Shen, J. et al.** (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. *Nat Cell Biol* **7**, 1118-1123.

**Grimm, S.** (2012). The ER-mitochondria interface: the social network of cell death. *Biochim Biophys Acta* **1823**, 327-334.

**Grunberg, J., Walter, J., Loetscher, H., Deuschle, U., Jacobsen, H. and Haass, C.** (1998). Alzheimer's disease associated presenilin-1 holoprotein and its 18-20 kDa C-terminal fragment are death substrates for proteases of the caspase family. *Biochemistry* **37**, 2263-2270.

**Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M. and Binder, L. I.** (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc Natl Acad Sci U S A* **83**, 4913-4917.

**Guglielmotto, M., Aragno, M., Autelli, R., Giliberto, L., Novo, E., Colombatto, S., Danni, O., Parola, M., Smith, M. A., Perry, G. et al.** (2009). The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. *J Neurochem* **108**, 1045-1056.

**Gulyaeva, N. V., Kudryashov, I. E. and Kudryashova, I. V.** (2003). Caspase activity is essential for long-term potentiation. *J Neurosci Res* **73**, 853-864.

**Guo, H., Albrecht, S., Bourdeau, M., Petzke, T., Bergeron, C. and LeBlanc, A. C.** (2004). Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. *Am J Pathol* **165**, 523-531.

**Gura, T.** (2008). Hope in Alzheimer's fight emerges from unexpected places. *Nat Med* **14**, 894.

**Hamid, R., Kilger, E., Willem, M., Vassallo, N., Kostka, M., Bornhovd, C., Reichert, A. S., Kretzschmar, H. A., Haass, C. and Herms, J.** (2007). Amyloid precursor protein intracellular domain modulates cellular calcium homeostasis and ATP content. *J Neurochem* **102**, 1264-1275.

**Handler, M., Yang, X. and Shen, J.** (2000). Presenilin-1 regulates neuronal differentiation during neurogenesis. *Development* **127**, 2593-2606.

**Hansson, C. A., Popescu, B. O., Laudon, H., Cedazo-Minguez, A., Popescu, L. M., Winblad, B. and Ankarcona, M.** (2006). Caspase cleaved presenilin-1 is part of active gamma-secretase complexes. *J Neurochem* **97**, 356-364.

**Hansson, C. A., Frykman, S., Farmery, M. R., Tjernberg, L. O., Nilsberth, C., Purglove, S. E., Ito, A., Winblad, B., Cowburn, R. F., Thyberg, J. et al.** (2004). Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. *J Biol Chem* **279**, 51654-51660.

**Hansson Petersen, C. A., Alikhani, N., Behbahani, H., Wiehager, B., Pavlov, P. F., Alafuzoff, I., Leinonen, V., Ito, A., Winblad, B., Glaser, E. et al.** (2008). The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. *Proc Natl Acad Sci U S A* **105**, 13145-13150.

**Hardy, J. and Selkoe, D. J.** (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**, 353-356.

**Hauptmann, S., Scherping, I., Drose, S., Brandt, U., Schulz, K. L., Jendrach, M., Leuner, K., Eckert, A. and Muller, W. E.** (2009). Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. *Neurobiol Aging* **30**, 1574-1586.

**Hayashi, T. and Su, T. P.** (2001). Regulating ankyrin dynamics: Roles of sigma-1 receptors. *Proc Natl Acad Sci U S A* **98**, 491-496.

**Hayashi, T. and Su, T. P.** (2003). Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. *J Pharmacol Exp Ther* **306**, 718-725.

**Hayashi, T. and Su, T. P.** (2005). The sigma receptor: evolution of the concept in neuropsychopharmacology. *Curr Neuropharmacol* **3**, 267-280.

**Hayashi, T. and Su, T. P.** (2007). Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. *Cell* **131**, 596-610.

**Hayashi, T. and Su, T. P.** (2008). An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand. *Expert Opin Ther Targets* **12**, 45-58.

**Hayashi, T., Rizzuto, R., Hajnoczky, G. and Su, T. P.** (2009). MAM: more than just a housekeeper. *Trends in cell biology* **19**, 81-88.

**He, G., Luo, W., Li, P., Remmers, C., Netzer, W. J., Hendrick, J., Bettayeb, K., Flajolet, M., Gorelick, F., Wennogle, L. P. et al.** (2010). Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. *Nature* **467**, 95-98.

**Hebert, S. S., Horre, K., Nicolai, L., Papadopoulou, A. S., Mandemakers, W., Silaharoglu, A. N., Kauppinen, S., Delacourte, A. and De Strooper, B.** (2008). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. *Proc Natl Acad Sci U S A* **105**, 6415-6420.

**Hedskog, L., Zhang, S. and Ankarcona, M.** (2012). Strategic role for mitochondria in Alzheimer's disease and cancer. *Antioxid Redox Signal* **16**, 1476-1491.

**Heerssen, H. M. and Segal, R. A.** (2002). Location, location, location: a spatial view of neurotrophin signal transduction. *Trends in neurosciences* **25**, 160-165.

**Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M. et al.** (2001). Mitochondrial abnormalities in Alzheimer's disease. *J Neurosci* **21**, 3017-3023.

**Ho, A. and Sudhof, T. C.** (2004). Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. *Proc Natl Acad Sci U S A* **101**, 2548-2553.

**Hook, V., Funkelstein, L., Wegrzyn, J., Bark, S., Kindy, M. and Hook, G.** (2012). Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. *Biochim Biophys Acta* **1824**, 89-104.

**Hoyer, S., Oesterreich, K. and Wagner, O.** (1988). Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? *Journal of neurology* **235**, 143-148.

**Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S. and Malinow, R.** (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. *Neuron* **52**, 831-843.

**Hu, X., Crick, S. L., Bu, G., Frieden, C., Pappu, R. V. and Lee, J. M.** (2009). Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. *Proc Natl Acad Sci U S A* **106**, 20324-20329.

**Hu, X., Hicks, C. W., He, W., Wong, P., Macklin, W. B., Trapp, B. D. and Yan, R.** (2006). Bace1 modulates myelination in the central and peripheral nervous system. *Nature neuroscience* **9**, 1520-1525.

**Hung, A. Y. and Selkoe, D. J.** (1994). Selective ectodomain phosphorylation and regulated cleavage of beta-amyloid precursor protein. *The EMBO journal* **13**, 534-542.

**Hur, J. Y., Welander, H., Behbahani, H., Aoki, M., Franberg, J., Winblad, B., Frykman, S. and Tjernberg, L. O.** (2008). Active gamma-secretase is localized to detergent-resistant membranes in human brain. *FEBS J* **275**, 1174-1187.

**Hur, J. Y., Teranishi, Y., Kihara, T., Yamamoto, N. G., Inoue, M., Hosia, W., Hashimoto, M., Winblad, B., Frykman, S. and Tjernberg, L. O.** (2012). Identification of novel gamma-secretase-associated proteins in detergent-resistant membranes from brain. *J Biol Chem* **287**, 11991-12005.

**Hutter-Paier, B., Huttunen, H. J., Puglielli, L., Eckman, C. B., Kim, D. Y., Hofmeister, A., Moir, R. D., Domnitz, S. B., Frosch, M. P., Windisch, M. et al.** (2004). The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. *Neuron* **44**, 227-238.

**Hyman, B. T.** (2011). Caspase activation without apoptosis: insight into Abeta initiation of neurodegeneration. *Nature neuroscience* **14**, 5-6.

**Iqbal, K., Alonso Adel, C., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C. X., Khatoon, S., Li, B., Liu, F., Rahman, A. et al.** (2005). Tau pathology in Alzheimer disease and other tauopathies. *Biochim Biophys Acta* **1739**, 198-210.

**Ito, E., Oka, K., Etcheberrigaray, R., Nelson, T. J., McPhie, D. L., Tofel-Grehl, B., Gibson, G. E. and Alkon, D. L.** (1994). Internal Ca<sup>2+</sup> mobilization is altered in fibroblasts from patients with Alzheimer disease. *Proc Natl Acad Sci U S A* **91**, 534-538.

**Iversen, L. L., Mortishire-Smith, R. J., Pollack, S. J. and Shearman, M. S.** (1995). The toxicity in vitro of beta-amyloid protein. *Biochem J* **311** ( Pt 1), 1-16.

**Izumi, Y., Ishii, K., Katsuki, H., Benz, A. M. and Zorumski, C. F.** (1998). beta-Hydroxybutyrate fuels synaptic function during development. Histological and physiological evidence in rat hippocampal slices. *J Clin Invest* **101**, 1121-1132.

**Jan, A., Gokce, O., Luthi-Carter, R. and Lashuel, H. A.** (2008). The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. *J Biol Chem* **283**, 28176-28189.

**Jansen, K. L., Faull, R. L., Storey, P. and Leslie, R. A.** (1993). Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss. *Brain Res* **623**, 299-302.

**Jefferson, T., Causevic, M., auf dem Keller, U., Schilling, O., Isbert, S., Geyer, R., Maier, W., Tschickardt, S., Jumpertz, T., Weggen, S. et al.** (2011). Metalloprotease meprin beta generates nontoxic N-terminal amyloid precursor protein fragments in vivo. *J Biol Chem* **286**, 27741-27750.

**Jing, C. H., Wang, L., Liu, P. P., Wu, C., Ruan, D. and Chen, G.** (2012). Autophagy activation is associated with neuroprotection against apoptosis via a mitochondrial pathway in a rat model of subarachnoid hemorrhage. *Neuroscience* **213**, 144-153.

**Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S. C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G. et al.** (2011). Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. *Nature neuroscience* **14**, 545-547.

**Johannessen, M., Fontanilla, D., Mavlyutov, T., Ruoho, A. E. and Jackson, M. B.** (2011). Antagonist action of progesterone at sigma-receptors in the modulation of voltage-gated sodium channels. *Am J Physiol Cell Physiol* **300**, C328-337.

**Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J. et al.** (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature* **488**, 96-99.

**Jumpertz, T., Rennhack, A., Ness, J., Baches, S., Pietrzik, C. U., Bulic, B. and Weggen, S.** (2012). Presenilin is the molecular target of acidic gamma-secretase modulators in living cells. *PLoS one* **7**, e30484.

**Katayama, T., Imaizumi, K., Manabe, T., Hitomi, J., Kudo, T. and Tohyama, M.** (2004). Induction of neuronal death by ER stress in Alzheimer's disease. *Journal of chemical neuroanatomy* **28**, 67-78.

**Kerr, M. L. and Small, D. H.** (2005). Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. *J Neurosci Res* **80**, 151-159.

**Kieburz, K., McDermott, M. P., Voss, T. S., Corey-Bloom, J., Deuel, L. M., Dorsey, E. R., Factor, S., Geschwind, M. D., Hodgeman, K., Kayson, E. et al.** (2010). A randomized, placebo-controlled trial of latrepirdine in Huntington disease. *Arch Neurol* **67**, 154-160.

**Kim, T. W., Pettingell, W. H., Jung, Y. K., Kovacs, D. M. and Tanzi, R. E.** (1997). Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. *Science* **277**, 373-376.

**Kimura, N., Nakamura, S. I., Honda, T., Takashima, A., Nakayama, H., Ono, F., Sakakibara, I., Doi, K., Kawamura, S. and Yoshikawa, Y.** (2001). Age-related changes in the localization of presenilin-1 in cynomolgus monkey brain. *Brain Res* **922**, 30-41.

**Kindy, M. S., Yu, J., Zhu, H., El-Amouri, S. S., Hook, V. and Hook, G. R.** (2012). Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AbetaPP containing the wild-type beta-secretase site sequence. *J Alzheimers Dis* **29**, 827-840.

**Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogioacomo, F., Chang, L. J., Wilson, J. M., DiStefano, L. M. and Nobrega, J. N.** (1992). Brain cytochrome oxidase in Alzheimer's disease. *J Neurochem* **59**, 776-779.

**Klouz, A., Sapena, R., Liu, J., Maurice, T., Tillement, J. P., Papadopoulos, V. and Morin, D.** (2002). Evidence for sigma-1-like receptors in isolated rat liver mitochondrial membranes. *Br J Pharmacol* **135**, 1607-1615.

**Knott, A. B., Perkins, G., Schwarzenbacher, R. and Bossy-Wetzel, E.** (2008). Mitochondrial fragmentation in neurodegeneration. *Nat Rev Neurosci* **9**, 505-518.

**Kornmann, B., Currie, E., Collins, S. R., Schuldiner, M., Nunnari, J., Weissman, J. S. and Walter, P.** (2009). An ER-mitochondria tethering complex revealed by a synthetic biology screen. *Science* **325**, 477-481.

**Kuhn, P. H., Koroniak, K., Hogg, S., Colombo, A., Zeitschel, U., Willem, M., Volbracht, C., Schepers, U., Imhof, A., Hoffmeister, A. et al.** (2012). Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. *The EMBO journal* **31**, 3157-3168.

**Kuperstein, I., Broersen, K., Benilova, I., Rozanski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers-Nolten, I., Van Der Werf, K., Subramaniam, V. et al.** (2010). Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. *The EMBO journal* **29**, 3408-3420.

**Laird, F. M., Cai, H., Savonenko, A. V., Farah, M. H., He, K., Melnikova, T., Wen, H., Chiang, H. C., Xu, G., Koliatsos, V. E. et al.** (2005). BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. *J Neurosci* **25**, 11693-11709.

**Lambert, J. C. and Amouyel, P.** (2011). Genetics of Alzheimer's disease: new evidences for an old hypothesis? *Curr Opin Genet Dev* **21**, 295-301.

**Lamkanfi, M., Festjens, N., Declercq, W., Vanden Berghe, T. and Vandenabeele, P.** (2007). Caspases in cell survival, proliferation and differentiation. *Cell Death Differ* **14**, 44-55.

**Lazarov, O., Lee, M., Peterson, D. A. and Sisodia, S. S.** (2002). Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. *J Neurosci* **22**, 9785-9793.

**LeBlanc, A.** (1995). Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. *J Neurosci* **15**, 7837-7846.

**Lee, J. H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G. et al.** (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. *Cell* **141**, 1146-1158.

**Leo, S., Szabadkai, G. and Rizzuto, R.** (2008). The mitochondrial antioxidants MitoE(2) and MitoQ(10) increase mitochondrial Ca(2+) load upon cell stimulation by inhibiting Ca(2+) efflux from the organelle. *Ann N Y Acad Sci* **1147**, 264-274.

**Lermontova, N. N., Lukoyanov, N. V., Serkova, T. P., Lukoyanova, E. A. and Bachurin, S. O.** (2000). Dimebon improves learning in animals with experimental Alzheimer's disease. *Bull Exp Biol Med* **129**, 544-546.

**Leuner, K., Schutt, T., Kurz, C., Eckert, S. H., Schiller, C., Occhipinti, A., Mai, S., Jendrach, M., Eckert, G. P., Kruse, S. E. et al.** (2012). Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. *Antioxid Redox Signal* **16**, 1421-1433.

**Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C. E., Jondro, P. D., Schmidt, S. D., Wang, K. et al.** (1995). Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* **269**, 973-977.

**Li, Z., Jo, J., Jia, J. M., Lo, S. C., Whitcomb, D. J., Jiao, S., Cho, K. and Sheng, M.** (2010). Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. *Cell* **141**, 859-871.

**Lleo, A. and Saura, C. A.** (2011). gamma-secretase substrates and their implications for drug development in Alzheimer's disease. *Curr Top Med Chem* **11**, 1513-1527.

**Lorenzo, A., Yuan, M., Zhang, Z., Paganetti, P. A., Sturchler-Pierrat, C., Staufenbiel, M., Mautino, J., Vigo, F. S., Sommer, B. and Yankner, B. A.** (2000). Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. *Nature neuroscience* **3**, 460-464.

**Louneva, N., Cohen, J. W., Han, L. Y., Talbot, K., Wilson, R. S., Bennett, D. A., Trojanowski, J. Q. and Arnold, S. E.** (2008a). Caspase-3 Is Enriched in Postsynaptic Densities and Increased in Alzheimer's Disease. *Am J Pathol*.

**Louneva, N., Cohen, J. W., Han, L. Y., Talbot, K., Wilson, R. S., Bennett, D. A., Trojanowski, J. Q. and Arnold, S. E.** (2008b). Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. *Am J Pathol* **173**, 1488-1495.

**Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M. et al.** (2004). ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. *Science* **304**, 448-452.

**Luty, A. A., Kwok, J. B., Dobson-Stone, C., Loy, C. T., Coupland, K. G., Karlstrom, H., Sobow, T., Tchorzewska, J., Maruszak, A., Barcikowska, M. et al.** (2010). Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. *Ann Neurol* **68**, 639-649.

**Manczak, M., Jung, Y., Park, B. S., Partovi, D. and Reddy, P. H.** (2005). Time-course of mitochondrial gene expressions in mice brains: implications for mitochondrial dysfunction, oxidative damage, and cytochrome c in aging. *J Neurochem* **92**, 494-504.

**Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J. and Reddy, P. H.** (2006). Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. *Hum Mol Genet* **15**, 1437-1449.

**Marambaud, P., Shioi, J., Serban, G., Georgakopoulos, A., Sarner, S., Nagy, V., Baki, L., Wen, P., Efthimiopoulos, S., Shao, Z. et al.** (2002). A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. *The EMBO journal* **21**, 1948-1956.

**Markesbery, W. R. and Carney, J. M.** (1999). Oxidative alterations in Alzheimer's disease. *Brain Pathol* **9**, 133-146.

**Marotta, C. A., Majocha, R. E. and Tate, B.** (1992). Molecular and cellular biology of Alzheimer amyloid. *J Mol Neurosci* **3**, 111-125.

**Marrazzo, A., Caraci, F., Salinaro, E. T., Su, T. P., Copani, A. and Ronsisvalle, G.** (2005). Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. *Neuroreport* **16**, 1223-1226.

**Martin, V., Fabelo, N., Santpere, G., Puig, B., Marin, R., Ferrer, I. and Diaz, M.** Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. *J Alzheimers Dis* **19**, 489-502.

**Marx, C. E., Trost, W. T., Shampine, L. J., Stevens, R. D., Hulette, C. M., Steffens, D. C., Ervin, J. F., Butterfield, M. I., Blazer, D. G., Massing, M. W. et al.** (2006). The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. *Biol Psychiatry* **60**, 1287-1294.

**Masters, C. L. and Selkoe, D. J.** (2012). Biochemistry of Amyloid beta-Protein and Amyloid Deposits in Alzheimer Disease. *Cold Spring Harb Perspect Med* **2**, a006262.

**Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L. and Beyreuther, K.** (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A* **82**, 4245-4249.

**Mattson, M. P.** (2000). Apoptosis in neurodegenerative disorders. *Nat Rev Mol Cell Biol* **1**, 120-129.

**Mattson, M. P.** (2004). Pathways towards and away from Alzheimer's disease. *Nature* **430**, 631-639.

**Mattson, M. P., Keller, J. N. and Begley, J. G.** (1998). Evidence for synaptic apoptosis. *Experimental neurology* **153**, 35-48.

**Matveeva, I. A.** (1983). [Action of dimebon on histamine receptors]. *Farmakol Toksikol* **46**, 27-29.

**Maurice, T.** (2001). Beneficial effect of the sigma(1) receptor agonist PRE-084 against the spatial learning deficits in aged rats. *Eur J Pharmacol* **431**, 223-227.

- Maurice, T. and Su, T. P.** (2009). The pharmacology of sigma-1 receptors. *Pharmacol Ther* **124**, 195-206.
- McCarthy, J. V.** (2005). Involvement of presenilins in cell-survival signalling pathways. *Biochemical Society transactions* **33**, 568-572.
- McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P. et al.** (2005). Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. *Neuron* **47**, 191-199.
- McManus, M. J., Murphy, M. P. and Franklin, J. L.** (2011). The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. *J Neurosci* **31**, 15703-15715.
- Menendez-Gonzalez, M., Perez-Pinera, P., Martinez-Rivera, M., Calatayud, M. T. and Blazquez Menes, B.** (2005). APP processing and the APP-KPI domain involvement in the amyloid cascade. *Neuro-degenerative diseases* **2**, 277-283.
- Meunier, J. and Hayashi, T.** (2010). Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. *J Pharmacol Exp Ther* **332**, 388-397.
- Meunier, J., Ieni, J. and Maurice, T.** (2006). The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. *Br J Pharmacol* **149**, 998-1012.
- Mielke, M. M., Bandaru, V. V., Haughey, N. J., Rabins, P. V., Lyketsos, C. G. and Carlson, M. C.** (2010). Serum sphingomyelins and ceramides are early predictors of memory impairment. *Neurobiol Aging* **31**, 17-24.
- Miners, J. S., Baig, S., Palmer, J., Palmer, L. E., Kehoe, P. G. and Love, S.** (2008). Abeta-degrading enzymes in Alzheimer's disease. *Brain Pathol* **18**, 240-252.
- Mironov, S. L. and Symonchuk, N.** (2006). ER vesicles and mitochondria move and communicate at synapses. *J Cell Sci* **119**, 4926-4934.
- Mironov, S. L., Ivannikov, M. V. and Johansson, M.** (2005). [Ca<sup>2+</sup>]<sub>i</sub> signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules. From mitochondrial permeability transition pore to Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release. *J Biol Chem* **280**, 715-721.
- Mishina, M., Ohyama, M., Ishii, K., Kitamura, S., Kimura, Y., Oda, K., Kawamura, K., Sasaki, T., Kobayashi, S., Katayama, Y. et al.** (2008). Low density of sigma1 receptors in early Alzheimer's disease. *Ann Nucl Med* **22**, 151-156.
- Miyoshi, K., Ohyagi, Y., Sakae, N., Motomura, K., Ma, L., Taniwaki, T., Furuya, H., Tabira, T. and Kira, J.** (2009). Enhancement of activation of caspases by presenilin 1 gene mutations and its inhibition by secretase inhibitors. *J Alzheimers Dis* **16**, 551-564.
- Moechars, D., Lorent, K., De Strooper, B., Dewachter, I. and Van Leuven, F.** (1996). Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. *The EMBO journal* **15**, 1265-1274.
- Molinuevo, J. L., Llado, A. and Rami, L.** (2005). Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. *Am J Alzheimers Dis Other Demen* **20**, 77-85.
- Morozova, M. A., Beniashvili, A. G., Lepilkina, T. A. and Rupchev, G. E.** (2012). Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission. *Psychiatr Danub* **24**, 159-166.
- Mosconi, L.** (2005). Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. *European journal of nuclear medicine and molecular imaging* **32**, 486-510.
- Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., Tsui, W., De Santi, S. and de Leon, M. J.** (2007). Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. *Proc Natl Acad Sci U S A* **104**, 19067-19072.
- Muller, W. E., Eckert, A., Kurz, C., Eckert, G. P. and Leuner, K.** (2010). Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. *Mol Neurobiol* **41**, 159-171.
- Munoz, D. G. and Feldman, H.** (2000). Causes of Alzheimer's disease. *CMAJ* **162**, 65-72.
- Murphy, M. P. and Smith, R. A.** (2007). Targeting antioxidants to mitochondria by conjugation to lipophilic cations. *Annu Rev Pharmacol Toxicol* **47**, 629-656.
- Nakamura, T., Wang, L., Wong, C. C., Scott, F. L., Eckelman, B. P., Han, X., Tzitzilonis, C., Meng, F., Gu, Z., Holland, E. A. et al.** (2010). Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. *Molecular cell* **39**, 184-195.

- Navarro, A. and Boveris, A.** (2007). The mitochondrial energy transduction system and the aging process. *Am J Physiol Cell Physiol* **292**, C670-686.
- Newington, J. T., Pitts, A., Chien, A., Arseneault, R., Schubert, D. and Cumming, R. C.** (2011). Amyloid beta resistance in nerve cell lines is mediated by the Warburg effect. *PLoS one* **6**, e19191.
- Nikolaev, A., McLaughlin, T., O'Leary, D. D. and Tessier-Lavigne, M.** (2009). APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature* **457**, 981-989.
- Nilsson, P et al.** (2012) Autophagy deficiency increases beta-amyloid pathology and memory impairment in APP transgenic mice. Poster P014, AAIC, Vancouver, Canada
- O'Riordan, M. X., Bauler, L. D., Scott, F. L. and Duckett, C. S.** (2008). Inhibitor of apoptosis proteins in eukaryotic evolution and development: a model of thematic conservation. *Dev Cell* **15**, 497-508.
- Ohta, K., Mizuno, A., Ueda, M., Li, S., Suzuki, Y., Hida, Y., Hayakawa-Yano, Y., Itoh, M., Ohta, E., Kobori, M. et al.** (2010). Autophagy impairment stimulates PS1 expression and gamma-secretase activity. *Autophagy* **6**, 345-352.
- Papa, S.** (1996). Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. *Biochim Biophys Acta* **1276**, 87-105.
- Pardossi-Piquard, R., Petit, A., Kawarai, T., Sunyach, C., Alves da Costa, C., Vincent, B., Ring, S., D'Adamio, L., Shen, J., Muller, U. et al.** (2005). Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. *Neuron* **46**, 541-554.
- Park, S. A., Shaked, G. M., Bredesen, D. E. and Koo, E. H.** (2009). Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein. *Biochemical and biophysical research communications* **388**, 450-455.
- Parker, W. D., Jr. and Parks, J. K.** (1995). Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. *Neurology* **45**, 482-486.
- Parker, W. D., Jr., Filley, C. M. and Parks, J. K.** (1990). Cytochrome oxidase deficiency in Alzheimer's disease. *Neurology* **40**, 1302-1303.
- Parodi, J., Sepulveda, F. J., Roa, J., Opazo, C., Inestrosa, N. C. and Aguayo, L. G.** (2010). Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. *J Biol Chem* **285**, 2506-2514.
- Pasternak, S. H., Bagshaw, R. D., Guiral, M., Zhang, S., Ackerley, C. A., Pak, B. J., Callahan, J. W. and Mahuran, D. J.** (2003). Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. *J Biol Chem* **278**, 26687-26694.
- Patil, S. P., Ballard, R., Sanchez, S., Osborn, J. and Santangelo, D., Jr.** (2012). ApoE: the link between Alzheimer's-related glucose hypometabolism and Abeta deposition? *Med Hypotheses* **78**, 494-496.
- Pavlov, P. F., Wichager, B., Sakai, J., Frykman, S., Behbahani, H., Winblad, B. and Ankarcrone, M.** (2011). Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. *FASEB J* **25**, 78-88.
- Pettigrew, J. W., Panchalingam, K., Hamilton, R. L. and McClure, R. J.** (2001). Brain membrane phospholipid alterations in Alzheimer's disease. *Neurochem Res* **26**, 771-782.
- Pievani, M., Galluzzi, S., Thompson, P. M., Rasser, P. E., Bonetti, M. and Frisoni, G. B.** (2011). APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. *Neuroimage* **55**, 909-919.
- Pivovarova, N. B., Pozzo-Miller, L. D., Hongpaisan, J. and Andrews, S. B.** (2002). Correlated calcium uptake and release by mitochondria and endoplasmic reticulum of CA3 hippocampal dendrites after afferent synaptic stimulation. *J Neurosci* **22**, 10653-10661.
- Portelius, E., Mattsson, N., Andreasson, U., Blennow, K. and Zetterberg, H.** (2011). Novel abeta isoforms in Alzheimer's disease - their role in diagnosis and treatment. *Curr Pharm Des* **17**, 2594-2602.
- Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A., Berezovska, O., Hyman, B. T., Chang, T. Y., Tanzi, R. E. and Kovacs, D. M.** (2001). Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. *Nat Cell Biol* **3**, 905-912.
- Quintanilla, R. A., Matthews-Roberson, T. A., Dolan, P. J. and Johnson, G. V.** (2009). Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. *J Biol Chem* **284**, 18754-18766.
- Quintanilla, R. A., Dolan, P. J., Jin, Y. N. and Johnson, G. V.** (2012). Truncated tau and Abeta cooperatively impair mitochondria in primary neurons. *Neurobiol Aging* **33**, 619 e625-635.
- Ramachandran, S., Chu, U. B., Mavlyutov, T. A., Pal, A., Pyne, S. and Ruoho, A. E.** (2009). The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids. *Eur J Pharmacol* **609**, 19-26.



**Reddy, P. H.** (2007). Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. *Antioxid Redox Signal* **9**, 1647-1658.

**Reddy, P. H. and Beal, M. F.** (2005). Are mitochondria critical in the pathogenesis of Alzheimer's disease? *Brain Res Brain Res Rev* **49**, 618-632.

**Reddy, P. H., McWeeney, S., Park, B. S., Manczak, M., Gutala, R. V., Partovi, D., Jung, Y., Yau, V., Searles, R., Mori, M. et al.** (2004). Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. *Hum Mol Genet* **13**, 1225-1240.

**Rhein, V., Song, X., Wiesner, A., Ittner, L. M., Baysang, G., Meier, F., Ozmen, L., Bluethmann, H., Drose, S., Brandt, U. et al.** (2009). Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. *Proc Natl Acad Sci U S A* **106**, 20057-20062.

**Ring, S., Weyer, S. W., Kilian, S. B., Waldron, E., Pietrzik, C. U., Filippov, M. A., Herms, J., Buchholz, C., Eckman, C. B., Korte, M. et al.** (2007). The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. *J Neurosci* **27**, 7817-7826.

**Rizzuto, R., Pinton, P., Carrington, W., Fay, F. S., Fogarty, K. E., Lifshitz, L. M., Tuft, R. A. and Pozzan, T.** (1998). Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca<sup>2+</sup> responses. *Science* **280**, 1763-1766.

**Rockenstein, E., Mallory, M., Mante, M., Sisk, A. and Masliah, E.** (2001). Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). *J Neurosci Res* **66**, 573-582.

**Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H. et al.** (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat Genet* **39**, 168-177.

**Rohn, T. T., Vyas, V., Hernandez-Estrada, T., Nichol, K. E., Christie, L. A. and Head, E.** (2008). Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. *J Neurosci* **28**, 3051-3059.

**Ronnback, A., Sagelius, H., Bergstedt, K. D., Naslund, J., Westermark, G. T., Winblad, B. and Graff, C.** (2012). Amyloid neuropathology in the single Arctic APP transgenic model affects interconnected brain regions. *Neurobiol Aging* **33**, 831 e811-839.

**Roses, A. D., Lutz, M. W., Amrine-Madsen, H., Saunders, A. M., Crenshaw, D. G., Sundseth, S. S., Huentelman, M. J., Welsh-Bohmer, K. A. and Reiman, E. M.** (2009). A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. *The pharmacogenomics journal*.

**Rui, Y., Tiwari, P., Xie, Z. and Zheng, J. Q.** (2006). Acute impairment of mitochondrial trafficking by beta-amyloid peptides in hippocampal neurons. *J Neurosci* **26**, 10480-10487.

**Ruscher, K., Shamloo, M., Rickhag, M., Ladunga, I., Soriano, L., Gisselsson, L., Toresson, H., Ruslim-Litrus, L., Oksenberg, D., Urfer, R. et al.** (2011). The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. *Brain* **134**, 732-746.

**Rusinol, A. E., Cui, Z., Chen, M. H. and Vance, J. E.** (1994). A unique mitochondria-associated membrane fraction from rat liver has a high capacity for lipid synthesis and contains pre-Golgi secretory proteins including nascent lipoproteins. *J Biol Chem* **269**, 27494-27502.

**Sadleir, K. R. and Vassar, R.** (2012). Cdk5 protein inhibition and Abeta42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. *J Biol Chem* **287**, 7224-7235.

**Salehi, A., Delcroix, J. D., Belichenko, P. V., Zhan, K., Wu, C., Valletta, J. S., Takimoto-Kimura, R., Kleschevnikov, A. M., Sambamurti, K., Chung, P. P. et al.** (2006). Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. *Neuron* **51**, 29-42.

**Sano, R., Annunziata, I., Patterson, A., Moshiach, S., Gomero, E., Opferman, J., Forte, M. and d'Azzo, A.** (2009). GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. *Molecular cell* **36**, 500-511.

**Santos, S. F., Tasiaux, B., Sindic, C. and Octave, J. N.** (2011). Inhibition of neuronal calcium oscillations by cell surface APP phosphorylated on T668. *Neurobiol Aging* **32**, 2308-2313.

**Saura, C. A., Chen, G., Malkani, S., Choi, S. Y., Takahashi, R. H., Zhang, D., Gouras, G. K., Kirkwood, A., Morris, R. G. and Shen, J.** (2005). Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. *J Neurosci* **25**, 6755-6764.

**Schatz, G.** (1996). The protein import system of mitochondria. *J Biol Chem* **271**, 31763-31766.

Schriner, S. E., Linford, N. J., Martin, G. M., Treuting, P., Ogburn, C. E., Emond, M., Coskun, P. E., Ladiges, W., Wolf, N., Van Remmen, H. et al. (2005). Extension of murine life span by overexpression of catalase targeted to mitochondria. *Science* **308**, 1909-1911.

Selkoe, D. and Kopan, R. (2003). Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. *Annu Rev Neurosci* **26**, 565-597.

Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. *Science* **298**, 789-791.

Seppet, E., Gruno, M., Peetsalu, A., Gizatullina, Z., Nguyen, H. P., Vielhaber, S., Wussling, M. H., Trumbeckaite, S., Arandarcikaite, O., Jerzembeck, D. et al. (2009). Mitochondria and energetic depression in cell pathophysiology. *Int J Mol Sci* **10**, 2252-2303.

Shen, J. and Kelleher, R. J., 3rd. (2007). The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. *Proc Natl Acad Sci U S A* **104**, 403-409.

Shen, L., Kim, S., Risacher, S. L., Nho, K., Swaminathan, S., West, J. D., Foroud, T., Pankratz, N., Moore, J. H., Sloan, C. D. et al. (2010). Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. *Neuroimage* **53**, 1051-1063.

Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K. et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* **375**, 754-760.

Simmen, T., Aslan, J. E., Blagoveshchenskaya, A. D., Thomas, L., Wan, L., Xiang, Y., Feliciangeli, S. F., Hung, C. H., Crump, C. M. and Thomas, G. (2005). PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. *The EMBO journal* **24**, 717-729.

Sitia, R. and Meldolesi, J. (1992). Endoplasmic reticulum: a dynamic patchwork of specialized subregions. *Mol Biol Cell* **3**, 1067-1072.

Soba, P., Eggert, S., Wagner, K., Zentgraf, H., Siehl, K., Kreger, S., Lower, A., Langer, A., Merdes, G., Paro, R. et al. (2005). Homo- and heterodimerization of APP family members promotes intercellular adhesion. *The EMBO journal* **24**, 3624-3634.

Sprecher, C. A., Grant, F. J., Grimm, G., O'Hara, P. J., Norris, F., Norris, K. and Foster, D. C. (1993). Molecular cloning of the cDNA for a human amyloid precursor protein homolog: evidence for a multigene family. *Biochemistry* **32**, 4481-4486.

St George-Hyslop, P. H. (2000). Molecular genetics of Alzheimer's disease. *Biol Psychiatry* **47**, 183-199.

Stadelmann, C., Deckwerth, T. L., Srinivasan, A., Bancher, C., Bruck, W., Jellinger, K. and Lassmann, H. (1999a). Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. *Am J Pathol* **155**, 1459-1466.

Stadelmann, C., Deckwerth, T. L., Srinivasan, A., Bancher, C., Bruck, W., Jellinger, K. and Lassmann, H. (1999b). Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. *Am J Pathol* **155**, 1459-1466.

Steele, J. W., Kim, S. H., Cirrito, J. R., Verges, D. K., Restivo, J. L., Westaway, D., Fraser, P., Hyslop, P. S., Sano, M., Bezprozvanny, I. et al. (2009). Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. *Mol Neurodegener* **4**, 51.

Stefani, M. and Liguri, G. (2009). Cholesterol in Alzheimer's disease: unresolved questions. *Current Alzheimer research* **6**, 15-29.

Su, T. P., London, E. D. and Jaffe, J. H. (1988). Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. *Science* **240**, 219-221.

Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E. and Song, W. (2006). Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. *Proc Natl Acad Sci U S A* **103**, 18727-18732.

Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J. and Alberini, C. M. (2011). Astrocyte-neuron lactate transport is required for long-term memory formation. *Cell* **144**, 810-823.

Swerdlow, R. H., Burns, J. M. and Khan, S. M. (2010). The Alzheimer's disease mitochondrial cascade hypothesis. *J Alzheimers Dis* **20 Suppl 2**, S265-279.

Tagliatalata, G et al. (2012) Absence of Abeta oligomers at mitochondria in the hippocampus of individuals with AD neuropathology who remain cognitively intact. Poster P4-357 AAIC, Vancouver, Canada

**Takami, M., Nagashima, Y., Sano, Y., Ishihara, S., Morishima-Kawashima, M., Funamoto, S. and Ihara, Y.** (2009). gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. *J Neurosci* **29**, 13042-13052.

**Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M., Takahashi, Y., Thinakaran, G. and Iwatsubo, T.** (2003). The role of presenilin cofactors in the gamma-secretase complex. *Nature* **422**, 438-441.

**Takuma, K., Yan, S. S., Stern, D. M. and Yamada, K.** (2005a). Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. *Journal of pharmacological sciences* **97**, 312-316.

**Takuma, K., Yao, J., Huang, J., Xu, H., Chen, X., Luddy, J., Trillat, A. C., Stern, D. M., Arancio, O. and Yan, S. S.** (2005b). ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. *FASEB J* **19**, 597-598.

**Tamayev, R., Matsuda, S., Arancio, O. and D'Adamio, L.** (2012). beta- but not gamma-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. *EMBO Mol Med* **4**, 171-179.

**Tarassishin, L., Yin, Y. I., Bassit, B. and Li, Y. M.** (2004). Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinct. *Proc Natl Acad Sci U S A* **101**, 17050-17055.

**Taylor, C. J., Ireland, D. R., Ballagh, I., Bourne, K., Marechal, N. M., Turner, P. R., Bilkey, D. K., Tate, W. P. and Abraham, W. C.** (2008). Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. *Neurobiol Dis* **31**, 250-260.

**Teranishi, Y., Hur, J. Y., Gu, G. J., Kihara, T., Ishikawa, T., Nishimura, T., Winblad, B., Behbahani, H., Kamali-Moghaddam, M., Frykman, S. et al.** (2012). Erlin-2 is associated with active gamma-secretase in brain and affects amyloid beta-peptide production. *Biochemical and biophysical research communications* **424**, 476-481.

**Terry, R. D.** (2000). Cell death or synaptic loss in Alzheimer disease. *J Neuropathol Exp Neurol* **59**, 1118-1119.

**Tesco, G., Koh, Y. H. and Tanzi, R. E.** (2003). Caspase activation increases beta-amyloid generation independently of caspase cleavage of the beta-amyloid precursor protein (APP). *J Biol Chem* **278**, 46074-46080.

**Tesco, G., Koh, Y. H., Kang, E. L., Cameron, A. N., Das, S., Sena-Esteves, M., Hiltunen, M., Yang, S. H., Zhong, Z., Shen, Y. et al.** (2007). Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. *Neuron* **54**, 721-737.

**Thathiah, A., Spittaels, K., Hoffmann, M., Staes, M., Cohen, A., Horre, K., Vanbrabant, M., Coun, F., Baekelandt, V., Delacourte, A. et al.** (2009). The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. *Science* **323**, 946-951.

**Thinakaran, G. and Sisodia, S. S.** (2006). Presenilins and Alzheimer disease: the calcium conspiracy. *Nature neuroscience* **9**, 1354-1355.

**Tomita, T.** (2009). Secretase inhibitors and modulators for Alzheimer's disease treatment. *Expert Rev Neurother* **9**, 661-679.

**Town, T.** (2010). Inflammation, immunity, and Alzheimer's disease. *CNS Neurol Disord Drug Targets* **9**, 129-131.

**Trushina, E., Nemutlu, E., Zhang, S., Christensen, T., Camp, J., Mesa, J., Siddiqui, A., Tamura, Y., Sesaki, H., Wengenack, T. M. et al.** (2012). Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. *PloS one* **7**, e32737.

**Tsai, S. Y., Hayashi, T., Harvey, B. K., Wang, Y., Wu, W. W., Shen, R. F., Zhang, Y., Becker, K. G., Hoffer, B. J. and Su, T. P.** (2009). Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1xGTP pathway. *Proc Natl Acad Sci U S A* **106**, 22468-22473.

**Tu, H., Nelson, O., Bezprozvanny, A., Wang, Z., Lee, S. F., Hao, Y. H., Serneels, L., De Strooper, B., Yu, G. and Bezprozvanny, I.** (2006). Presenilins form ER Ca<sup>2+</sup> leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. *Cell* **126**, 981-993.

**Tuppo, E. E. and Arias, H. R.** (2005). The role of inflammation in Alzheimer's disease. *Int J Biochem Cell Biol* **37**, 289-305.

**Turner, P. R., O'Connor, K., Tate, W. P. and Abraham, W. C.** (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. *Prog Neurobiol* **70**, 1-32.

**Turner, P. R., Bourne, K., Garama, D., Carne, A., Abraham, W. C. and Tate, W. P.** (2007). Production, purification and functional validation of human secreted amyloid precursor proteins for use as neuropharmacological reagents. *J Neurosci Methods* **164**, 68-74.

Uemura, K., Lill, C. M., Li, X., Peters, J. A., Ivanov, A., Fan, Z., DeStrooper, B., Bacsikai, B. J., Hyman, B. T. and Berezovska, O. (2009). Allosteric modulation of PS1/gamma-secretase conformation correlates with amyloid beta(42/40) ratio. *PLoS one* **4**, e7893.

Urano, Y., Hayashi, I., Iiso, N., Reid, P. C., Shibasaki, Y., Noguchi, N., Tomita, T., Iwatsubo, T., Hamakubo, T. and Kodama, T. (2005). Association of active gamma-secretase complex with lipid rafts. *J Lipid Res* **46**, 904-912.

Uribe, V., Wong, B. K., Graham, R. K., Cusack, C. L., Skotte, N. H., Pouladi, M. A., Xie, Y., Feinberg, K., Ou, Y., Ouyang, Y. et al. (2012). Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. *Hum Mol Genet* **21**, 1954-1967.

Wallace, D. C. (1982). Structure and evolution of organelle genomes. *Microbiol Rev* **46**, 208-240.

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J. and Selkoe, D. J. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* **416**, 535-539.

van de Craen, M., de Jonghe, C., van den Brande, I., Declercq, W., van Gassen, G., van Crielinge, W., Vanderhoeven, I., Fiers, W., van Broeckhoven, C., Hendriks, L. et al. (1999). Identification of caspases that cleave presenilin-1 and presenilin-2. Five presenilin-1 (PS1) mutations do not alter the sensitivity of PS1 to caspases. *FEBS Lett* **445**, 149-154.

van Waarde, A., Ramakrishnan, N. K., Rybczynska, A. A., Elsinga, P. H., Ishiwata, K., Nijholt, I. M., Luiten, P. G. and Diereckx, R. A. (2011). The cholinergic system, sigma-1 receptors and cognition. *Behav Brain Res* **221**, 543-554.

Wang, J. M., Singh, C., Liu, L., Irwin, R. W., Chen, S., Chung, E. J., Thompson, R. F. and Brinton, R. D. (2010). Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A* **107**, 6498-6503.

Wang, P., Yang, G., Mosier, D. R., Chang, P., Zaidi, T., Gong, Y. D., Zhao, N. M., Dominguez, B., Lee, K. F., Gan, W. B. et al. (2005). Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. *J Neurosci* **25**, 1219-1225.

Wang, X., Su, B., Lee, H. G., Li, X., Perry, G., Smith, M. A. and Zhu, X. (2009). Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. *J Neurosci* **29**, 9090-9103.

Wang, X., Su, B., Siedlak, S. L., Moreira, P. I., Fujioka, H., Wang, Y., Casadesus, G. and Zhu, X. (2008). Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. *Proc Natl Acad Sci U S A* **105**, 19318-19323.

Wanngren, J., Franberg, J., Svensson, A. I., Laudon, H., Olsson, F., Winblad, B., Liu, F., Naslund, J., Lundkvist, J. and Karlstrom, H. (2010). The large hydrophilic loop of presenilin 1 is important for regulating gamma-secretase complex assembly and dictating the amyloid beta peptide (Abeta) Profile without affecting Notch processing. *J Biol Chem* **285**, 8527-8536.

Vassar, R. (2004). BACE1: the beta-secretase enzyme in Alzheimer's disease. *J Mol Neurosci* **23**, 105-114.

Vassar, R., Kovacs, D. M., Yan, R. and Wong, P. C. (2009). The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. *J Neurosci* **29**, 12787-12794.

Waterman-Storer, C. M. and Salmon, E. D. (1998). Endoplasmic reticulum membrane tubules are distributed by microtubules in living cells using three distinct mechanisms. *Curr Biol* **8**, 798-806.

Wei, W., Nguyen, L. N., Kessels, H. W., Hagiwara, H., Sisodia, S. and Malinow, R. (2010). Amyloid beta from axons and dendrites reduces local spine number and plasticity. *Nature neuroscience* **13**, 190-196.

Weibel (1979) *Stereological methods: Practical methods for biological morphology*. Academic press, London, 1, 91-100).

Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J. M., Masters, C. L. and Beyreuther, K. (1989). Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. *Cell* **57**, 115-126.

Welander, H., Franberg, J., Graff, C., Sundstrom, E., Winblad, B. and Tjernberg, L. O. (2009). Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. *J Neurochem* **110**, 697-706.

Welte, M. A. (2004). Bidirectional transport along microtubules. *Curr Biol* **14**, R525-537.

Wen, Y., Li, W., Poteet, E. C., Xie, L., Tan, C., Yan, L. J., Ju, X., Liu, R., Qian, H., Marvin, M. A. et al. (2011). Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. *J Biol Chem* **286**, 16504-16515.

**Wenk, G. L.** (2003). Neuropathologic changes in Alzheimer's disease. *J Clin Psychiatry* **64 Suppl 9**, 7-10.

**Verghese, P. B., Castellano, J. M. and Holtzman, D. M.** (2011). Apolipoprotein E in Alzheimer's disease and other neurological disorders. *Lancet Neurol* **10**, 241-252.

**Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H. and Thinakaran, G.** (2004). Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. *The Journal of biological chemistry* **279**, 44945-44954.

**Veurink, G., Fuller, S. J., Atwood, C. S. and Martins, R. N.** (2003). Genetics, lifestyle and the roles of amyloid beta and oxidative stress in Alzheimer's disease. *Ann Hum Biol* **30**, 639-667.

**Wieckowski, M. R., Giorgi, C., Lebedzinska, M., Duszynski, J. and Pinton, P.** (2009). Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. *Nature protocols* **4**, 1582-1590.

**Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C. and Haass, C.** (2006). Control of peripheral nerve myelination by the beta-secretase BACE1. *Science* **314**, 664-666.

**Wilson, C. A., Doms, R. W. and Lee, V. M.** (1999). Intracellular APP processing and A beta production in Alzheimer disease. *J Neuropathol Exp Neurol* **58**, 787-794.

**Vincent, B. and Govitrapong, P.** (2011). Activation of the alpha-secretase processing of AbetaPP as a therapeutic approach in Alzheimer's disease. *J Alzheimers Dis* **24 Suppl 2**, 75-94.

**Wirhth, O., Multhaup, G. and Bayer, T. A.** (2004). A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. *J Neurochem* **91**, 513-520.

**Wolozin, B., Iwasaki, K., Vito, P., Ganjei, J. K., Lacana, E., Sunderland, T., Zhao, B., Kusiak, J. W., Wasco, W. and D'Adamio, L.** (1996). Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. *Science* **274**, 1710-1713.

**Voss, C., Lahiri, S., Young, B. P., Loewen, C. J. and Prinz, W. A.** (2012). ER-shaping proteins facilitate lipid exchange between the ER and mitochondria in *S. cerevisiae*. *J Cell Sci*.

**Wu, J., Li, Q. and Bezprozvany, I.** (2008). Evaluation of Dimebon in cellular model of Huntington's disease. *Mol Neurodegener* **3**, 15.

**Xie, Y., Deng, S., Chen, Z., Yan, S. and Landry, D. W.** (2006). Identification of small-molecule inhibitors of the Abeta-ABAD interaction. *Bioorg Med Chem Lett* **16**, 4657-4660.

**Xie, Z., Dong, Y., Maeda, U., Moir, R. D., Xia, W., Culley, D. J., Crosby, G. and Tanzi, R. E.** (2007). The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. *J Neurosci* **27**, 1247-1254.

**Yamashita, M., Nonaka, T., Arai, T., Kametani, F., Buchman, V. L., Ninkina, N., Bachurin, S. O., Akiyama, H., Goedert, M. and Hasegawa, M.** (2009). Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. *FEBS Lett* **583**, 2419-2424.

**Yan, Y. and Wang, C.** (2007). Abeta40 protects non-toxic Abeta42 monomer from aggregation. *Journal of molecular biology* **369**, 909-916.

**Yang, L. B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X. L., Beach, T., Sue, L., Wong, P., Price, D. et al.** (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. *Nat Med* **9**, 3-4.

**Yao, J., Du, H., Yan, S., Fang, F., Wang, C., Lue, L. F., Guo, L., Chen, D., Stern, D. M., Gunn Moore, F. J. et al.** (2011). Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. *J Neurosci* **31**, 2313-2320.

**Youker, R. T., Shinde, U., Day, R. and Thomas, G.** (2009). At the crossroads of homeostasis and disease: roles of the PACS proteins in membrane traffic and apoptosis. *Biochem J* **421**, 1-15.

**Zampese, E., Fasolato, C., Kipanyula, M. J., Bortolozzi, M., Pozzan, T. and Pizzo, P.** (2011). Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca<sup>2+</sup> cross-talk. *Proc Natl Acad Sci U S A* **108**, 2777-2782.

**Zatti, G., Burgo, A., Giacomello, M., Barbiero, L., Ghidoni, R., Sinigaglia, G., Florean, C., Bagnoli, S., Binetti, G., Sorbi, S. et al.** (2006). Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. *Cell calcium* **39**, 539-550.

**Zempel, H., Thies, E., Mandelkow, E. and Mandelkow, E. M.** (2010). Abeta oligomers cause localized Ca<sup>(2+)</sup> elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *J Neurosci* **30**, 11938-11950.

**Zhang, C., Wu, B., Beglopoulos, V., Wines-Samuelson, M., Zhang, D., Dragatsis, I., Sudhof, T. C. and Shen, J.** (2009). Presenilins are essential for regulating neurotransmitter release. *Nature* **460**, 632-636.

- Zhang, H., Ma, Q., Zhang, Y. W. and Xu, H.** (2012). Proteolytic processing of Alzheimer's beta-amyloid precursor protein. *J Neurochem* **120 Suppl 1**, 9-21.
- Zhang, H., Sun, S., Herreman, A., De Strooper, B. and Bezprozvanny, I.** (2010). Role of presenilins in neuronal calcium homeostasis. *J Neurosci* **30**, 8566-8580.
- Zhang, Y. W., Thompson, R., Zhang, H. and Xu, H.** (2011). APP processing in Alzheimer's disease. *Mol Brain* **4**, 3.
- Zheng, H. and Koo, E. H.** (2006). The amyloid precursor protein: beyond amyloid. *Mol Neurodegener* **1**, 5.
- Zhou, S., Zhou, H., Walian, P. J. and Jap, B. K.** (2005). CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. *Proc Natl Acad Sci U S A* **102**, 7499-7504.
- Zuchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E. L., Zappia, M., Nelis, E., Patitucci, A., Senderek, J. et al.** (2004). Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. *Nat Genet* **36**, 449-451.